

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
28 February 2002 (28.02.2002)

PCT

(10) International Publication Number
WO 02/16416 A2

- (51) International Patent Classification⁷: C07K 14/00
- (21) International Application Number: PCT/US01/26089
- (22) International Filing Date: 21 August 2001 (21.08.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/227,159 22 August 2000 (22.08.2000) US
- (71) Applicants: **THE BRIGHAM AND WOMEN'S HOSPITAL, INC.** [US/US]; 75 Francis Street, Boston, MA 02115 (US). **PFIZER, INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).
- (72) Inventors: **LEE, Richard, T.**; 4 Country Drive, Weston, MA 02493 (US). **LANDSCHULZ, Katherine, T.**; 3 Grassy Hill Road, East Lyme, CT 06333 (US). **KENNEDY, Scott, P.**; 12 Windward Lane, Old Lyme, CT 06371 (US). **THOMPSON, John, F.**; 80 Hallmark Drive, Warwick, RI 02886 (US). **TURI, Thomas, G.**; 16 Fordham Trail, Old Saybrook, CT 06475 (US).
- (74) Agent: **PLUMER, Elizabeth, R.**; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR CONDITIONS



(57) Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to diagnostics and therapeutics involving isolated molecules that can be used to inhibit cardiac apoptotic cell-death.

WO 02/16416 A2

DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR CONDITIONS

Field of the Invention

This invention relates to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to inhibit cardiac apoptotic cell-death, and in particular, to the treatment of vascular and cardiovascular conditions including myocardial infarction, stroke, arteriosclerosis, and heart failure.

Background of the Invention

Despite significant advances in therapy, cardiovascular disease remains the single most common cause of morbidity and mortality in the developed world. Thus, prevention and therapy of cardiovascular conditions such as myocardial infarction and stroke is an area of major public health importance. Currently, several risk factors for future cardiovascular disorders have been described and are in wide clinical use in the detection of individuals at high risk. Such screening tests include evaluations of total and HDL cholesterol levels. However, a large number of cardiovascular disorders occur in individuals with apparently low to moderate risk profiles, and ability to identify such patients is limited. Moreover, accumulating data suggests that the beneficial effects of certain preventive and therapeutic treatments for patients at risk for or known to have cardiovascular disorders differs in magnitude among different patient groups. At this time, however, data describing diagnostic tests to determine whether certain therapies can be expected to be more or less effective are lacking.

Summary of the Invention

This invention provides methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, we have identified a number of genes that are upregulated in cardiac cells when the cells are subjected to mechanically-induced deformation. It has been discovered, unexpectedly, that such upregulation leads to inhibition of cardiac cell apoptosis. In view of these discoveries, it is believed that the molecules of the present invention can be used to inhibit cardiac cell-death, and in particular, to treat conditions that are characterized by cardiac cell apoptotic cell-death, such as vascular and cardiovascular conditions including myocardial infarction, stroke, arteriosclerosis, and heart failure.

Additionally, methods for using these molecules in the diagnosis of any of the foregoing vascular and cardiovascular conditions as well as cardiac hypertrophy, are also provided.

Furthermore, methods for using these molecules *in vivo* or *in vitro* for the purpose of
5 modulating apoptotic cell-death, methods for treating conditions associated with such cell-death, and compositions useful in the preparation of therapeutic preparations for the treatment of the foregoing conditions, are also provided.

The present invention thus involves, in several aspects, polypeptides modulating cardiac cell apoptotic activity, isolated nucleic acids encoding those polypeptides, functional
10 modifications and variants of the foregoing, useful fragments of the foregoing, as well as therapeutics and diagnostics, research methods, compositions and tools relating thereto.

According to one aspect of the invention, an isolated nucleic acid molecule selected from the group consisting of: (a) nucleic acid molecules which hybridize under stringent conditions to a molecule consisting of a nucleotide sequence set forth as SEQ ID NO:1 and
15 which code for a Mechanically Induced Vascular Receptor 1 (MIVR-1) polypeptide having cardiac cell anti-apoptotic activity, (b) deletions, additions and substitutions of (a) which code for a MIVR-1 polypeptide having cardiac cell anti-apoptotic activity, (c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and (d) complements of (a), (b) or (c), is provided. In
20 certain embodiments, the isolated nucleic acid molecule comprises the nucleotide sequence set forth as SEQ ID NO:1. In some embodiments, the isolated nucleic acid molecule consists of the nucleotide sequence set forth as SEQ ID NO:3 or a fragment thereof.

The invention in another aspect provides an isolated nucleic acid molecule selected from the group consisting of (a) unique fragments of a nucleotide sequence set forth as SEQ
25 ID NO:1, and (b) complements of (a), provided that a unique fragment of (a) includes a sequence of contiguous nucleotides which is not identical to any sequence selected from the sequence group consisting of: (1) sequences having SEQ ID NOs. 14-16, or 17, (2) complements of (1), and (3) fragments of (1) and (2). In any of the foregoing embodiments, complements refer to full-length complements.

30 In one embodiment, the sequence of contiguous nucleotides is selected from the group consisting of (1) at least two contiguous nucleotides nonidentical to the sequence group, (2) at least three contiguous nucleotides nonidentical to the sequence group, (3) at least four contiguous nucleotides nonidentical to the sequence group, (4) at least five contiguous

nucleotides nonidentical to the sequence group, (5) at least six contiguous nucleotides nonidentical to the sequence group, and (6) at least seven contiguous nucleotides nonidentical to the sequence group.

In another embodiment, the fragment has a size selected from the group consisting of
5 at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 40 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, 200 nucleotides, 1000 nucleotides and every integer length therebetween.

According to another aspect, the invention provides expression vectors, and host cells
10 transformed or transfected with such expression vectors, comprising the nucleic acid molecules described above.

According to another aspect of the invention, an isolated polypeptide is provided. The isolated polypeptide is encoded by the foregoing nucleic acid molecules of the invention. In some embodiments, the isolated polypeptide is encoded by the nucleic acid of SEQ ID NO:1,
15 giving rise to a polypeptide having the sequence of SEQ ID NO:2 that has cardiac cell anti-apoptotic activity. In other embodiments, the isolated polypeptide may be a fragment or variant of the foregoing of sufficient length to represent a sequence unique within the human genome, and identifying with a polypeptide that has cardiac cell anti-apoptotic activity, provided that the fragment includes a sequence of contiguous amino acids which is not
20 identical to any sequence encoded for by a nucleic acid sequence selected from the group consisting of SEQ ID NOs. 14-16, and 17. In another embodiment, immunogenic fragments of the polypeptide molecules described above are provided. The immunogenic fragments may or may not have cardiac cell anti-apoptotic activity.

According to another aspect of the invention, isolated binding polypeptides are
25 provided which selectively bind a polypeptide encoded by the foregoing nucleic acid molecules of the invention. Preferably the isolated binding polypeptides selectively bind a polypeptide which comprises the sequence of SEQ ID NO:2, or fragments thereof. In preferred embodiments, the isolated binding polypeptides include antibodies and fragments of antibodies (e.g., Fab, F(ab)₂, Fd and antibody fragments which include a CDR3 region which
30 binds selectively to the MIVR-1 polypeptide). In certain embodiments, the antibodies are human. In some embodiments, the antibodies are monoclonal antibodies. In one embodiment, the antibodies are polyclonal antisera. In further embodiments, the antibodies are humanized. In yet further embodiments, the antibodies are chimeric.

According to a further aspect of the invention, a method for determining the level of MIVR-1 expression in a subject, is provided. The method involves measuring expression of MIVR-1 in a test sample from a subject to determine the level of MIVR-1 expression in the subject. In certain embodiments, the measured MIVR-1 expression in the test sample is compared to MIVR-1 expression in a control containing a known level of MIVR-1 expression. Expression is defined as MIVR-1 mRNA expression, MIVR-1 polypeptide expression, or MIVR-1 cardiac cell anti-apoptotic activity as defined elsewhere herein. Various methods can be used to measure expression. Preferred embodiments of the invention include PCR and Northern blotting for measuring mRNA expression, MIVR-1 monoclonal antibodies or MIVR-1 polyclonal MIVR-1 antisera as reagents to measure MIVR-1 polypeptide expression, as well as methods for measuring MIVR-1 cardiac cell anti-apoptotic activity.

In certain embodiments, test samples such as biopsy samples, and biological fluids such as blood, are used as test samples. MIVR-1 expression in a test sample of a subject is compared to MIVR-1 expression in control.

According to another aspect of the invention, a method for identifying an agent useful in modulating cardiac cell anti-apoptotic activity of a molecule, is provided. The method involves (a) contacting a molecule having cardiac cell anti-apoptotic activity with a candidate agent, (b) measuring cardiac cell anti-apoptotic activity of the molecule, and (c) comparing the measured cardiac cell anti-apoptotic activity of the molecule to a control to determine whether the candidate agent modulates cardiac cell anti-apoptotic activity of the molecule, wherein the molecule is a nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1 (SEQ ID NO. 4), VDUP-1 (SEQ ID NO. 6), BTG-2 (SEQ ID NO. 8), and TIS-11d (SEQ ID NO. 10), or an expression product thereof (e.g., SEQ ID NOs. 2, 5, 7, 9, and 11, respectively). In certain embodiments, the control is cardiac cell anti-apoptotic activity of the molecule measured in the absence of the candidate agent.

According to still another aspect of the invention, a method of diagnosing a condition characterized by aberrant expression of a nucleic acid molecule or an expression product thereof, is provided. The method involves contacting a biological sample from a subject with an agent, wherein said agent specifically binds to said nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof, and measuring the amount of bound agent and determining therefrom if the expression of said nucleic acid molecule or an expression product thereof is aberrant, aberrant expression being diagnostic of the disorder,

wherein the nucleic acid molecule is at least one nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d. In some embodiments, the disorder is a cardiovascular condition selected from the group consisting of myocardial infarction, stroke, arteriosclerosis, and heart failure. In one embodiment, the disorder is cardiac hypertrophy.

According to still another aspect of the invention, a method for determining regression, progression or onset of a vascular condition in a subject characterized by aberrant expression of a nucleic acid molecule or an expression product thereof, is provided. The method involves monitoring a sample from a patient for a parameter selected from the group consisting of (i) a nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, (ii) a polypeptide encoded by the nucleic acid molecule, (iii) a peptide derived from the polypeptide, and (iv) an antibody which selectively binds the polypeptide or peptide, as a determination of regression, progression or onset of said vascular condition in the subject. In some embodiments, the sample is a biological fluid or a tissue as described in any of the foregoing embodiments. In certain embodiments, the step of monitoring comprises contacting the sample with a detectable agent selected from the group consisting of (a) an isolated nucleic acid molecule which selectively hybridizes under stringent conditions to the nucleic acid molecule of (i), (b) an antibody which selectively binds the polypeptide of (ii), or the peptide of (iii), and (c) a polypeptide or peptide which binds the antibody of (iv). The antibody, polypeptide, peptide, or nucleic acid can be labeled with a radioactive label or an enzyme. In further embodiments, the method further comprises assaying the sample for the peptide. In still further embodiments, monitoring the sample occurs over a period of time.

According to another aspect of the invention, a kit is provided. The kit comprises a package containing an agent that selectively binds to any of the foregoing MIVR-1 isolated nucleic acids, or expression products thereof, and a control for comparing to a measured value of binding of said agent any of the foregoing MIVR-1 isolated nucleic acids or expression products thereof. In some embodiments, the control is a predetermined value for comparing to the measured value. In certain embodiments, the control comprises an epitope of the expression product of any of the foregoing MIVR-1 isolated nucleic acids. In one embodiment, the kit further comprises a second agent that selectively binds to an isolated nucleic acid molecule selected from the group consisting of IEX-1, VDUP-1, BTG-2, TIS-11d, and/or an expression product thereof, and a control for comparing to a measured value of

binding of said second agent to said isolated nucleic acid molecule or expression product thereof.

According to a further aspect of the invention, a method of treating apoptotic cell-death of a cardiac cell in a subject, is provided. The method involves administering to a subject in need of such treatment an agent that modulates expression of a molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, in an effective amount to inhibit apoptotic cell-death of the cardiac cell in the subject. In certain embodiments, the cardiovascular condition is selected from the group consisting of myocardial infarction, stroke, arteriosclerosis, and heart failure. In some embodiments, the method further comprises co-administering an agent selected from the group consisting of an anti-inflammatory agent, an anti-thrombotic agent, an anti-platelet agent, a fibrinolytic agent, a lipid reducing agent, a direct thrombin inhibitor, a glycoprotein IIb/IIIa receptor inhibitor, an agent that binds to cellular adhesion molecules and inhibits the ability of white blood cells to attach to such molecules, a calcium channel blocker, a beta-adrenergic receptor blocker, a cyclooxygenase-2 inhibitor, or an angiotensin system inhibitor.

According to one aspect of the invention, a method for treating a cardiovascular condition, is provided. The method involves administering to a subject in need of such treatment a molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, in an amount effective to treat the cardiovascular condition. In certain embodiments, the cardiovascular condition is selected from the group consisting of myocardial infarction, stroke, arteriosclerosis, and heart failure. In some embodiments, the method further comprises co-administering an agent selected from the group consisting of an anti-inflammatory agent, an anti-thrombotic agent, an anti-platelet agent, a fibrinolytic agent, a lipid reducing agent, a direct thrombin inhibitor, a glycoprotein IIb/IIIa receptor inhibitor, an agent that binds to cellular adhesion molecules and inhibits the ability of white blood cells to attach to such molecules, a calcium channel blocker, a beta-adrenergic receptor blocker, a cyclooxygenase-2 inhibitor, or an angiotensin system inhibitor.

According to one aspect of the invention, a method for inhibiting apoptotic cell-death of a cell, is provided. The method involves contacting an isolated nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, with a cell under conditions that permit entry of the nucleic acid molecule into the cell, in an amount effective to inhibit apoptotic cell-death of the cell. In some embodiments, the cell is selected from the group consisting of a cardiomyocyte and a vascular endothelial cell.

According to still another aspect of the invention, a method for treating a condition mediated by increased apoptotic cell-death of vascular endothelial cells in a subject, is provided. The method involves administering to a subject in need of such treatment a molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, in an amount effective to inhibit increased apoptotic cell-death of vascular endothelial cells. In some embodiments, the molecule is a nucleic acid. In certain embodiments, the molecule is a polypeptide.

According to another aspect of the invention, a method for treating cardiac hypertrophy, is provided. The method involves administering to a subject in need of such treatment an agent that increases cardiac cell-death, in an amount effective to treat cardiac hypertrophy in the subject, wherein the agent that increases cardiac cell-death is an inhibitor of a nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, or an expression product thereof.

According to a further aspect of the invention, a method for treating a subject to reduce the risk of a cardiovascular condition developing in the subject, is provided. The method involves administering to a subject who is known to express decreased levels of a molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, an agent for reducing the risk of the cardiovascular disorder in an amount effective to lower the risk of the subject developing a future cardiovascular disorder, wherein the agent is an anti-inflammatory agent, an anti-thrombotic agent, an anti-platelet agent, a fibrinolytic agent, a lipid reducing agent, a direct thrombin inhibitor, a glycoprotein IIb/IIIa receptor inhibitor, an agent that binds to cellular adhesion molecules and inhibits the ability of white blood cells to attach to such molecules, a calcium channel blocker, a beta-adrenergic receptor blocker, a cyclooxygenase-2 inhibitor, or an angiotensin system inhibitor, or an agent that modulates expression of a molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

According to one aspect of the invention, a method for identifying a candidate agent useful in the treatment of a cardiovascular condition, is provided. The method involves determining expression of a set of nucleic acid molecules in a cardiac cell or tissue under conditions which, in the absence of a candidate agent, permit a first amount of expression of the set of nucleic acid molecules, wherein the set of nucleic acid molecules comprises at least one nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, contacting the cardiac cell or tissue with the candidate agent, and

detecting a test amount of expression of the set of nucleic acid molecules, wherein an increase in the test amount of expression in the presence of the candidate agent relative to the first amount of expression indicates that the candidate agent is useful in the treatment of the cardiovascular condition. In certain embodiments, the cardiovascular condition is selected from the group consisting of myocardial infarction, stroke, arteriosclerosis, and heart failure. In some embodiments, the set of nucleic acid molecules comprises at least two, at least three, at least four, or even at least five nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

According to another aspect of the invention, a method for identifying a candidate agent useful in the treatment of cardiac hypertrophy, is provided. The method involves determining expression of a set of nucleic acid molecules in a cardiac cell or tissue under conditions which, in the absence of a candidate agent, permit a first amount of expression of the set of nucleic acid molecules, wherein the set of nucleic acid molecules comprises at least one nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, contacting the cardiac cell or tissue with the candidate agent, and detecting a test amount of expression of the set of nucleic acid molecules, wherein a decrease in the test amount of expression in the presence of the candidate agent relative to the first amount of expression indicates that the candidate agent is useful in the treatment of cardiac hypertrophy. In certain embodiments, the set of nucleic acid molecules comprises at least two, at least three, at least four, or even at least five nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

According to another aspect of the invention, a pharmaceutical composition is provided. The composition comprises an agent comprising an isolated nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, or an expression product thereof, preferably in a pharmaceutically effective amount to treat a cardiovascular condition, and a pharmaceutically acceptable carrier. In some embodiments, the agent is an expression product of the isolated nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d. In certain embodiments, the cardiovascular condition is selected from the group consisting of myocardial infarction, stroke, arteriosclerosis, and heart failure.

According to yet another aspect of the invention, a pharmaceutical composition for treating cardiac hypertrophy, is provided. The composition comprises an agent that increases cardiac cell-death in a pharmaceutically effective amount to treat cardiac hypertrophy,

wherein the agent that increases cardiac cell-death is an inhibitor of a nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, or an expression product thereof, and a pharmaceutically acceptable carrier. In some embodiments, the subjects in need of such treatment are known to express increased levels of of a nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, or an expression product thereof.

According to a further aspect of the invention, methods for preparing medicaments useful in the treatment of a cardiovascular condition and/or cardiac hypertrophy, are provided.

According to still another aspect of the invention, a solid-phase nucleic acid molecule array, is provided. The array consists essentially of a set of nucleic acid molecules, expression products thereof, or fragments (of either the nucleic acid or the polypeptide molecule) thereof, each nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, fixed to a solid substrate. In some embodiments, the solid-phase array further comprises at least one control nucleic acid molecule. In certain embodiments, the set of nucleic acid molecules comprises at least one, at least two, at least three, at least four, or even at least five nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

These and other objects of the invention will be described in further detail in connection with the detailed description of the invention.

Brief Description of the Sequences

SEQ ID NO:1 is the nucleotide sequence of the human MIVR-1 cDNA.

SEQ ID NO:2 is the predicted amino acid sequence of the translation product of human MIVR-1 cDNA (SEQ ID NO:1).

SEQ ID NO:3 is the nucleotide sequence of the human MIVR-1 cDNA encoding the polypeptide of SEQ ID NO:2 (i.e., nucleotides 413-1273 of SEQ ID NO:1).

SEQ ID NO:4 is the nucleotide sequence of the human IEX-1 cDNA.

SEQ ID NO:5 is the predicted amino acid sequence of the translation product of human IEX-1 cDNA (SEQ ID NO:4).

SEQ ID NO:6 is the nucleotide sequence of the human VDUP-1 cDNA.

SEQ ID NO:7 is the predicted amino acid sequence of the translation product of human VDUP-1 cDNA (SEQ ID NO:6).

SEQ ID NO:8 is the nucleotide sequence of the human BTG-2 cDNA.

SEQ ID NO:9 is the predicted amino acid sequence of the translation product of human BTG-2 cDNA (SEQ ID NO:8).

SEQ ID NO:10 is the nucleotide sequence of the human TIS-11d cDNA.

5 SEQ ID NO:11 is the predicted amino acid sequence of the translation product of human TIS-11d cDNA (SEQ ID NO:10).

SEQ ID NO:12 is the nucleotide sequence of the mouse MIVR-1 cDNA.

SEQ ID NO:13 is the predicted amino acid sequence of the translation product of mouse MIVR-1 cDNA (SEQ ID NO:12).

10 SEQ ID NO:14 is the nucleotide sequence of GenBank Acc. No. AI761441.1, having partial homology to SEQ ID NO:1.

SEQ ID NO:15 is the nucleotide sequence of GenBank Acc. No. AI594390, having partial homology to SEQ ID NO:1.

SEQ ID NO:16 is the nucleotide sequence of GenBank Acc. No. NM_004338, having partial homology to SEQ ID NO:1.

15 SEQ ID NO:17 is the nucleotide sequence of GenBank Acc. No. AQ177461, having partial homology to SEQ ID NO:1.

Brief Description of the Drawings

Figure 1 depicts a kit embodying features of the present invention.

20

Detailed Description of the Invention

The invention involves the discovery of a number of genes that are upregulated in cardiac cells when the cells are subjected to a mechanically-induced strain deformation. It has been discovered that such upregulation leads, unexpectedly, to inhibition of cardiac cell apoptosis. In view of these discoveries, it is believed that the molecules of the present invention can be used to inhibit cardiac cell-death, and in particular, to treat conditions that are characterized by cardiac cell apoptotic cell-death, such as vascular and cardiovascular conditions including myocardial infarction, stroke, arteriosclerosis, and heart failure.

30 Additionally, methods for using these molecules in the diagnosis of any of the foregoing vascular and cardiovascular conditions as well as cardiac hypertrophy, are also provided.

Furthermore, methods for using these molecules *in vivo* or *in vitro* for the purpose of modulating apoptotic cell-death, methods for treating conditions associated with such cell-

death, and compositions useful in the preparation of therapeutic preparations for the treatment of the foregoing conditions, are also provided.

Apoptosis (also known as programmed cell-death) is a form of cell-death defined by morphological and biochemical characteristics. Apoptosis is a characteristic of the normal developmental process as well as a response of cells to stress or other environmental insults. Apoptosis is characterized by membrane blebbing, cellular and cytoplasmic shrinkage, chromosome fragmentation and condensation, and endonuclease activation resulting in the characteristic 180 bp DNA ladder. During this process, the nuclear lamins are cleaved inducing their disassembly. Apoptosis does not induce an inflammatory response because cells form apoptotic bodies which are phagocytosed by neighboring cells. A number of stresses can induce apoptosis *in vitro* and *in vivo*. The administration of glucocorticoids, reduction of hormone and/or growth factor levels, chemotherapy (toxic agents), mechanical injury and DNA damage can all result in apoptosis. Apoptosis is also induced by aberrant cell cycle activity, and it can be triggered in cells that express the Fas receptor with crosslinking antibodies or the natural Fas ligand. High frequencies of apoptotic cell-death are associated in a diverse array of pathological disorders. A number of standard tests are known in the art for detecting cell death in cells and/or tissue. For example, TdT-mediated biotin-dUDP nick-end labeling (TUNEL) staining, and the appearance of condensed chromatin and other morphological features characteristic of apoptosis in electron micrographs can be used to assess apoptosis in the cells of the invention and other cell types (see Examples section).

“Upregulated,” as used herein, refers to increased expression of a gene and/or its encoded polypeptide. Increased expression refers to increasing (i.e., to a detectable extent) replication, transcription, and/or translation of any of the nucleic acids of the invention (MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d), since upregulation of any of these processes results in concentration/amount increase of the polypeptide encoded by the gene (nucleic acid). Conversely, downregulation or decreased expression refers to decreased expression of a gene and/or its encoded polypeptide. The upregulation or downregulation of gene expression can be directly determined by detecting an increase or decrease, respectively, in the level of mRNA for the gene, or the level of protein expression of the gene-encoded polypeptide, using any suitable means known to the art, such as nucleic acid hybridization or antibody detection methods, respectively, and in comparison to controls. Upregulation or downregulation of gene expression can also be determined indirectly by detecting a change in cardiac cell anti-apoptotic activity of the gene.

“Cardiac cell anti-apoptotic activity” refers to the ability of a molecule to prevent or inhibit apoptotic cell-death of a cardiac cell and can be determined using, for example, standard tests known in the art (e.g., TUNEL staining, -see Examples section). A cardiac cell includes a cardiomyocyte and a vascular endothelial cell (including a smooth muscle cell).
5 A “molecule,” as used herein, embraces both “nucleic acids” and “polypeptides.” MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d molecules are capable of inhibiting apoptotic cell-death of a cell such as a cardiomyocyte, and/or a vascular endothelial cell (including a smooth muscle cell) both *in vivo* and *in vitro*.

“Expression,” as used herein, refers to nucleic acid and/or polypeptide expression, as well as to activity of the polypeptide molecule (e.g., cardiac cell anti-apoptotic activity of the molecule).
10

One aspect of the invention involves the cloning of a cDNA encoding MIVR-1. MIVR-1 according to the invention is an isolated nucleic acid molecule that comprises a nucleic acid molecule of SEQ ID NO:1, and codes for a polypeptide with cardiac cell anti-apoptotic activity. The sequence of the human MIVR-1 cDNA is presented as SEQ ID NO:1, and the predicted amino acid sequence of this cDNA’s encoded protein product is presented as SEQ ID NO:2.
15

As used herein, a subject is a mammal or a non-human mammal. In all embodiments human MIVR-1 and human subjects are preferred.
20

The invention thus involves in one aspect an isolated MIVR-1 polypeptide, the cDNA encoding this polypeptide, functional modifications and variants of the foregoing, useful fragments of the foregoing, as well as diagnostics and therapeutics relating thereto.

As used herein with respect to nucleic acids, the term “isolated” means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulated by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5’ and 3’ restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is
25
30

used herein because it is readily manipulated by standard techniques known to those of ordinary skill in the art.

As used herein with respect to polypeptides, the term "isolated" means separated from its native environment in sufficiently pure form so that it can be manipulated or used for any one of the purposes of the invention. Thus, isolated means sufficiently pure to be used (i) to raise and/or isolate antibodies, (ii) as a reagent in an assay, (iii) for sequencing, (iv) as a therapeutic, etc.

According to the invention, isolated nucleic acid molecules that code for a MIVR-1 polypeptide having cardiac cell anti-apoptotic activity include: (a) nucleic acid molecules which hybridize under stringent conditions to a molecule consisting of a nucleic acid of SEQ ID NO:1 and which code for a MIVR-1 polypeptide having cardiac cell anti-apoptotic activity, (b) deletions, additions and substitutions of (a) which code for a respective MIVR-1 polypeptide having cardiac cell anti-apoptotic activity, (c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and (d) complements of (a), (b) or (c). "Complements," as used herein, includes "full-length complements or 100% complements of (a), (b) or (c).

Homologs and alleles of the MIVR-1 nucleic acids of the invention can be identified by conventional techniques. Thus, an aspect of the invention is those nucleic acid sequences which code for MIVR-1 polypeptides and which hybridize to a nucleic acid molecule consisting of the coding region of SEQ ID NO:1, under stringent conditions. The term "stringent conditions," as used herein, refers to parameters with which the art is familiar. With nucleic acids, hybridization conditions are said to be stringent typically under conditions of low ionic strength and a temperature just below the melting temperature (T_m) of the DNA hybrid complex (typically, about 3°C below the T_m of the hybrid). Higher stringency makes for a more specific correlation between the probe sequence and the target. Stringent conditions used in the hybridization of nucleic acids are well known in the art and may be found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. An example of "stringent conditions" is hybridization at 65°C in 6 x SSC. Another example of stringent conditions is hybridization at 65°C in hybridization buffer that consists of 3.5 x SSC, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH₂PO₄[pH7], 0.5% SDS, 2mM EDTA.

(SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid). After hybridization, the membrane upon which the DNA is transferred is washed at 2 x SSC at room temperature and then at 0.1 x SSC/0.1 x SDS at temperatures up to 68°C. In a further example, an alternative to the use of an aqueous hybridization solution is the use of a formamide hybridization solution. Stringent hybridization conditions can thus be achieved using, for example, a 50% formamide solution and 42°C. There are other conditions, reagents, and so forth which can be used, and would result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of MIVR-1 nucleic acids of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

In general homologs and alleles typically will share at least 40% nucleotide identity and/or at least 50% amino acid identity to SEQ ID NO:1 and SEQ ID NO:2, respectively, in some instances will share at least 50% nucleotide identity and/or at least 65% amino acid identity and in still other instances will share at least 60% nucleotide identity and/or at least 75% amino acid identity. In further instances, homologs and alleles typically will share at least 90%, 95%, or even 99% nucleotide identity and/or at least 95%, 98%, or even 99% amino acid identity to SEQ ID NO:1 and SEQ ID NO:2, respectively. The homology can be calculated using various, publicly available software tools developed by NCBI (Bethesda, Maryland). Exemplary tools include the heuristic algorithm of Altschul SF, et al., (*J Mol Biol*, 1990, 215:403-410), also known as BLAST. Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydrophobic analysis can be obtained using public (EMBL, Heidelberg, Germany) and commercial (e.g., the MacVector sequence analysis software from Oxford Molecular Group/genetics Computer Group, Madison, WI). Watson-Crick complements of the foregoing nucleic acids also are embraced by the invention.

In screening for MIVR-1 related genes, such as homologs and alleles of MIVR-1, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film or a phosphorimager plate to detect the radioactive signal.

Given the teachings herein of a full-length human MIVR-1 cDNA clone, other mammalian sequences such as the mouse cDNA clone corresponding to the human MIVR-1 gene can be isolated from a cDNA library, using standard colony hybridization techniques.

The invention also includes degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating MIVR-1 polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code.

The invention also provides isolated unique fragments of SEQ ID NO:1 or SEQ ID NO:3 or complements of thereof. A unique fragment is one that is a 'signature' for the larger nucleic acid. For example, the unique fragment is long enough to assure that its precise sequence is not found in molecules within the human genome outside of the MIVR-1 nucleic acids defined above (and human alleles). Those of ordinary skill in the art may apply no more than routine procedures to determine if a fragment is unique within the human genome. Unique fragments, however, exclude fragments completely composed of the nucleotide sequences selected from the group consisting of SEQ ID NOs. 14-16, and 17, and/or other previously published sequences as of the filing date of this application(e.g., GenBank Acc. No. AL035541).

A fragment which is completely composed of the sequence described in the foregoing GenBank deposits is one which does not include any of the nucleotides unique to the sequences of the invention. Thus, a unique fragment according to the invention must contain a nucleotide sequence other than the exact sequence of those in the GenBank deposits or fragments thereof. The difference may be an addition, deletion or substitution with respect to the GenBank sequence or it may be a sequence wholly separate from the GenBank sequence.

Unique fragments can be used as probes in Southern and Northern blot assays to identify such nucleic acids, or can be used in amplification assays such as those employing PCR. As known to those skilled in the art, large probes such as 200, 250, 300 or more nucleotides are preferred for certain uses such as Southern and Northern blots, while smaller fragments will be preferred for uses such as PCR. Unique fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments, as demonstrated in the Examples, or for generating immunoassay components. Likewise, unique fragments can be employed to produce nonfused fragments of the MIVR-1 polypeptides, useful, for example, in the preparation of antibodies, immunoassays or therapeutic applications. Unique fragments further can be used as antisense molecules to inhibit the expression of MIVR-1 nucleic acids and polypeptides respectively.

As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of SEQ ID NO:1 or SEQ ID NO:3 and complements will require longer segments to be unique while others will require only short segments, typically between 12 and 32 nucleotides long (e.g. 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32 bases) or more, up to the entire length of the disclosed sequence. As mentioned above, this disclosure intends to embrace each and every fragment of each sequence, beginning at the first nucleotide, the second nucleotide and so on, up to 8 nucleotides short of the end, and ending anywhere from nucleotide number 8, 9, 10 and so on for each sequence, up to the very last nucleotide, (provided the sequence is unique as described above). Virtually any segment of the region of SEQ ID NO:1 beginning at nucleotide 1 and ending at nucleotide 1321, or SEQ ID NO:3 beginning at nucleotide 1 and ending at nucleotide 861, or complements thereof, that is 20 or more nucleotides in length will be unique. Those skilled in the art are well versed in methods for selecting such sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from other sequences in the human genome of the fragment to those on known databases typically is all that is necessary, although *in vitro* confirmatory hybridization and sequencing analysis may be performed.

As mentioned above, the invention embraces antisense oligonucleotides that selectively bind to a nucleic acid molecule encoding a MIVR-1 polypeptide, to decrease MIVR-1 activity.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified

oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon SEQ ID NO:1 or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., *Nat. Med.*, 1995, 1(11):1116-1118; *Nat. Biotech.*, 1996, 14:840-844). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted by antisense oligonucleotides. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which proteins are not expected to bind. Finally, although, SEQ ID No:1 discloses a cDNA sequence, one of ordinary skill in the art may easily derive the genomic DNA corresponding to this sequence. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to SEQ ID NO:1. Similarly, antisense to allelic or homologous MIVR-1 cDNAs and genomic DNAs are enabled without undue experimentation.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamidates, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding MIVR-1 polypeptides, together with pharmaceutically acceptable carriers. Antisense oligonucleotides may be administered as part of a pharmaceutical composition. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the antisense

oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art.

The invention also involves expression vectors coding for MIVR-1 proteins and fragments and variants thereof and host cells containing those expression vectors. Virtually any cells, prokaryotic or eukaryotic, which can be transformed with heterologous DNA or RNA and which can be grown or maintained in culture, may be used in the practice of the invention. Examples include bacterial cells such as *Escherichia coli* and mammalian cells such as mouse, hamster, pig, goat, primate, etc. They may be of a wide variety of tissue types, including mast cells, fibroblasts, oocytes and lymphocytes, and they may be primary cells or cell lines. Specific examples include CHO cells and COS cells. Cell-free transcription systems also may be used in lieu of cells.

As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector.

Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., β -galactosidase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of

heterologous DNA (RNA) encoding MIVR-1 polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen, Carlsbad, CA), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 α , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc. Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992). The use of the adenovirus as an Adeno.P1A recombinant is disclosed by Warnier et al., in intradermal injection in mice for immunization against P1A (*Int. J. Cancer*, 67:303-310, 1996).

The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of each of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included.

It will also be recognized that the invention embraces the use of the above described, MIVR-1 cDNA sequence containing expression vectors, to transfect host cells and cell lines, be these prokaryotic (e.g., *Escherichia coli*), or eukaryotic (e.g., CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as mouse, hamster, pig, goat, primate, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. Specific examples include dendritic cells, U293 cells, peripheral blood leukocytes, bone marrow stem cells and embryonic stem cells. The invention also permits the construction of MIVR-1 gene “knock-outs” in cells and in animals, providing materials for studying certain aspects of MIVR-1 activity.

The invention also provides isolated polypeptides (including whole proteins and partial proteins), encoded by the foregoing MIVR-1 nucleic acids, and include the polypeptide of SEQ ID NO:2 and unique fragments thereof. Such polypeptides are useful, for example, alone or as part of fusion proteins to generate antibodies, as components of an immunoassay, etc. Polypeptides can be isolated from biological samples including tissue or cell homogenates, and can also be expressed recombinantly in a variety of prokaryotic and eukaryotic expression systems by constructing an expression vector appropriate to the expression system, introducing the expression vector into the expression system, and isolating the recombinantly expressed protein. Short polypeptides, including antigenic peptides (such as are presented by MHC molecules on the surface of a cell for immune recognition) also can be synthesized chemically using well-established methods of peptide synthesis.

A unique fragment of a MIVR-1 polypeptide, in general, has the features and characteristics of unique fragments as discussed above in connection with nucleic acids. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon factors such as whether the fragment constitutes a portion of a conserved protein domain. Thus, some regions of SEQ ID NO:2 will require longer segments to be unique while others will require only short segments, typically between 5 and 12 amino acids (e.g. 5, 6, 7, 8, 9, 10, 11 and 12 amino acids long or more, including each integer up to the full length, 287 amino acids long).

Unique fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the polypeptide. Functional capabilities which can be retained in a unique fragment of a polypeptide include interaction with antibodies, interaction with other polypeptides or fragments thereof, interaction with other molecules, etc. One important activity is the ability to act as a signature for identifying the polypeptide. Those skilled in the art are well versed in methods for selecting unique amino acid sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from non-family members. A comparison of the sequence of the fragment to those on known databases typically is all that is necessary.

The invention embraces variants of the MIVR-1 polypeptides described above. As used herein, a "variant" of a MIVR-1 polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a MIVR-1 polypeptide. Modifications which create a MIVR-1 polypeptide variant are typically made to the nucleic acid which encodes the MIVR-1 polypeptide, and can include deletions, point mutations,

truncations, amino acid substitutions and addition of amino acids or non-amino acid moieties to: 1) reduce or eliminate an activity of a MIVR-1 polypeptide; 2) enhance a property of a MIVR-1 polypeptide, such as protein stability in an expression system or the stability of protein-ligand binding; 3) provide a novel activity or property to a MIVR-1 polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety; or 4) to provide equivalent or better binding to a MIVR-1 polypeptide receptor or other molecule. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the MIVR-1 amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus “design” a variant MIVR-1 polypeptide according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87, 1997, whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary only a portion of the polypeptide sequence. By applying the computational methods of Dahiyat and Mayo, specific variants of the MIVR-1 polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

Variants can include MIVR-1 polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a MIVR-1 polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encodes a MIVR-1 polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with the desired properties. Further mutations can be made to variants (or to non-variant MIVR-1 polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a

particular host. The preferred codons for translation of a nucleic acid in, e.g., *Escherichia coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a MIVR-1 gene or cDNA clone to enhance expression of the polypeptide.

5 The skilled artisan will realize that conservative amino acid substitutions may be made in MIVR-1 polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e, the variants retain the functional capabilities of the MIVR-1 polypeptides. As used herein, a “conservative amino acid substitution” refers to an amino acid substitution which does not significantly alter the the tertiary structure and/or activity of the polypeptide.

10 Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art, and include those that are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons,

15 Inc., New York. Exemplary functionally equivalent variants of the MIVR-1 polypeptides include conservative amino acid substitutions of SEQ ID NO:2. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

Thus functionally equivalent variants of MIVR-1 polypeptides, i.e., variants of MIVR-1 polypeptides which retain the function of the natural MIVR-1 polypeptides, are contemplated by the invention. Conservative amino-acid substitutions in the amino acid sequence of MIVR-1 polypeptides to produce functionally equivalent variants of MIVR-1 polypeptides typically are made by alteration of a nucleic acid encoding MIVR-1 polypeptides (SEQ ID NOs:1, 3). Such substitutions can be made by a variety of methods

20 known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a MIVR-1 polypeptide. The activity of functionally equivalent fragments of MIVR-1 polypeptides can be tested by cloning the gene encoding the altered MIVR-1 polypeptide

30 into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered MIVR-1 polypeptide, and testing for a functional capability of the MIVR-1 polypeptides as disclosed herein (e.g., cardiac cell anti-apoptotic activity, etc.).

The invention as described herein has a number of uses, some of which are described elsewhere herein. First, the invention permits isolation of MIVR-1 polypeptides. A variety of methodologies well-known to the skilled practitioner can be utilized to obtain isolated MIVR-1 molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of MIVR-1 mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce MIVR-1 polypeptides. Those skilled in the art also can readily follow known methods for isolating MIVR-1 polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

The invention also provides, in certain embodiments, "dominant negative" polypeptides derived from MIVR-1 polypeptides. A dominant negative polypeptide is an inactive variant of a protein, which, by interacting with the cellular machinery, displaces an active protein from its interaction with the cellular machinery or competes with the active protein, thereby reducing the effect of the active protein. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand. Likewise, a dominant negative catalytically-inactive kinase which interacts normally with target proteins but does not phosphorylate the target proteins can reduce phosphorylation of the target proteins in response to a cellular signal. Similarly, a dominant negative transcription factor which binds to a promoter site in the control region of a gene but does not increase gene transcription can reduce the effect of a normal transcription factor by occupying promoter binding sites without increasing transcription.

The end result of the expression of a dominant negative polypeptide in a cell is a reduction in function of active proteins. One of ordinary skill in the art can assess the potential for a dominant negative variant of a protein, and use standard mutagenesis techniques to create one or more dominant negative variant polypeptides. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in a selected activity and/or for

retention of such an activity. Other similar methods for creating and testing dominant negative variants of a protein will be apparent to one of ordinary skill in the art.

The isolation of the MIVR-1 cDNA also makes it possible for the artisan to diagnose a disorder characterized by an aberrant expression of MIVR-1. These methods involve determining expression of the MIVR-1 gene, and/or MIVR-1 polypeptides derived therefrom. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or assaying with labeled hybridization probes as exemplified below. In the latter situation, such determination can be carried out via any standard immunological assay using, for example, antibodies which bind to the secreted MIVR-1 protein.

The invention also embraces isolated peptide binding agents which, for example, can be antibodies or fragments of antibodies ("binding polypeptides"), having the ability to selectively bind to MIVR-1 polypeptides. Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology. In certain embodiments, the invention excludes binding agents (e.g., antibodies) that bind to the polypeptides encoded by the nucleic acids having sequences selected from the group consisting of SEQ ID NOs. 14-17.

Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')₂ fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of

the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3).
5 The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies while retaining the epitopic specificity of the original antibody. This is most clearly
10 manifested in the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. See, e.g., U.S. patents 4,816,567, 5,225,539, 5,585,089, 5,693,762 and 5,859,205. Thus, for example, PCT International Publication Number WO 92/04381 teaches the production and use of humanized murine RSV antibodies in which at least a portion of the
15 murine FR regions have been replaced by FR regions of human origin. Such antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')₂, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or
20 FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab')₂ fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by
25 homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies.

Thus, the invention involves polypeptides of numerous size and type that bind specifically to MIVR-1 polypeptides, and complexes of both MIVR-1 polypeptides and their
30 binding partners. These polypeptides may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared in solution, in immobilized form, as bacterial flagella peptide display libraries or as phage display libraries. Combinatorial libraries also

can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptides and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array. One then can select phage-bearing inserts which bind to the MIVR-1 polypeptide or a complex of MIVR-1 and a binding partner. This process can be repeated through several cycles of reselection of phage that bind to the MIVR-1 polypeptide or complex. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the MIVR-1 polypeptide or complex can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the MIVR-1 polypeptides. Thus, the MIVR-1 polypeptides of the invention, or a fragment thereof, or complexes of MIVR-1 and a binding partner can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the MIVR-1 polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly with the functioning of MIVR-1 and for other purposes that will be apparent to those of ordinary skill in the art.

An MIVR-1 polypeptide, or a fragment thereof, also can be used to isolate their native binding partners. Isolation of binding partners may be performed according to well-known methods. For example, isolated MIVR-1 polypeptides can be attached to a substrate, and then a solution suspected of containing a MIVR-1 binding partner may be applied to the substrate. If the binding partner for MIVR-1 polypeptides is present in the solution, then it will bind to the substrate-bound MIVR-1 polypeptide. The binding partner then may be isolated. Other proteins which are binding partners for MIVR-1, may be isolated by similar methods without undue experimentation.

The invention also provides methods to measure the level of MIVR-1 expression in a subject. This can be performed by first obtaining a test sample from the subject. The test sample can be tissue or biological fluid. Tissues include brain, heart, serum, breast, colon,

bladder, uterus, prostate, stomach, testis, ovary, pancreas, pituitary gland, adrenal gland, thyroid gland, salivary gland, mammary gland, kidney, liver, intestine, spleen, thymus, blood vessels, bone marrow, trachea, and lung. In certain embodiments, test samples originate from heart and blood vessel tissues, and biological fluids include blood, saliva and urine. Both
5 invasive and non-invasive techniques can be used to obtain such samples and are well documented in the art. At the molecular level both PCR and Northern blotting can be used to determine the level of MIVR-1 mRNA using products of this invention described herein, and protocols well known in the art that are found in references which compile such methods. At the protein level, MIVR-1 expression can be determined using either polyclonal or
10 monoclonal anti-MIVR-1 sera in combination with standard immunological assays. The preferred methods will compare the measured level of MIVR-1 expression of the test sample to a control. A control can include a known amount of a nucleic acid probe, a MIVR-1 epitope (such as a MIVR-1 expression product), or a similar test sample of a subject with a control or 'normal' level of MIVR-1 expression.

15 MIVR-1 polypeptides preferably are produced recombinantly, although such polypeptides may be isolated from biological extracts. Recombinantly produced MIVR-1 polypeptides include chimeric proteins comprising a fusion of a MIVR-1 protein with another polypeptide, e.g., a polypeptide capable of providing or enhancing protein-protein binding, sequence specific nucleic acid binding (such as GAL4), enhancing stability of the MIVR-1
20 polypeptide under assay conditions, or providing a detectable moiety, such as green fluorescent protein. A polypeptide fused to a MIVR-1 polypeptide or fragment may also provide means of readily detecting the fusion protein, e.g., by immunological recognition or by fluorescent labeling.

The invention also is useful in the generation of transgenic non-human animals. As
25 used herein, "transgenic non-human animals" includes non-human animals having one or more exogenous nucleic acid molecules incorporated in germ line cells and/or somatic cells. Thus the transgenic animals include "knockout" animals having a homozygous or heterozygous gene disruption by homologous recombination, animals having episomal or chromosomally incorporated expression vectors, etc. Knockout animals can be prepared by
30 homologous recombination using embryonic stem cells as is well known in the art. The recombination may be facilitated using, for example, the cre/lox system or other recombinase systems known to one of ordinary skill in the art. In certain embodiments, the recombinase system itself is expressed conditionally, for example, in certain tissues or cell types, at certain

embryonic or post-embryonic developmental stages, is induced by the addition of a compound which increases or decreases expression, and the like. In general, the conditional expression vectors used in such systems use a variety of promoters which confer the desired gene expression pattern (e.g., temporal or spatial). Conditional promoters also can be operably
5 linked to MIVR-1 nucleic acid molecules to increase expression of MIVR-1 in a regulated or conditional manner. *Trans*-acting negative regulators of MIVR-1 activity or expression also can be operably linked to a conditional promoter as described above. Such *trans*-acting regulators include antisense MIVR-1 nucleic acids molecules, nucleic acid molecules which encode dominant negative MIVR-1 molecules, ribozyme molecules specific for MIVR-1
10 nucleic acids, and the like. The transgenic non-human animals are useful in experiments directed toward testing biochemical or physiological effects of diagnostics or therapeutics for conditions characterized by increased or decreased MIVR-1 expression. Other uses will be apparent to one of ordinary skill in the art.

The invention also contemplates gene therapy. The procedure for performing *ex vivo*
15 gene therapy is outlined in U.S. Patent 5,399,346 and in exhibits submitted in the file history of that patent, all of which are publicly available documents. In general, it involves introduction *in vitro* of a functional copy of a gene into a cell(s) of a subject which contains a defective copy of the gene, and returning the genetically engineered cell(s) to the subject. The functional copy of the gene is under operable control of regulatory elements which permit
20 expression of the gene in the genetically engineered cell(s). Numerous transfection and transduction techniques as well as appropriate expression vectors are well known to those of ordinary skill in the art, some of which are described in PCT application WO95/00654. *In vivo* gene therapy using vectors such as adenovirus, retroviruses, herpes virus, and targeted liposomes also is contemplated according to the invention.

The invention further provides efficient methods of identifying agents or lead
25 compounds for agents active at the level of a MIVR-1 or MIVR-1 fragment dependent cellular function. In particular, such functions include interaction with other polypeptides or fragments. Generally, the screening methods involve assaying for compounds which interfere with MIVR-1 activity (such as MIVR-1 cardiac cell anti-apoptotic activity), although
30 compounds which enhance MIVR-1 cardiac cell anti-apoptotic activity also can be assayed using the screening methods. Such methods are adaptable to automated, high throughput screening of compounds. Target indications include cellular processes modulated by MIVR-1 such as cardiac cell anti-apoptotic activity.

A wide variety of assays for candidate (pharmacological) agents are provided, including, labeled *in vitro* protein-ligand binding assays, electrophoretic mobility shift assays, immunoassays, cell-based assays such as two- or three-hybrid screens, expression assays, etc. The transfected nucleic acids can encode, for example, combinatorial peptide libraries or cDNA libraries. Convenient reagents for such assays, e.g., GAL4 fusion proteins, are known in the art. An exemplary cell-based assay involves transfecting a cell with a nucleic acid encoding a MIVR-1 polypeptide fused to a GAL4 DNA binding domain and a nucleic acid encoding a reporter gene operably linked to a gene expression regulatory region, such as one or more GAL4 binding sites. Activation of reporter gene transcription occurs when the MIVR-1 and reporter fusion polypeptide binds such as to enable transcription of the reporter gene. Agents which modulate a MIVR-1 polypeptide mediated cell function are then detected through a change in the expression of reporter gene. Methods for determining changes in the expression of a reporter gene are known in the art.

MIVR-1 fragments used in the methods, when not produced by a transfected nucleic acid are added to an assay mixture as an isolated polypeptide. MIVR-1 polypeptides preferably are produced recombinantly, although such polypeptides may be isolated from biological extracts. Recombinantly produced MIVR-1 polypeptides include chimeric proteins comprising a fusion of a MIVR-1 protein with another polypeptide, e.g., a polypeptide capable of providing or enhancing protein-protein binding, sequence specific nucleic acid binding (such as GAL4), enhancing stability of the MIVR-1 polypeptide under assay conditions, or providing a detectable moiety, such as green fluorescent protein or Flag epitope.

The assay mixture is comprised of a natural intracellular MIVR-1 binding target capable of interacting with MIVR-1. While natural MIVR-1 binding targets may be used, it is frequently preferred to use portions (e.g., peptides or nucleic acid fragments) or analogs (i.e., agents which mimic the MIVR-1 binding properties of the natural binding target for purposes of the assay) of the MIVR-1 binding target so long as the portion or analog provides binding affinity and avidity to the MIVR-1 fragment measurable in the assay.

The assay mixture also comprises a candidate agent. Typically, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a different response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration of agent or at a concentration of agent below the limits of assay detection. Candidate agents encompass numerous chemical classes, although typically

they are organic compounds. Preferably, the candidate agents are small organic compounds, i.e., those having a molecular weight of more than 50 yet less than about 2500, preferably less than about 1000 and, more preferably, less than about 500. Candidate agents comprise functional chemical groups necessary for structural interactions with polypeptides and/or nucleic acids, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups and more preferably at least three of the functional chemical groups. The candidate agents can comprise cyclic carbon or heterocyclic structure and/or aromatic or polyaromatic structures substituted with one or more of the above-identified functional groups. Candidate agents also can be biomolecules such as peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the like. Where the agent is a nucleic acid, the agent typically is a DNA or RNA molecule, although modified nucleic acids as defined herein are also contemplated.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides, synthetic organic combinatorial libraries, phage display libraries of random peptides, and the like. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds can be modified through conventional chemical, physical, and biochemical means. Further, known (pharmacological) agents may be subjected to directed or random chemical modifications such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs of the agents.

A variety of other reagents also can be included in the mixture. These include reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein and/or protein-nucleic acid binding. Such a reagent may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease, inhibitors, nuclease inhibitors, antimicrobial agents, and the like may also be used.

The mixture of the foregoing assay materials is incubated under conditions whereby, but for the presence of the candidate agent, the MIVR-1 polypeptide specifically binds a cellular binding target, a portion thereof or analog thereof. The order of addition of

components, incubation temperature, time of incubation, and other parameters of the assay may be readily determined. Such experimentation merely involves optimization of the assay parameters, not the fundamental composition of the assay. Incubation temperatures typically are between 4°C and 40°C. Incubation times preferably are minimized to facilitate rapid, high
5 throughput screening, and typically are between 0.1 and 10 hours.

After incubation, the presence or absence of specific binding between the MIVR-1 polypeptide and one or more binding targets is detected by any convenient method available to the user. For cell free binding type assays, a separation step is often used to separate bound from unbound components. The separation step may be accomplished in a variety of ways.
10 Conveniently, at least one of the components is immobilized on a solid substrate, from which the unbound components may be easily separated. The solid substrate can be made of a wide variety of materials and in a wide variety of shapes, e.g., microtiter plate, microbead, dipstick, resin particle, etc. The substrate preferably is chosen to maximum signal to noise ratios, primarily to minimize background binding, as well as for ease of separation and cost.

Separation may be effected for example, by removing a bead or dipstick from a reservoir, emptying or diluting a reservoir such as a microtiter plate well, rinsing a bead, particle, chromatographic column or filter with a wash solution or solvent. The separation step preferably includes multiple rinses or washes. For example, when the solid substrate is a microtiter plate, the wells may be washed several times with a washing solution, which
20 typically includes those components of the incubation mixture that do not participate in specific bindings such as salts, buffer, detergent, non-specific protein, etc. Where the solid substrate is a magnetic bead, the beads may be washed one or more times with a washing solution and isolated using a magnet.

Detection may be effected in any convenient way for cell-based assays such as two- or
25 three-hybrid screens. The transcript resulting from a reporter gene transcription assay of MIVR-1 polypeptide interacting with a target molecule typically encodes a directly or indirectly detectable product, e.g., β -galactosidase activity, luciferase activity, and the like. For cell free binding assays, one of the components usually comprises, or is coupled to, a detectable label. A wide variety of labels can be used, such as those that provide direct
30 detection (e.g., radioactivity, luminescence, optical or electron density, etc), or indirect detection (e.g., epitope tag such as the FLAG epitope, enzyme tag such as horseradish peroxidase, etc.). The label may be bound to a MIVR-1 binding partner, or incorporated into the structure of the binding partner.

A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the solid substrate or subsequent to separation from the solid substrate. Labels may be directly detected through optical or electron density, radioactive emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, streptavidin-biotin conjugates, etc. Methods for detecting the labels are well known in the art.

The invention provides MIVR-1-specific binding agents, methods of identifying and making such agents, and their use in diagnosis, therapy and pharmaceutical development. For example, MIVR-1-specific pharmacological agents are useful in a variety of diagnostic and therapeutic applications, especially where disease or disease prognosis is associated with altered MIVR-1 binding characteristics. Novel MIVR-1-specific binding agents include MIVR-1-specific antibodies, cell surface receptors, and other natural intracellular and extracellular binding agents identified with assays such as two hybrid screens, and non-natural intracellular and extracellular binding agents identified in screens of chemical libraries and the like.

In general, the specificity of MIVR-1 binding to a specific molecule is determined by binding equilibrium constants. Targets which are capable of selectively binding a MIVR-1 polypeptide preferably have binding equilibrium constants of at least about $10^7 M^{-1}$, more preferably at least about $10^8 M^{-1}$, and most preferably at least about $10^9 M^{-1}$. A wide variety of cell based and cell free assays may be used to demonstrate MIVR-1-specific binding. Cell based assays include one, two and three hybrid screens, assays in which MIVR-1-mediated transcription is inhibited or increased, etc. Cell free assays include MIVR-1-protein binding assays, immunoassays, etc. Other assays useful for screening agents which bind MIVR-1 polypeptides include fluorescence resonance energy transfer (FRET), and electrophoretic mobility shift analysis (EMSA).

According to another aspect of the invention, a method for identifying an agent useful in modulating cardiac cell anti-apoptotic activity of a molecule of the invention, is provided. The method involves (a) contacting a molecule having cardiac cell anti-apoptotic activity with a candidate agent, (b) measuring cardiac cell anti-apoptotic activity of the molecule, and (c) comparing the measured cardiac cell anti-apoptotic activity of the molecule to a control to determine whether the candidate agent modulates cardiac cell anti-apoptotic activity of the molecule, wherein the molecule is a nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, or an expression product thereof.

“Contacting” refers to both direct and indirect contacting of a molecule having cardiac cell anti-apoptotic activity with the candidate agent. “Indirect” contacting means that the candidate agent exerts its effects on the cardiac cell anti-apoptotic activity of the molecule via a third agent (e.g., a messenger molecule, a receptor, etc.). In certain embodiments, the control is cardiac cell anti-apoptotic activity of the molecule measured in the absence of the candidate agent. Assaying methods and candidate agents are as described above in the foregoing embodiments with respect to MIVR-1.

According to still another aspect of the invention, a method of diagnosing a disorder characterized by aberrant expression of a nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof, is provided. The method involves contacting a biological sample isolated from a subject with an agent that specifically binds to the nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof, and determining the interaction between the agent and the nucleic acid molecule or the expression product as a determination of the disorder, wherein the nucleic acid molecule is selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d. In some embodiments, the disorder is a cardiovascular condition selected from the group consisting of myocardial infarction, stroke, arteriosclerosis, and heart failure. In one embodiment, the disorder is cardiac hypertrophy.

In the case where the molecule is a nucleic acid molecule, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or assaying with labeled hybridization probes as exemplified herein. In the case where the molecule is an expression product of the nucleic acid molecule, or a fragment of an expression product of the nucleic acid molecule, such determination can be carried out via any standard immunological assay using, for example, antibodies which bind to any of the polypeptide expression products.

“Aberrant expression” refers to decreased expression (underexpression) or increased expression (overexpression) of any of the foregoing molecules (MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, nucleic acids and/or polypeptides) in comparison with a control (i.e., expression of the same molecule in a healthy or “normal” subject). A “healthy subject”, as used herein, refers to a subject who is not at risk for developing a future cardiovascular condition (see earlier discussion and Harrison’s). Healthy subjects also do not otherwise exhibit symptoms of disease. In other words, such subjects, if examined by a medical

professional, would be characterized as healthy and free of symptoms of a cardiovascular disorder or at risk of developing a cardiovascular disorder.

When the disorder is a cardiovascular condition selected from the group consisting of myocardial infarction, stroke, arteriosclerosis, and heart failure, decreased expression of any of the foregoing molecules in comparison with a control (e.g., a healthy individual) is indicative of the presence of the disorder, or indicative of the risk for developing such disorder in the future.

When the disorder is cardiac hypertrophy, increased expression of any of the foregoing molecules in comparison with a control (e.g., a healthy individual) is indicative of the presence of the disorder, or indicative of the risk for developing such disorder in the future.

The invention also provides novel kits which could be used to measure the levels of the nucleic acids of the invention, or expression products of the invention.

In one embodiment, a kit comprises a package containing an agent that selectively binds to any of the foregoing MIVR-1 isolated nucleic acids, or expression products thereof, and a control for comparing to a measured value of binding of said agent any of the foregoing MIVR-1 isolated nucleic acids or expression products thereof. In some embodiments, the control is a predetermined value for comparing to the measured value. In certain embodiments, the control comprises an epitope of the expression product of any of the foregoing MIVR-1 isolated nucleic acids. In one embodiment, the kit further comprises a second agent that selectively binds to an isolated nucleic acid molecule selected from the group consisting of IEX-1, VDUP-1, BTG-2, TIS-11d, and/or an expression product thereof, and a control for comparing to a measured value of binding of said second agent to said isolated nucleic acid molecule or expression product thereof.

In the case of nucleic acid detection, pairs of primers for amplifying a nucleic acid molecule of the invention can be included. The preferred kits would include controls such as known amounts of nucleic acid probes, epitopes (such as IEX-1, VDUP-1, BTG-2, TIS-11d expression products) or anti-epitope antibodies, as well as instructions or other printed material. In certain embodiments the printed material can characterize risk of developing a cardiovascular condition based upon the outcome of the assay. The reagents may be packaged in containers and/or coated on wells in predetermined amounts, and the kits may include standard materials such as labeled immunological reagents (such as labeled anti-IgG antibodies) and the like. One kit is a packaged polystyrene microtiter plate coated with

MIVR-1 protein and a container containing labeled anti-human IgG antibodies. A well of the plate is contacted with, for example, a biological fluid, washed and then contacted with the anti-IgG antibody. The label is then detected. A kit embodying features of the present invention, generally designated by the numeral 11, is illustrated in Figure 1. Kit 11 is comprised of the following major elements: packaging 15, an agent of the invention 17, a control agent 19 and instructions 21. Packaging 15 is a box-like structure for holding a vial (or number of vials) containing an agent of the invention 17, a vial (or number of vials) containing a control agent 19, and instructions 21. Individuals skilled in the art can readily modify packaging 15 to suit individual needs.

According to another aspect of the invention, a method for treating cardiac hypertrophy, is provided. The method involves administering to a subject in need of such treatment an agent that increases cardiac cell-death, in an amount effective to treat cardiac hypertrophy in the subject, wherein the agent that increases cardiac cell-death is an inhibitor of a nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, or an expression product thereof.

Types of inhibitors of nucleic acid molecules or expression products thereof, are well known in the art. These include antisense oligonucleotides and nucleotides, promoter decoys, and dominant negatives, that can be used to downregulate expression of the desired molecule.

As used herein, "downregulating expression" refers to inhibiting (i.e., reducing to a detectable extent) replication, transcription, and/or translation of a nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, or an expression product thereof, since inhibition of any of these processes results in a decrease in the concentration/amount of the polypeptide encoded by the gene. The term also refers to inhibition of post-translational modifications on the polypeptide (e.g., in its phosphorylation), since inhibition of such modifications may also prevent proper expression (i.e., expression as in a wild type cell) of the encoded polypeptide. The term also refers to an increase in, or facilitation of, polypeptide degradation (e.g., *via* increased ubiquitination). Polypeptide turnover can be determined using methods well known in the art and described elsewhere herein. The inhibition of gene expression can be directly determined by detecting a decrease in the level of mRNA for the gene, or the level of protein expression of the gene, using any suitable means known to the art, such as nucleic acid hybridization or antibody detection methods, respectively. Inhibition of gene expression can also be determined indirectly by detecting a change in cardiac cell anti-apoptotic activity of the molecule as a whole.

The invention also embraces methods for treating a cardiovascular condition. In some embodiments, the method involves administering to a subject in need of such treatment a molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, in an amount effective to treat the cardiovascular condition. In certain embodiments, the method involves administering to a subject in need of such treatment an agent that modulates expression of any of the foregoing molecules (MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d), in an amount effective to treat the cardiovascular condition.

“Agents that modulate expression” of a nucleic acid or a polypeptide, as used herein, are known in the art, and refer to sense and antisense nucleic acids, dominant negative nucleic acids, antibodies to the polypeptides, and the like. Any agents that modulate expression of a molecule (and as described herein, modulate its activity), are useful according to the invention.

According to a further aspect of the invention, a method of treating apoptotic cell-death of a cardiac cell in a subject, is provided. The method involves administering to a subject in need of such treatment an agent that modulates expression of a molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, in an effective amount to inhibit apoptotic cell-death of the cardiac cell in the subject.

In certain embodiments, the molecule is a nucleic acid. In some embodiments the nucleic acid is operatively coupled to a gene expression sequence which directs the expression of the nucleic acid molecule within a eukaryotic cell such as a cardiomyocyte and/or a vascular endothelial cell (including a smooth muscle cell). The “gene expression sequence” is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the nucleic acid to which it is operably linked. The gene expression sequence may, for example, be a mammalian or viral promoter, such as a constitutive or inducible promoter. Constitutive mammalian promoters include, but are not limited to, the promoters for the following genes: hypoxanthine phosphoribosyl transferase (HPTR), adenosine deaminase, pyruvate kinase, α -actin promoter and other constitutive promoters. Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from the simian virus, papilloma virus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus, cytomegalovirus, the long terminal repeats (LTR) of moloney leukemia virus and other retroviruses, and the thymidine kinase promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art. The promoters useful as gene

expression sequences of the invention also include inducible promoters. Inducible promoters are activated in the presence of an inducing agent. For example, the metallothionein promoter is activated to increase transcription and translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

5 In general, the gene expression sequence shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined nucleic acid.
10 The gene expression sequences optionally includes enhancer sequences or upstream activator sequences as desired.

Preferably, any of the nucleic acid molecules of the invention (e.g., MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d) is linked to a gene expression sequence which permits expression of the nucleic acid molecule in a cell such as a cardiomyocyte and/or a vascular
15 endothelial cell (including a smooth muscle cell). More preferably, the gene expression sequence permits expression of the nucleic acid molecule in a cell (such as a cardiomyocyte and/or a vascular endothelial cell) and does not permit expression of the molecule in a cell selected from the group consisting of a neuronal cell, a fibroblasts and a cell of hematopoietic origin. A sequence which permits expression of the nucleic acid molecule in a cell such as
20 a cardiomyocyte and/or a vascular endothelial cell, is one which is selectively active in such a cell type, thereby causing expression of the nucleic acid molecule in these cells. The cardiac myosin heavy chain gene promoter, for example, can be used to express any of the foregoing nucleic acid molecules of the invention in a cardiomyocyte; and the von Willebrand factor gene promoter, for example, can be used to express a nucleic acid molecule in a vascular
25 endothelial cell. Those of ordinary skill in the art will be able to easily identify alternative promoters that are capable of expressing a nucleic acid molecule in any of the preferred cells of the invention.

The nucleic acid sequence and the gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or
30 translation of the nucleic acid coding sequence (e.g, in the case of MIVR-1, SEQ ID NO. 3) under the influence or control of the gene expression sequence. If it is desired that the nucleic acid sequence be translated into a functional protein, two DNA sequences are said to be operably linked if induction of a promoter in the 5' gene expression sequence results in the

transcription of the nucleic acid sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the nucleic acid sequence, and/or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to a nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that nucleic acid sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The molecules of the invention can be delivered to the preferred cell types of the invention alone or in association with a vector. In its broadest sense, a "vector" is any vehicle capable of facilitating: (1) delivery of a molecule to a target cell and/or (2) uptake of the molecule by a target cell. Preferably, the vectors transport the molecule into the target cell with reduced degradation relative to the extent of degradation that would result in the absence of the vector. Optionally, a "targeting ligand" can be attached to the vector to selectively deliver the vector to a cell which expresses on its surface the cognate receptor for the targeting ligand. In this manner, the vector (containing a nucleic acid or a protein) can be selectively delivered to a cardiomyocyte cell in, e.g., the myocardium. Methodologies for targeting include conjugates, such as those described in U.S. Patent 5,391,723 to Priest. Another example of a well-known targeting vehicle is a liposome. Liposomes are commercially available from Gibco BRL. Numerous methods are published for making targeted liposomes. Preferably, the molecules of the invention are targeted for delivery to cardiomyocytes, and/or vascular endothelial cells.

In general, the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the nucleic acid sequences of the invention, and additional nucleic acid fragments (e.g., enhancers, promoters) which can be attached to the nucleic acid sequences of the invention. Viral vectors are a preferred type of vector and include, but are not limited to, nucleic acid sequences from the following viruses: adenovirus; adeno-associated virus; retrovirus, such as moloney murine leukemia virus; harvey murine sarcoma virus; murine mammary tumor virus; rouse sarcoma virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus. One can readily employ other vectors not named but known in the art.

A particularly preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus is capable of infecting a wide range of cell types and species and can be engineered to be replication-deficient. It further has advantages, such as heat and lipid solvent stability, high transduction frequencies in cells of diverse lineages, including hematopoietic cells, and lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, the adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression. In addition, wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

In general, other preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Adenoviruses and retroviruses have been approved for human gene therapy trials. In general, the retroviruses are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., "Gene Transfer and Expression, A Laboratory Manual," W.H. Freeman C.O., New York (1990) and Murry, E.J. Ed. "Methods in Molecular Biology," vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

Another preferred retroviral vector is the vector derived from the moloney murine leukemia virus, as described in Nabel, E.G., et al., *Science*, 1990, 249:1285-1288. These vectors reportedly were effective for the delivery of genes to all three layers of the arterial wall, including the media. Other preferred vectors are disclosed in Flugelman, et al., *Circulation*, 1992, 85:1110-1117. Additional vectors that are useful for delivering molecules of the invention are described in U.S. Patent No. 5,674,722 by Mulligan, et. al.

In addition to the foregoing vectors, other delivery methods may be used to deliver a molecule of the invention to a cell such as a cardiomyocyte and/or a vascular endothelial cell, and facilitate uptake thereby.

A preferred such delivery method of the invention is a colloidal dispersion system. Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a liposome. Liposomes are artificial membrane vessels which are useful as a delivery vector *in vivo* or *in vitro*. It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2 - 4.0 μm can encapsulate large macromolecules. RNA, DNA, and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., *Trends Biochem. Sci.*, 1981, 6:77). In order for a liposome to be an efficient gene transfer vector, one or more of the following characteristics should be present: (1) encapsulation of the gene of interest at high efficiency with retention of biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information.

Liposomes may be targeted to a particular tissue, such as the myocardium or the vascular cell wall, by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein. Ligands which may be useful for targeting a liposome to the vascular wall include, but are not limited to the viral coat protein of the Hemagglutinating virus of Japan. Additionally, the vector may be coupled to a nuclear targeting peptide, which will direct the nucleic acid to the nucleus of the host cell.

Liposomes are commercially available from Gibco BRL, for example, as LIPOFECTIN™ and LIPOFECTACE™, which are formed of cationic lipids such as N-[1-(2, 3 dioleyloxy)-propyl]-N, N, N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many publications. Liposomes also have been reviewed by Gregoriadis, G. in *Trends in Biotechnology*, V. 3, p. 235-241 (1985). Novel liposomes for the intracellular delivery of macromolecules, including nucleic acids, are also described in PCT International application no. PCT/US96/07572 (Publication No. WO 96/40060, entitled "Intracellular Delivery of Macromolecules").

In one particular embodiment, the preferred vehicle is a biocompatible micro particle or implant that is suitable for implantation into the mammalian recipient. Exemplary

bioerodible implants that are useful in accordance with this method are described in PCT International application no. PCT/US/03307 (Publication No. WO 95/24929, entitled "Polymeric Gene Delivery System", claiming priority to U.S. patent application serial no. 213,668, filed March 15, 1994). PCT/US/0307 describes a biocompatible, preferably
5 biodegradable polymeric matrix for containing an exogenous gene under the control of an appropriate promoter. The polymeric matrix is used to achieve sustained release of the exogenous gene in the patient. In accordance with the instant invention, the nucleic acids described herein are encapsulated or dispersed within the biocompatible, preferably biodegradable polymeric matrix disclosed in PCT/US/03307. The polymeric matrix
10 preferably is in the form of a micro particle such as a micro sphere (wherein a nucleic acid is dispersed throughout a solid polymeric matrix) or a microcapsule (wherein a nucleic acid is stored in the core of a polymeric shell). Other forms of the polymeric matrix for containing the nucleic acids of the invention include films, coatings, gels, implants, and stents. The size and composition of the polymeric matrix device is selected to result in favorable release
15 kinetics in the tissue into which the matrix device is implanted. The size of the polymeric matrix device further is selected according to the method of delivery which is to be used, typically injection into a tissue or administration of a suspension by aerosol into the nasal and/or pulmonary areas. The polymeric matrix composition can be selected to have both favorable degradation rates and also to be formed of a material which is bioadhesive, to
20 further increase the effectiveness of transfer when the device is administered to a vascular surface. The matrix composition also can be selected not to degrade, but rather, to release by diffusion over an extended period of time.

Both non-biodegradable and biodegradable polymeric matrices can be used to deliver the nucleic acids of the invention to the subject. Biodegradable matrices are preferred. Such
25 polymers may be natural or synthetic polymers. Synthetic polymers are preferred. The polymer is selected based on the period of time over which release is desired, generally in the order of a few hours to a year or longer. Typically, release over a period ranging from between a few hours and three to twelve months is most desirable. The polymer optionally is in the form of a hydrogel that can absorb up to about 90% of its weight in water and further,
30 optionally is cross-linked with multi-valent ions or other polymers.

In general, the nucleic acids of the invention are delivered using the bioerodible implant by way of diffusion, or more preferably, by degradation of the polymeric matrix. Exemplary synthetic polymers which can be used to form the biodegradable delivery system

include: polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terephthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, poly-vinyl halides, polyvinylpyrrolidone, polyglycolides, polysiloxanes, polyurethanes and co-polymers thereof, alkyl cellulose, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, polymers of acrylic and methacrylic esters, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxy-propyl methyl cellulose, hydroxybutyl methyl cellulose, cellulose acetate, cellulose propionate, cellulose acetate butyrate, cellulose acetate phthalate, carboxylethyl cellulose, cellulose triacetate, cellulose sulphate sodium salt, poly(methyl methacrylate), poly(ethyl methacrylate), poly(butylmethacrylate), poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), polyethylene, polypropylene, poly(ethylene glycol), poly(ethylene oxide), poly(ethylene terephthalate), poly(vinyl alcohols), polyvinyl acetate, poly vinyl chloride, polystyrene and polyvinylpyrrolidone.

Examples of non-biodegradable polymers include ethylene vinyl acetate, poly(meth) acrylic acid, polyamides, copolymers and mixtures thereof.

Examples of biodegradable polymers include synthetic polymers such as polymers of lactic acid and glycolic acid, polyanhydrides, poly(ortho)esters, polyurethanes, poly(butic acid), poly(valeric acid), and poly(lactide-cocaprolactone), and natural polymers such as alginate and other polysaccharides including dextran and cellulose, collagen, chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art), albumin and other hydrophilic proteins, zein and other prolamines and hydrophobic proteins, copolymers and mixtures thereof. In general, these materials degrade either by enzymatic hydrolysis or exposure to water *in vivo*, by surface or bulk erosion.

Bioadhesive polymers of particular interest include bioerodible hydrogels described by H.S. Sawhney, C.P. Pathak and J.A. Hubell in *Macromolecules*, 1993, 26, 581-587, the teachings of which are incorporated herein, polyhyaluronic acids, casein, gelatin, glutin, polyanhydrides, polyacrylic acid, alginate, chitosan, poly(methyl methacrylates), poly(ethyl methacrylates), poly(butylmethacrylate), poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecyl acrylate). Thus, the invention provides a composition of the above-described

molecules of the invention for use as a medicament, methods for preparing the medicament and methods for the sustained release of the medicament *in vivo*.

5 Compaction agents also can be used in combination with a vector of the invention. A “compaction agent”, as used herein, refers to an agent, such as a histone, that neutralizes the negative charges on the nucleic acid and thereby permits compaction of the nucleic acid into a fine granule. Compaction of the nucleic acid facilitates the uptake of the nucleic acid by the target cell. The compaction agents can be used alone, i.e., to deliver an isolated nucleic acid of the invention in a form that is more efficiently taken up by the cell or, more preferably, in combination with one or more of the above-described vectors.

10 Other exemplary compositions that can be used to facilitate uptake by a target cell of the nucleic acids of the invention include calcium phosphate and other chemical mediators of intracellular transport, microinjection compositions, electroporation and homologous recombination compositions (e.g., for integrating a nucleic acid into a preselected location within the target cell chromosome).

15 The invention also provides methods for the diagnosis and therapy of vascular and cardiovascular disorders. Such disorders include myocardial infarction, stroke, arteriosclerosis, heart failure, and cardiac hypertrophy.

20 The methods of the invention are useful in both the acute and the prophylactic treatment of any of the foregoing conditions. As used herein, an acute treatment refers to the treatment of subjects having a particular condition. Prophylactic treatment refers to the treatment of subjects at risk of having the condition, but not presently having or experiencing the symptoms of the condition.

25 In its broadest sense, the terms “treatment” or “to treat” refer to both acute and prophylactic treatments. If the subject in need of treatment is experiencing a condition (or has or is having a particular condition), then treating the condition refers to ameliorating, reducing or eliminating the condition or one or more symptoms arising from the condition. In some preferred embodiments, treating the condition refers to ameliorating, reducing or eliminating a specific symptom or a specific subset of symptoms associated with the condition. If the subject in need of treatment is one who is at risk of having a condition, then treating the subject refers to reducing the risk of the subject having the condition.

30 Stroke (also referred to herein as ischemic stroke and/or cerebrovascular ischemia) is often cited as the third most common cause of death in the industrial world, ranking behind ischemic heart disease and cancer. Strokes are responsible for about 300,000 deaths annually

in the United States and are a leading cause of hospital admissions and long-term disabilities. Accordingly, the socioeconomic impact of stroke and its attendant burden on society is practically immeasurable.

5 “Stroke” is defined by the World Health Organization as a rapidly developing clinical sign of focal or global disturbance of cerebral function with symptoms lasting at least 24 hours. Strokes are also implicated in deaths where there is no apparent cause other than an effect of vascular origin.

10 Strokes are typically caused by blockages or occlusions of the blood vessels to the brain or within the brain. With complete occlusion, arrest of cerebral circulation causes cessation of neuronal electrical activity within seconds. Within a few minutes after the deterioration of the energy state and ion homeostasis, depletion of high energy phosphates, membrane ion pump failure, efflux of cellular potassium, influx of sodium chloride and water, and membrane depolarization occur. If the occlusion persists for more than five to ten minutes, irreversible damage results. With incomplete ischemia, however, the outcome is
15 difficult to evaluate and depends largely on residual perfusion and the availability of oxygen. After a thrombotic occlusion of a cerebral vessel, ischemia is rarely total. Some residual perfusion usually persists in the ischemic area, depending on collateral blood flow and local perfusion pressure.

20 Cerebral blood flow can compensate for drops in mean arterial blood pressure from 90 to 60 mm Hg by autoregulation. This phenomenon involves dilatation of downstream resistant vessels. Below the lower level of autoregulation (about 60 mm Hg), vasodilatation is inadequate and the cerebral blood flow falls. The brain, however, has perfusion reserves that can compensate for the fall in cerebral blood flow. This reserve exists because under normal conditions only about 35% of the oxygen delivered by the blood is extracted.
25 Therefore, increased oxygen extraction can take place, provided that normoxia and normocapnea exist. When distal blood pressure falls below approximately 30 mm Hg, the two compensatory mechanisms (autoregulation and perfusion reserve) are inadequate to prevent failure of oxygen delivery.

30 As blood flow drops below the ischemic threshold of 23 ml/100g/minute, symptoms of tissue hypoxia develop. Severe ischemia may be lethal. When the ischemia is moderate, it will result in “penumbra.” In the neurological context, penumbra refers to a zone of brain tissue with moderate ischemia and paralyzed neuronal function, which is reversible with restoration of adequate perfusion. The penumbra forms a zone of collaterally perfused tissue

surrounding a core of severe ischemia in which an infarct has developed. In other words, the penumbra is the tissue area that can be saved, and is essentially in a state between life and death.

Although an ischemic event can occur anywhere in the vascular system, the carotid
5 artery bifurcation and the origin of the internal carotid artery are the most frequent sites for thrombotic occlusions of cerebral blood vessels, which result in cerebral ischemia. The symptoms of reduced blood flow due to stenosis or thrombosis are similar to those caused by middle cerebral artery disease. Flow through the ophthalmic artery is often affected sufficiently to produce amaurosis fugax or transient monocular blindness. Severe bilateral
10 internal carotid artery stenosis may result in cerebral hemispheric hypoperfusion. This manifests with acute headache ipsilateral to the acutely ischemic hemisphere. Occlusions or decrease of the blood flow with resulting ischemia of one anterior cerebral artery distal to the anterior communicating artery produces motor and cortical sensory symptoms in the contralateral leg and, less often, proximal arm. Other manifestations of occlusions or
15 underperfusion of the anterior cerebral artery include gait ataxia and sometimes urinary incontinence due to damage to the parasagittal frontal lobe. Language disturbances manifested as decreased spontaneous speech may accompany generalized depression of psychomotor activity.

Most ischemic strokes involve portions or all of the territory of the middle cerebral
20 artery with emboli from the heart or extracranial carotid arteries accounting for most cases. Emboli may occlude the main stem of the middle cerebral artery, but more frequently produce distal occlusion of either the superior or the inferior branch. Occlusions of the superior branch cause weakness and sensory loss that are greatest in the face and arm. Occlusions of the posterior cerebral artery distal to its penetrating branches cause complete contralateral loss
25 of vision. Difficulty in reading (dyslexia) and in performing calculations (dyscalculia) may follow ischemia of the dominant posterior cerebral artery. Proximal occlusion of the posterior cerebral artery causes ischemia of the branches penetrating to calamic and limbic structures. The clinical results are hemisensory disturbances that may chronically change to intractable pain of the defective side (thalamic pain).

30 A subject having a stroke is so diagnosed by symptoms experienced and/or by a physical examination including interventional and non-interventional diagnostic tools such as CT and MR imaging. The methods of the invention are advantageous for the treatment of various clinical presentations of stroke subjects. A subject having a stroke may present with

one or more of the following symptoms: paralysis, weakness, decreased sensation and/or vision, numbness, tingling, aphasia (e.g., inability to speak or slurred speech, difficulty reading or writing), agnosia (i.e., inability to recognize or identify sensory stimuli), loss of memory, co-ordination difficulties, lethargy, sleepiness or unconsciousness, lack of bladder or
5 bowel control and cognitive decline (e.g., dementia, limited attention span, inability to concentrate). Using medical imaging techniques, it may be possible to identify a subject having a stroke as one having an infarct or one having hemorrhage in the brain.

An important embodiment of the invention is treatment of a subject with an abnormally elevated risk of an ischemic stroke. As used herein, subjects having an
10 abnormally elevated risk of an ischemic stroke are a category determined according to conventional medical practice (see earlier discussion); such subjects may also be identified in conventional medical practice as having known risk factors for stroke or having increased risk of cerebrovascular events. This category includes, for example, subjects which are having elected vascular surgery. Typically, the risk factors associated with cardiac disease are the
15 same as are associated with stroke. The primary risk factors include hypertension, hypercholesterolemia, and smoking. Atrial fibrillation or recent myocardial infarction are also important risk factors. In addition, modified levels of expression of a nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, or an expression product thereof, are also, according to the present invention, important
20 risk factors.

As used herein, subjects having an abnormally elevated risk of an ischemic stroke also include individuals undergoing surgical or diagnostic procedures which risk release of emboli, lowering of blood pressure or decrease in blood flow to the brain, such as carotid endarterectomy, brain angiography, neurosurgical procedures in which blood vessels are
25 compressed or occluded, cardiac catheterization, angioplasty, including balloon angioplasty, coronary by-pass surgery, or similar procedures. Subjects having an abnormally elevated risk of an ischemic stroke also include individuals having any cardiac condition that may lead to decreased blood flow to the brain, such as atrial fibrillation, ventricular tachycardia, dilated cardiomyopathy and other cardiac conditions requiring anticoagulation. Subjects having an
30 abnormally elevated risk of an ischemic stroke also include individuals having conditions including arteriopathy or brain vasculitis, such as that caused by lupus, congenital diseases of blood vessels, such as CADASIL syndrome, or migraine, especially prolonged episodes.

The treatment of stroke can be for patients who have experienced a stroke or can be a prophylactic treatment. Short term prophylactic treatment is indicated for subjects having surgical or diagnostic procedures which risk release of emboli, lowering of blood pressure or decrease in blood flow to the brain, to reduce the injury due to any ischemic event that occurs
5 as a consequence of the procedure. Longer term or chronic prophylactic treatment is indicated for subjects having cardiac conditions that may lead to decreased blood flow to the brain, or conditions directly affecting brain vasculature. If prophylactic, then the treatment is for subjects having an abnormally elevated risk of an ischemic stroke, as described above. If the subject has experienced a stroke, then the treatment can include acute treatment. Acute
10 treatment for stroke subjects means administration of an agent of the invention at the onset of symptoms of the condition or within 48 hours of the onset, preferably within 24 hours, more preferably within 12 hours, more preferably within 6 hours, and even more preferably within 3 hours of the onset of symptoms of the condition.

Criteria for defining hypercholesterolemic and/or hypertriglyceridemic subjects are well known in the art (see, e.g., Harrison's Principles of Experimental Medicine, 13th Edition, McGraw-Hill, Inc., N.Y.- hereinafter "Harrison's). Hypercholesterolemic subjects and hypertriglyceridemic subjects are associated with increased incidence of premature coronary heart disease. A hypercholesterolemic subject has an LDL level of >160 mg/dL or >130 mg/dL and at least two risk factors selected from the group consisting of male gender,
20 family history of premature coronary heart disease, cigarette smoking (more than 10 per day), hypertension, low HDL (<35 mg/dL), diabetes mellitus, hyperinsulinemia, abdominal obesity, high lipoprotein (a), and personal history of cerebrovascular disease or occlusive peripheral vascular disease. A hypertriglyceridemic subject has a triglyceride (TG) level of >250 mg/dL. Thus, a hyperlipidemic subject is defined as one whose cholesterol and triglyceride
25 levels equal or exceed the limits set as described above for both the hypercholesterolemic and hypertriglyceridemic subjects.

"Myocardial infarction" is a focus of necrosis resulting from inadequate perfusion of the cardiac tissue. Myocardial infarction generally occurs with the abrupt decrease in coronary blood flow that follows a thrombotic occlusion of a coronary artery previously
30 narrowed by atherosclerosis. Generally, infarction occurs when an atherosclerotic plaque fissures, ruptures, or ulcerates, and a mural thrombus forms leading to coronary artery occlusion.

The diagnosis of myocardial infarction in a subject determines the need for treating the subject according to the methods of the invention. A number of laboratory tests, well known in the art, are described, for example, in Harrison's: Principles of Internal Medicine (McGraw Hill, Inc., New York). Generally, the tests may be divided into four main categories: (1) nonspecific indexes of tissue necrosis and inflammation, (2) electrocardiograms, (3) serum enzyme changes (e.g., creatine phosphokinase levels), and (4) cardiac imaging. A person of ordinary skill in the art could easily apply any of the foregoing tests to determine when a subject is at risk, is suffering, or has suffered, a myocardial infarction. In addition, decreased levels of expression of a nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, or an expression product thereof, are also, according to the present invention, important risk factors. A positively identified subject would thus benefit from a method of treatment of the invention.

According to the invention, the method involves administering to a subject having a myocardial infarction any of the foregoing molecules (MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d) in an amount effective to treat the cardiovascular disorder in the subject. By "having a myocardial infarction" it is meant that the subject is at risk of developing, is currently having, or has suffered a myocardial infarction. It is believed that immediate administration of the molecule would greatly benefit the subject by inhibiting apoptotic cell-death of cardiomyocytes (the cells mostly affected by the infarct) prior to, or following the infarct. By "immediate" it is meant that administration occurs before (if it is diagnosed in time), or within 48 hours from the myocardial infarct, although administration up to 14 days after the episode may also be beneficial to the subject.

Another important embodiment of the invention is the treatment of ischemic injury resulting from arteriosclerosis. Arteriosclerosis is a term used to describe a thickening and hardening of the arterial wall. It is believed to be responsible for the majority of deaths in the United States and in most westernized societies. Atherosclerosis is one type of arteriosclerosis that is believed to be the cause of most coronary artery disease, aortic aneurysm and arterial disease of the lower extremities (including peripheral vascular arteriopathy), as well as contributing to cerebrovascular disease. Atherosclerosis is the leading cause of death in the United States.

A normal artery typically is lined on its inner-side only by a single layer of endothelial cells, the intima. The intima overlays the media, which contains only a single cell type, the smooth muscle cell. The outer-most layer of the artery is the adventitia. With aging, there is

a continuous increase in the thickness of the intima, believed to result in part from migration and proliferation of smooth muscle cells from the media. A similar increase in the thickness of the intima also occurs as a result of various traumatic events or interventions, such as occurs when, for example, a balloon dilatation procedure causes injury to the vessel wall. The invention is used in connection with treating ischemic injury resulting from arteriosclerotic conditions. An arteriosclerotic condition as used herein means classical atherosclerosis, accelerated atherosclerosis, atherosclerosis lesions and any other arteriosclerotic conditions characterized by undesirable endothelial and/or vascular smooth muscle cell proliferation, including vascular complications of diabetes.

Another important embodiment of the invention is the treatment of heart failure. Heart failure is a clinical syndrome of diverse etiologies linked by the common denominator of impaired heart pumping and is characterized by the failure of the heart to pump blood commensurate with the requirements of the metabolizing tissues, or to do so only from an elevating filling pressure.

Another important embodiment of the invention is the treatment of cardiac hypertrophy. This condition is typically characterized by left ventricular hypertrophy, usually of a nondilated chamber, without obvious antecedent cause. Current methods of diagnosis include the electrocardiogram and the echocardiogram. Many patients, however, are asymptomatic and may be relatives of patients with known disease. Unfortunately, the first manifestation of the disease may be sudden death, frequently occurring in children and young adults, often during or after physical exertion.

Agents for reducing the risk of or treating a cardiovascular disorder include those selected from the group consisting of anti-inflammatory agents, anti-thrombotic agents, anti-platelet agents, fibrinolytic agents, lipid reducing agents, direct thrombin inhibitors, glycoprotein II b/IIIa receptor inhibitors, agents that bind to cellular adhesion molecules and inhibit the ability of white blood cells to attach to such molecules (e.g. anti-cellular adhesion molecule antibodies), calcium channel blockers, beta-adrenergic receptor blockers, cyclooxygenase-2 inhibitors, angiotensin system inhibitors, and/or any combinations thereof.

One preferred agent is aspirin.

The mode of administration and dosage of a therapeutic agent of the invention will vary with the particular stage of the condition being treated, the age and physical condition of the subject being treated, the duration of the treatment, the nature of the concurrent therapy (if

any), the specific route of administration, and the like factors within the knowledge and expertise of the health practitioner.

As described herein, the agents of the invention are administered in effective amounts to treat any of the foregoing cardiovascular disorders. In general, an effective amount is any amount that can cause a beneficial change in a desired tissue of a subject. Preferably, an effective amount is that amount sufficient to cause a favorable phenotypic change in a particular condition such as a lessening, alleviation or elimination of a symptom or of a condition as a whole.

In general, an effective amount is that amount of a pharmaceutical preparation that alone, or together with further doses, produces the desired response. This may involve only slowing the progression of the condition temporarily, although more preferably, it involves halting the progression of the condition permanently or delaying the onset of or preventing the condition from occurring. This can be monitored by routine methods. Generally, doses of active compounds would be from about 0.01 mg/kg per day to 1000 mg/kg per day. It is expected that doses ranging from 50-500 mg/kg will be suitable, preferably orally and in one or several administrations per day.

Such amounts will depend, of course, on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. Lower doses will result from certain forms of administration, such as intravenous administration. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of compounds. It is preferred generally that a maximum dose be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.

The agents of the invention may be combined, optionally, with a pharmaceutically-acceptable carrier to form a pharmaceutical preparation. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The

term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy. In some aspects, the pharmaceutical preparations comprise an agent of the invention in an amount effective to treat a disorder.

The pharmaceutical preparations may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; or phosphoric acid in a salt. The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens or thimerosal.

A variety of administration routes are available. The particular mode selected will depend, of course, upon the particular drug selected, the severity of the condition being treated and the dosage required for therapeutic efficacy. The methods of the invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral, rectal, topical, nasal, intradermal, transdermal, or parenteral routes. The term "parenteral" includes subcutaneous, intravenous, intramuscular, or infusion. Intravenous or intramuscular routes are not particularly suitable for long-term therapy and prophylaxis. As an example, pharmaceutical compositions for the acute treatment of subjects having a migraine headache may be formulated in a variety of different ways and for a variety of administration modes including tablets, capsules, powders, suppositories, injections and nasal sprays.

The pharmaceutical preparations may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, elixir or an emulsion.

Compositions suitable for parenteral administration conveniently comprise a sterile aqueous preparation of an agent of the invention, which is preferably isotonic with the blood of the recipient. This aqueous preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Formulations suitable for oral, subcutaneous, intravenous, intramuscular, etc. administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.

According to one aspect of the invention, a method for inhibiting apoptotic cell-death of a cell, is provided. The method involves contacting an isolated nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, or an expression product thereof, fragments thereof, with a cell under conditions that permit entry of the nucleic acid molecule (or of an expression product thereof) into the cell, in an amount effective to inhibit apoptotic cell-death of the cell.

The term "permit entry" of a molecule into a cell according to the invention has the following meanings depending upon the nature of the molecule. For an isolated nucleic acid it is meant to describe entry of the nucleic acid through the cell membrane and into the cell nucleus, where upon the "nucleic acid transgene" can utilize the cell machinery to produce functional polypeptides encoded by the nucleic acid. By "nucleic acid transgene" it is meant to describe all of the nucleic acids of the invention with or without the associated vectors. For a polypeptide, it is meant to describe entry of the polypeptide through the cell membrane and into the cell cytoplasm, and if necessary, utilization of the cell cytoplasmic machinery to functionally modify the polypeptide (e.g., to an active form).

Various techniques may be employed for introducing nucleic acids of the invention into cells, depending on whether the nucleic acids are introduced *in vitro* or *in vivo* in a host. Such techniques include transfection of nucleic acid-CaPO₄ precipitates, transfection of nucleic acids associated with DEAE, transfection with a retrovirus including the nucleic acid of interest, liposome mediated transfection, and the like. For certain uses, it is preferred to

target the nucleic acid to particular cells. In such instances, a vehicle used for delivering a nucleic acid of the invention into a cell (e.g., a retrovirus, or other virus; a liposome) can have a targeting molecule attached thereto. For example, a molecule such as an antibody specific for a surface membrane protein on the target cell or a ligand for a receptor on the target cell
5 can be bound to or incorporated within the nucleic acid delivery vehicle. For example, where liposomes are employed to deliver the nucleic acids of the invention, proteins which bind to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation for targeting and/or to facilitate uptake. Such proteins include capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo
10 internalization in cycling, proteins that target intracellular localization and enhance intracellular half life, and the like. Polymeric delivery systems also have been used successfully to deliver nucleic acids into cells, as is known by those skilled in the art. Such systems even permit oral delivery of nucleic acids.

Other delivery systems can include time-release, delayed release or sustained release
15 delivery systems. Such systems can avoid repeated administrations of an agent of the present invention, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides.
20 Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Patent 5,075,109. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono- di- and tri-glycerides; hydrogel release systems; silyastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients;
25 partially fused implants; and the like. Specific examples include, but are not limited to: (a) erosional systems in which an agent of the invention is contained in a form within a matrix such as those described in U.S. Patent Nos. 4,452,775, 4,675,189, and 5,736,152, and (b) diffusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Patent Nos. 3,854,480, 5,133,974 and 5,407,686. In
30 addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation.

Use of a long-term sustained release implant may be desirable. Long-term release, as used herein, means that the implant is constructed and arranged to deliver therapeutic levels of

the active ingredient for at least 30 days, and preferably 60 days. Long-term sustained release implants are well-known to those of ordinary skill in the art and include some of the release systems described above. Specific examples include, but are not limited to, long-term sustained release implants described in U.S. Patent No. 4,748,024, and Canadian Patent No. 1330939.

The invention also involves the administration, and in some embodiments co-administration, of agents other than the molecules of the invention (MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, nucleic acids and polypeptides, and/or fragments thereof) that when administered in effective amounts can act cooperatively, additively or synergistically with a molecule of the invention to: (i) modulate cardiac cell anti-apoptotic activity, and (ii) treat any of the conditions in which cardiac cell anti-apoptotic activity of a molecule of the invention is involved. Agents other than the molecules of the invention include anti-inflammatory agents, anti-thrombotic agents, anti-coagulants, anti-platelet agents, fibrinolytic agents, lipid reducing agents, direct thrombin inhibitors, glycoprotein IIb/IIIa receptor inhibitors, agents that bind to cellular adhesion molecules and inhibit the ability of white blood cells to attach to such molecules, calcium channel blockers, beta-adrenergic receptor blockers, cyclooxygenase-2 inhibitors, angiotensin system inhibitors, anti-hypertensive agents, and/or combinations thereof.

“Anti-inflammatory” agents include Alclofenac; Alclometasone Dipropionate; Algestone Acetonide; Alpha Amylase; Amcinafal; Amcinafide; Amfenac Sodium; Amiprilose Hydrochloride; Anakinra; Anirolac; Anitrazafen; Apazone; Balsalazide Disodium; Bendazac; Benoxaprofen; Benzydamine Hydrochloride; Bromelains; Broperamole; Budesonide; Carprofen; Cicloprofen; Cintazone; Cliprofen; Clobetasol Propionate; Clobetasone Butyrate; Clopirac; Cloticasone Propionate; Cormethasone Acetate; Cortodoxone; Deflazacort; Desonide; Desoximetasone; Dexamethasone Dipropionate; Diclofenac Potassium; Diclofenac Sodium; Diflorasone Diacetate; Diflumidone Sodium; Diflunisal; Difluprednate; Diftalone; Dimethyl Sulfoxide; Drocinonide; Endryson; Enlimomab; Enolicam Sodium; Epirizole; Etodolac; Etofenamate; Felbinac; Fenamole; Fenbufen; Fenclofenac; Fenclorac; Fendosal; Fenpipalone; Fentiazac; Flazalone; Fluazacort; Flufenamic Acid; Flumizole; Flunisolid Acetate; Flunixin; Flunixin Meglumine; Fluocortin Butyl; Fluorometholone Acetate; Fluquazone; Flurbiprofen; Fluretofen; Fluticasone Propionate; Furaprofen; Furobufen; Halcinonide; Halobetasol Propionate; Halopredone Acetate; Ibufenac; Ibuprofen; Ibuprofen Aluminum; Ibuprofen Piconol; Ilonidap; Indomethacin; Indomethacin Sodium; Indoprofen;

Indoxole; Intrazole; Isoflupredone Acetate; Isoxepac; Isoxicam; Ketoprofen; Lofemizole Hydrochloride; Lornoxicam; Loteprednol Etabonate; Meclofenamate Sodium; Meclofenamic Acid; Meclorisona Dibutyrate; Mefenamic Acid; Mesalamine; Meseclazone; Methylprednisolone Suleptanate; Morniflumate; Nabumetone; Naproxen; Naproxen Sodium; 5 Naproxol; Nimazone; Olsalazine Sodium; Orgotein; Orpanoxin; Oxaprozin; Oxyphenbutazone; Paranyline Hydrochloride; Pentosan Polysulfate Sodium; Phenbutazone Sodium Glycerate; Pirfenidone; Piroxicam; Piroxicam Cinnamate; Piroxicam Olamine; Pirprofen; Prednazate; Prifelone; Prodolic Acid; Proquazone; Proxazole; Proxazole Citrate; Rimexolone; Romazarit; Salcolex; Salsalate; Salicylates; Sanguinarium Chloride; 10 Seclazone; Sermetacin; Sudoxicam; Sulindac; Suprofen; Talmetacin; Talniflumate; Talosalate; Tebufelone; Tenidap; Tenidap Sodium; Tenoxicam; Tesicam; Tesimide; Tetrydamine; Tiopinac; Tixocortol Pivalate; Tolmetin; Tolmetin Sodium; Triclonide; Triflumidate; Zidometacin; Glucocorticoids; Zomepirac Sodium. One preferred anti-inflammatory agent is aspirin.

15 “Anti-thrombotic” and/or “fibrinolytic” agents include Plasminogen (to plasmin via interactions of prekallikrein, kininogens, Factors XII, XIIIa, plasminogen proactivator, and tissue plasminogen activator[TPA]) Streptokinase; Urokinase; Anisoylated Plasminogen-Streptokinase Activator Complex; Pro-Urokinase; (Pro-UK); rTPA (alteplase or activase; r denotes recombinant); rPro-UK; Abbokinase; Eminase; Streptase Anagrelide Hydrochloride; 20 Bivalirudin; Dalteparin Sodium; Danaparoid Sodium; Dazoxiben Hydrochloride; Efgatran Sulfate; Enoxaparin Sodium; Ifetroban; Ifetroban Sodium; Tinzaparin Sodium; retaplastase; Trifenagrel; Warfarin; Dextran.

25 “Anti-platelet” agents include Clopidogrel; Sulfinpyrazone; Aspirin; Dipyridamole; Clofibrate; Pyridinol Carbamate; PGE; Glucagon; Antiserotonin drugs; Caffeine; Theophyllin Pentoxifyllin; Ticlopidine; Anagrelide.

“Lipid reducing” agents include gemfibrozil, cholestyramine, colestipol, nicotinic acid, probucol lovastatin, fluvastatin, simvastatin, atorvastatin, pravastatin, cirivastatin.

“Direct thrombin inhibitors” include hirudin, hirugen, hirulog, agatroban, PPACK, thrombin aptamers.

30 “Glycoprotein IIb/IIIa receptor inhibitors” are both antibodies and non-antibodies, and include but are not limited to ReoPro (abcixamab), lamifiban, tirofiban.

“Calcium channel blockers” are a chemically diverse class of compounds having important therapeutic value in the control of a variety of diseases including several

cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmias (Fleckenstein, *Cir. Res.* v. 52, (suppl. 1), p.13-16 (1983); Fleckenstein, *Experimental Facts and Therapeutic Prospects*, John Wiley, New York (1983); McCall, D., *Curr Pract Cardiol*, v. 10, p. 1-11 (1985)). Calcium channel blockers are a heterogeneous group of drugs that prevent or slow the entry of calcium into cells by regulating cellular calcium channels. (Remington, *The Science and Practice of Pharmacy*, Nineteenth Edition, Mack Publishing Company, Eaton, PA, p.963 (1995)). Most of the currently available calcium channel blockers, and useful according to the present invention, belong to one of three major chemical groups of drugs, the dihydropyridines, such as nifedipine, the phenyl alkyl amines, such as verapamil, and the benzothiazepines, such as diltiazem. Other calcium channel blockers useful according to the invention, include, but are not limited to, amrinone, amlodipine, bencyclane, felodipine, fendiline, flunarizine, isradipine, nicardipine, nimodipine, perhexilene, gallopamil, tiapamil and tiapamil analogues (such as 1993RO-11-2933), phenytoin, barbiturates, and the peptides dynorphin, omega-conotoxin, and omega-agatoxin, and the like and/or pharmaceutically acceptable salts thereof.

“Beta-adrenergic receptor blocking agents” are a class of drugs that antagonize the cardiovascular effects of catecholamines in angina pectoris, hypertension, and cardiac arrhythmias. Beta-adrenergic receptor blockers include, but are not limited to, atenolol, acebutolol, alprenolol, befunolol, betaxolol, bunitrolol, carteolol, celiprolol, hedroxalol, indenolol, labetalol, levobunolol, mepindolol, methypranol, metindol, metoprolol, metrizoranolol, oxprenolol, pindolol, propranolol, practolol, sotalolnadolol, tiprenolol, tomalolol, timolol, bupranolol, penbutolol, trimepranol, 2-(3-(1,1-dimethylethyl)-amino-2-hydroxypropoxy)-3-pyridenecarbonitrilHCl, 1-butylamino-3-(2,5-dichlorophenoxy)-2-propanol, 1-isopropylamino-3-(4-(2-cyclopropylmethoxyethyl)phenoxy)-2-propanol, 3-isopropylamino-1-(7-methylindan-4-yloxy)-2-butanol, 2-(3-t-butylamino-2-hydroxypropylthio)-4-(5-carbamoyl-2-thienyl)thiazol,7-(2-hydroxy-3-t-butylaminpropoxy)phthalide. The above-identified compounds can be used as isomeric mixtures, or in their respective levorotating or dextrorotating form.

Cyclooxygenase-2 (COX-2) is a recently identified form of a cyclooxygenase. “Cyclooxygenase” is an enzyme complex present in most tissues that produces various prostaglandins and thromboxanes from arachidonic acid. Non-steroidal, anti-inflammatory drugs exert most of their anti-inflammatory, analgesic and antipyretic activity and inhibit hormone-induced uterine contractions and certain types of cancer growth through inhibition

of the cyclooxygenase (also known as *prostaglandin G/H synthase* and/or *prostaglandin-endoperoxide synthase*). Initially, only one form of cyclooxygenase was known, the “constitutive enzyme” or cyclooxygenase-1 (COX-1). It and was originally identified in bovine seminal vesicles.

5 Cyclooxygenase-2 (COX-2) has been cloned, sequenced and characterized initially from chicken, murine and human sources (See, e.g., U.S. Patent 5,543,297, issued August 6, 1996 to Cromlish, *et al.*, and assigned to Merck Frosst Canada, Inc., Kirkland, CA, entitled: “Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity”). This enzyme is distinct from the COX-1. COX-2 is rapidly and readily inducible by a number
10 of agents including mitogens, endotoxin, hormones, cytokines and growth factors. As prostaglandins have both physiological and pathological roles, the constitutive enzyme, COX-1, is responsible, in large part, for endogenous basal release of prostaglandins and hence is important in their physiological functions such as the maintenance of gastrointestinal integrity and renal blood flow. By contrast, it is believed that the inducible form, COX-2, is mainly
15 responsible for the pathological effects of prostaglandins where rapid induction of the enzyme would occur in response to such agents as inflammatory agents, hormones, growth factors, and cytokines. Therefore, it is believed that a selective inhibitor of COX-2 has similar anti-inflammatory, antipyretic and analgesic properties to a conventional non-steroidal anti-inflammatory drug, and in addition inhibits hormone-induced uterine contractions and also
20 has potential anti-cancer effects, but with reduced side effects. In particular, such COX-2 inhibitors are believed to have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and possibly a decreased potential to induce asthma attacks in aspirin-sensitive asthmatic subjects, and are therefore useful according to the present invention.

25 A number of selective “COX-2 inhibitors” are known in the art. These include, but are not limited to, COX-2 inhibitors described in U.S. Patent 5,474,995 “Phenyl heterocycles as cox-2 inhibitors”; U.S. Patent 5,521,213 “Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2”; U.S. Patent 5,536,752 “Phenyl heterocycles as COX-2 inhibitors”; U.S. Patent 5,550,142 “Phenyl heterocycles as COX-2 inhibitors”; U.S. Patent 5,552,422 “Aryl
30 substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents”; U.S. Patent 5,604,253 “N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors”; U.S. Patent 5,604,260 “5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2”; U.S. Patent 5,639,780 N-benzyl indol-3-yl butanoic acid derivatives as

cyclooxygenase inhibitors”; U.S. Patent 5,677,318 “Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents”; U.S. Patent 5,691,374 “Diaryl-5-oxygenated-2-(5H)-furanones as COX-2 inhibitors”; U.S. Patent 5,698,584 “3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to COX-2 inhibitors”; U.S. Patent 5,710,140 “Phenyl heterocycles as COX-2 inhibitors”; U.S. Patent 5,733,909 “Diphenyl stilbenes as prodrugs to COX-2 inhibitors”; U.S. Patent 5,789,413 “Alkylated styrenes as prodrugs to COX-2 inhibitors”; U.S. Patent 5,817,700 “Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors”; U.S. Patent 5,849,943 “Stilbene derivatives useful as cyclooxygenase-2 inhibitors”; U.S. Patent 5,861,419 “Substituted pyridines as selective cyclooxygenase-2 inhibitors”; U.S. Patent 5,922,742 “Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors”; U.S. Patent 5,925,631 “Alkylated styrenes as prodrugs to COX-2 inhibitors”; all of which are commonly assigned to Merck Frosst Canada, Inc. (Kirkland, CA). Additional COX-2 inhibitors are also described in U.S. Patent 5,643,933, assigned to G. D. Searle & Co. (Skokie, IL), entitled: “Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors.”

A number of the above-identified COX-2 inhibitors are prodrugs of selective COX-2 inhibitors, and exert their action by conversion *in vivo* to the active and selective COX-2 inhibitors. The active and selective COX-2 inhibitors formed from the above-identified COX-2 inhibitor prodrugs are described in detail in WO 95/00501, published January 5, 1995, WO 95/18799, published July 13, 1995 and U.S. Patent 5,474,995, issued December 12, 1995. Given the teachings of U.S. Patent 5,543,297, entitled: “Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity,” a person of ordinary skill in the art would be able to determine whether an agent is a selective COX-2 inhibitor or a precursor of a COX-2 inhibitor, and therefore part of the present invention.

An “angiotensin system inhibitor” is an agent that interferes with the function, synthesis or catabolism of angiotensin II. These agents include, but are not limited to, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II antagonists, angiotensin II receptor antagonists, agents that activate the catabolism of angiotensin II, and agents that prevent the synthesis of angiotensin I from which angiotensin II is ultimately derived. The renin-angiotensin system is involved in the regulation of hemodynamics and water and electrolyte balance. Factors that lower blood volume, renal perfusion pressure, or the concentration of Na⁺ in plasma tend to activate the system, while factors that increase these parameters tend to suppress its function.

Angiotensin I and angiotensin II are synthesized by the enzymatic renin-angiotensin pathway. The synthetic process is initiated when the enzyme renin acts on angiotensinogen, a pseudoglobulin in blood plasma, to produce the decapeptide angiotensin I. Angiotensin I is converted by angiotensin converting enzyme (ACE) to angiotensin II (angiotensin-[1-8] octapeptide). The latter is an active pressor substance which has been implicated as a causative agent in several forms of hypertension in various mammalian species, e.g., humans.

Angiotensin (renin-angiotensin) system inhibitors are compounds that act to interfere with the production of angiotensin II from angiotensinogen or angiotensin I or interfere with the activity of angiotensin II. Such inhibitors are well known to those of ordinary skill in the art and include compounds that act to inhibit the enzymes involved in the ultimate production of angiotensin II, including renin and ACE. They also include compounds that interfere with the activity of angiotensin II, once produced. Examples of classes of such compounds include antibodies (e.g., to renin), amino acids and analogs thereof (including those conjugated to larger molecules), peptides (including peptide analogs of angiotensin and angiotensin I), pro-renin related analogs, etc. Among the most potent and useful renin-angiotensin system inhibitors are renin inhibitors, ACE inhibitors, and angiotensin II antagonists. In a preferred embodiment of the invention, the renin-angiotensin system inhibitors are renin inhibitors, ACE inhibitors, and angiotensin II antagonists.

“Angiotensin II antagonists” are compounds which interfere with the activity of angiotensin II by binding to angiotensin II receptors and interfering with its activity. Angiotensin II antagonists are well known and include peptide compounds and non-peptide compounds. Most angiotensin II antagonists are slightly modified congeners in which agonist activity is attenuated by replacement of phenylalanine in position 8 with some other amino acid; stability can be enhanced by other replacements that slow degeneration *in vivo*. Examples of angiotensin II antagonists include: peptidic compounds (e.g., saralasin, [(San¹)(Val⁵)(Ala⁸)] angiotensin -(1-8) octapeptide and related analogs); N-substituted imidazole-2-one (US Patent Number 5,087,634); imidazole acetate derivatives including 2-N-butyl-4-chloro-1-(2-chlorobenzile) imidazole-5-acetic acid (see Long et al., *J. Pharmacol. Exp. Ther.* 247(1), 1-7 (1988)); 4, 5, 6, 7-tetrahydro-1H-imidazo [4, 5-c] pyridine-6-carboxylic acid and analog derivatives (US Patent Number 4,816,463); N2-tetrazole beta-glucuronide analogs (US Patent Number 5,085,992); substituted pyrroles, pyrazoles, and tryazoles (US Patent Number 5,081,127); phenol and heterocyclic derivatives such as 1, 3-imidazoles (US Patent Number 5,073,566); imidazo-fused 7-member ring heterocycles (US

Patent Number 5,064,825); peptides (e.g., US Patent Number 4,772,684); antibodies to angiotensin II (e.g., US Patent Number 4,302,386); and aralkyl imidazole compounds such as biphenyl-methyl substituted imidazoles (e.g., EP Number 253,310, January 20, 1988); ES8891 (N-morpholinoacetyl-(-1-naphthyl)-L-alanyl-(4, thiazolyl)-L-alanyl (35, 45)-4-amino-3-hydroxy-5-cyclo-hexapentanoyl-N-hexylamide, Sankyo Company, Ltd., Tokyo, Japan); SKF108566 (E-alpha-2-[2-butyl-1-(carboxy phenyl) methyl] 1H-imidazole-5-yl[methylane]-2-thiophenepropanoic acid, Smith Kline Beecham Pharmaceuticals, PA); Losartan (DUP753/MK954, DuPont Merck Pharmaceutical Company); Remikirin (RO42-5892, F. Hoffman LaRoche AG); A₂ agonists (Marion Merrill Dow) and certain non-peptide heterocycles (G.D.Searle and Company).

“Angiotensin converting enzyme (ACE), is an enzyme which catalyzes the conversion of angiotensin I to angiotensin II. ACE inhibitors include amino acids and derivatives thereof, peptides, including di- and tri- peptides and antibodies to ACE which intervene in the renin-angiotensin system by inhibiting the activity of ACE thereby reducing or eliminating the formation of pressor substance angiotensin II. ACE inhibitors have been used medically to treat hypertension, congestive heart failure, myocardial infarction and renal disease. Classes of compounds known to be useful as ACE inhibitors include acylmercapto and mercaptoalkanoyl prolines such as captopril (US Patent Number 4,105,776) and zofenopril (US Patent Number 4,316,906), carboxyalkyl dipeptides such as enalapril (US Patent Number 4,374,829), lisinopril (US Patent Number 4,374,829), quinapril (US Patent Number 4,344,949), ramipril (US Patent Number 4,587,258), and perindopril (US Patent Number 4,508,729), carboxyalkyl dipeptide mimics such as cilazapril (US Patent Number 4,512,924) and benazapril (US Patent Number 4,410,520), phosphinylalkanoyl prolines such as fosinopril (US Patent Number 4,337,201) and trandolopril.

“Renin inhibitors” are compounds which interfere with the activity of renin. Renin inhibitors include amino acids and derivatives thereof, peptides and derivatives thereof, and antibodies to renin. Examples of renin inhibitors that are the subject of United States patents are as follows: urea derivatives of peptides (US Patent Number 5,116,835); amino acids connected by nonpeptide bonds (US Patent Number 5,114,937); di- and tri- peptide derivatives (US Patent Number 5,106,835); amino acids and derivatives thereof (US Patent Numbers 5,104,869 and 5,095,119); diol sulfonamides and sulfinyls (US Patent Number 5,098,924); modified peptides (US Patent Number 5,095,006); peptidyl beta-aminoacyl aminodiols carbamates (US Patent Number 5,089,471); pyrrolimidazolones (US Patent Number

5,075,451); fluorine and chlorine statine or statone containing peptides (US Patent Number 5,066,643); peptidyl amino diols (US Patent Numbers 5,063,208 and 4,845,079); N-morpholino derivatives (US Patent Number 5,055,466); pepstatin derivatives (US Patent Number 4,980,283); N-heterocyclic alcohols (US Patent Number 4,885,292); monoclonal antibodies to renin (US Patent Number 4,780,401); and a variety of other peptides and analogs thereof (US Patent Numbers 5,071,837, 5,064,965, 5,063,207, 5,036,054, 5,036,053, 5,034,512, and 4,894,437).

Agents that bind to cellular adhesion molecules and inhibit the ability of white blood cells to attach to such molecules include polypeptide agents. Such polypeptides include polyclonal and monoclonal antibodies, prepared according to conventional methodology. Such antibodies already are known in the art and include anti-ICAM 1 antibodies as well as other such antibodies (see earlier discussion on antibodies).

Anticoagulant agents include, but are not limited to, Ancrod; Anticoagulant Citrate Dextrose Solution; Anticoagulant Citrate Phosphate Dextrose Adenine Solution; Anticoagulant Citrate Phosphate Dextrose Solution; Anticoagulant Heparin Solution; Anticoagulant Sodium Citrate Solution; Ardeparin Sodium; Bivalirudin; Bromindione; Dalteparin Sodium; Desirudin; Dicumarol; Heparin Calcium; Heparin Sodium; Lyapolate Sodium; Nafamostat Mesylate; Phenprocoumon; Tinzaparin Sodium; Warfarin Sodium.

Heparin may stabilize symptoms in evolving stroke, but anticoagulants are useless (and possibly dangerous) in acute completed stroke, and are contraindicated in hypertensives because of the increased possibility of hemorrhage into the brain or other organs. Although the timing is controversial, anticoagulants may be started to prevent recurrent cardiogenic emboli. Clot lysing agents, including tissue plasminogen activator and streptokinase, are being evaluated for the very early treatment of acute stroke. Nimodipine has recently been shown to improve survival and clinical outcome after ischemic stroke.

Other than aspirin, ticlopidine is another antiplatelet agent that has been shown to be beneficial for stroke treatment. Endarterectomy may be indicated in patients with 70 to 99 percent narrowing of a symptomatic internal carotid artery. However, most authorities agree that carotid endarterectomy is not indicated in patients with TIAs that are referable to the basilar-vertebral system, in patients with significant deficits from prior strokes, or in patients in whom a stroke is evolving.

HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase is the microsomal enzyme that catalyzes the rate limiting reaction in cholesterol biosynthesis

(HMG-CoA6Mevalonate). An HMG-CoA reductase inhibitor inhibits HMG-CoA reductase, and as a result inhibits the synthesis of cholesterol. A number of HMG-CoA reductase inhibitors has been used to treat individuals with hypercholesterolemia. More recently, HMG-CoA reductase inhibitors have been shown to be beneficial in the treatment of stroke
5 (Endres M, et al., *Proc Natl Acad Sci U S A*, 1998, 95:8880-5).

HMG-CoA reductase inhibitors useful for co-administration with the agents of the invention include, but are not limited to, simvastatin (U.S. Patent No. 4, 444,784), lovastatin (U.S. Patent No. 4,231,938), pravastatin sodium (U.S. Patent No. 4,346,227), fluvastatin (U.S. Patent No. 4,739,073), atorvastatin (U.S. Patent No. 5,273,995), cerivastatin, and numerous
10 others described in U.S. Patent No. 5,622,985, U.S. Patent No. 5,135,935, U.S. Patent No. 5,356,896, U.S. Patent No. 4,920,109, U.S. Patent No. 5,286,895, U.S. Patent No. 5,262,435, U.S. Patent No. 5,260,332, U.S. Patent No. 5,317,031, U.S. Patent No. 5,283,256, U.S. Patent No. 5,256,689, U.S. Patent No. 5,182,298, U.S. Patent No. 5,369,125, U.S. Patent No. 5,302,604, U.S. Patent No. 5,166,171, U.S. Patent No. 5,202,327, U.S. Patent No. 5,276,021,
15 U.S. Patent No. 5,196,440, U.S. Patent No. 5,091,386, U.S. Patent No. 5,091,378, U.S. Patent No. 4,904,646, U.S. Patent No. 5,385,932, U.S. Patent No. 5,250,435, U.S. Patent No. 5,132,312, U.S. Patent No. 5,130,306, U.S. Patent No. 5,116,870, U.S. Patent No. 5,112,857, U.S. Patent No. 5,102,911, U.S. Patent No. 5,098,931, U.S. Patent No. 5,081,136, U.S. Patent No. 5,025,000, U.S. Patent No. 5,021,453, U.S. Patent No. 5,017,716, U.S. Patent No.
20 5,001,144, U.S. Patent No. 5,001,128, U.S. Patent No. 4,997,837, U.S. Patent No. 4,996,234, U.S. Patent No. 4,994,494, U.S. Patent No. 4,992,429, U.S. Patent No. 4,970,231, U.S. Patent No. 4,968,693, U.S. Patent No. 4,963,538, U.S. Patent No. 4,957,940, U.S. Patent No. 4,950,675, U.S. Patent No. 4,946,864, U.S. Patent No. 4,946,860, U.S. Patent No. 4,940,800, U.S. Patent No. 4,940,727, U.S. Patent No. 4,939,143, U.S. Patent No. 4,929,620, U.S. Patent
25 No. 4,923,861, U.S. Patent No. 4,906,657, U.S. Patent No. 4,906,624 and U.S. Patent No. 4,897,402, the disclosures of which patents are incorporated herein by reference.

Nitric oxide (NO) has been recognized as a messenger molecule with many physiologic roles, in the cardiovascular, neurologic and immune systems (Griffith, TM et al., *J Am Coll Cardiol*, 1988, 12:797-806). It mediates blood vessel relaxation, neurotransmission
30 and pathogen suppression. NO is produced from the guanidino nitrogen of L-arginine by NO Synthase (Moncada, S and Higgs, EA, *Eur J Clin Invest*, 1991, 21:361-374). Agents that upregulate endothelial cell Nitric Oxide Synthase include, but are not limited to, L-arginine, *rho* GTPase function inhibitors (see International Application WO 99/47153, the disclosure of

which is incorporated herein by reference), and agents that disrupt actin cytoskeletal organization (see International Application WO 00/03746, the disclosure of which is incorporated herein by reference).

“Co-administering,” as used herein, refers to administering simultaneously two or
5 more compounds of the invention (e.g., a MIVR-1, IEX-1, VDUP-1, BTG-2, and/or TIS-11d, nucleic acid and/or polypeptide, and an agent known to be beneficial in the treatment of, for example, a cardiovascular condition -e.g., an anticoagulant-), as an admixture in a single composition, or sequentially, close enough in time so that the compounds may exert an additive or even synergistic effect, i.e., on reducing cardiomyocyte cell-death in a
10 cardiovascular condition.

The invention also embraces solid-phase nucleic acid molecule arrays. The array consists essentially of a set of nucleic acid molecules, expression products thereof, or fragments (of either the nucleic acid or the polypeptide molecule) thereof, each nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-
15 11d, fixed to a solid substrate. In some embodiments, the solid-phase array further comprises at least one control nucleic acid molecule. In certain embodiments, the set of nucleic acid molecules comprises at least one, at least two, at least three, at least four, or even at least five nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d. In preferred embodiments, the set of nucleic acid molecules comprises
20 a maximum number of 100 different nucleic acid molecules. In important embodiments, the set of nucleic acid molecules comprises a maximum number of 10 different nucleic acid molecules.

According to the invention, standard hybridization techniques of microarray technology are utilized to assess patterns of nucleic acid expression and identify nucleic acid
25 expression. Microarray technology, which is also known by other names including: DNA chip technology, gene chip technology, and solid-phase nucleic acid array technology, is well known to those of ordinary skill in the art and is based on, but not limited to, obtaining an array of identified nucleic acid probes (e.g., molecules described elsewhere herein such as MIVR-1, IEX-1, VDUP-1, BTG-2, and/or TIS-11d) on a fixed substrate, labeling target
30 molecules with reporter molecules (e.g., radioactive, chemiluminescent, or fluorescent tags such as fluorescein, Cy3-dUTP, or Cy5-dUTP), hybridizing target nucleic acids to the probes, and evaluating target-probe hybridization. A probe with a nucleic acid sequence that perfectly matches the target sequence will, in general, result in detection of a stronger

reporter-molecule signal than will probes with less perfect matches. Many components and techniques utilized in nucleic acid microarray technology are presented in *The Chipping Forecast*, Nature Genetics, Vol.21, Jan 1999, the entire contents of which is incorporated by reference herein.

5 According to the present invention, microarray substrates may include but are not limited to glass, silica, aluminosilicates, borosilicates, metal oxides such as alumina and nickel oxide, various clays, nitrocellulose, or nylon. In all embodiments a glass substrate is preferred. According to the invention, probes are selected from the group of nucleic acids including, but not limited to: DNA, genomic DNA, cDNA, and oligonucleotides; and may be
10 natural or synthetic. Oligonucleotide probes preferably are 20 to 25-mer oligonucleotides and DNA/cDNA probes preferably are 500 to 5000 bases in length, although other lengths may be used. Appropriate probe length may be determined by one of ordinary skill in the art by following art-known procedures. In one embodiment, preferred probes are sets of two or more of the nucleic acid molecules set forth as SEQ ID NOs: 1, 3, 4, 6, 8, 10, and/or 12.
15 Probes may be purified to remove contaminants using standard methods known to those of ordinary skill in the art such as gel filtration or precipitation.

 In one embodiment, the microarray substrate may be coated with a compound to enhance synthesis of the probe on the substrate. Such compounds include, but are not limited to, oligoethylene glycols. In another embodiment, coupling agents or groups on the substrate
20 can be used to covalently link the first nucleotide or oligonucleotide to the substrate. These agents or groups may include, but are not limited to: amino, hydroxy, bromo, and carboxy groups. These reactive groups are preferably attached to the substrate through a hydrocarbyl radical such as an alkylene or phenylene divalent radical, one valence position occupied by the chain bonding and the remaining attached to the reactive groups. These hydrocarbyl
25 groups may contain up to about ten carbon atoms, preferably up to about six carbon atoms. Alkylene radicals are usually preferred containing two to four carbon atoms in the principal chain. These and additional details of the process are disclosed, for example, in U.S. Patent 4,458,066, which is incorporated by reference in its entirety.

 In one embodiment, probes are synthesized directly on the substrate in a
30 predetermined grid pattern using methods such as light-directed chemical synthesis, photochemical deprotection, or delivery of nucleotide precursors to the substrate and subsequent probe production.

In another embodiment, the substrate may be coated with a compound to enhance binding of the probe to the substrate. Such compounds include, but are not limited to: polylysine, amino silanes, amino-reactive silanes (Chipping Forecast, 1999) or chromium (Gwynne and Page, 2000). In this embodiment, presynthesized probes are applied to the substrate in a precise, predetermined volume and grid pattern, utilizing a computer-controlled robot to apply probe to the substrate in a contact-printing manner or in a non-contact manner such as ink jet or piezo-electric delivery. Probes may be covalently linked to the substrate with methods that include, but are not limited to, UV-irradiation. In another embodiment probes are linked to the substrate with heat.

Targets are nucleic acids selected from the group, including but not limited to: DNA, genomic DNA, cDNA, RNA, mRNA and may be natural or synthetic. In all embodiments, nucleic acid molecules from subjects suspected of developing or having a cardiovascular condition, are preferred. In certain embodiments of the invention, one or more control nucleic acid molecules are attached to the substrate. Preferably, control nucleic acid molecules allow determination of factors including but not limited to: nucleic acid quality and binding characteristics; reagent quality and effectiveness; hybridization success; and analysis thresholds and success. Control nucleic acids may include, but are not limited to, expression products of genes such as housekeeping genes or fragments thereof.

To select a set of cardiovascular disease markers, the expression data generated by, for example, microarray analysis of gene expression, is preferably analyzed to determine which genes in different categories of patients (each category of patients being a different cardiovascular disorder), are significantly differentially expressed. The significance of gene expression can be determined using Permax computer software, although any standard statistical package that can discriminate significant differences in expression may be used. Permax performs permutation 2-sample t-tests on large arrays of data. For high dimensional vectors of observations, the Permax software computes t-statistics for each attribute, and assesses significance using the permutation distribution of the maximum and minimum overall attributes. The main use is to determine the attributes (genes) that are the most different between two groups (e.g., control healthy subject and a subject with a particular cardiovascular disorder), measuring "most different" using the value of the t-statistics, and their significance levels.

Expression of cardiovascular disease nucleic acid molecules can also be determined using protein measurement methods to determine expression of SEQ ID NOs: 2, 5, 7, 9,

and/or 11, e.g., by determining the expression of polypeptides encoded by SEQ ID NOs: 1, 4, 6, 8, and/or 10, respectively. Preferred methods of specifically and quantitatively measuring proteins include, but are not limited to: mass spectroscopy-based methods such as surface enhanced laser desorption ionization (SELDI; e.g., Ciphergen ProteinChip System), non-mass spectroscopy-based methods, and immunohistochemistry-based methods such as 2-dimensional gel electrophoresis.

SELDI methodology may, through procedures known to those of ordinary skill in the art, be used to vaporize microscopic amounts of tumor protein and to create a “fingerprint” of individual proteins, thereby allowing simultaneous measurement of the abundance of many proteins in a single sample. Preferably SELDI-based assays may be utilized to characterize cardiovascular conditions as well as stages of such conditions. Such assays preferably include, but are not limited to the following examples. Gene products discovered by RNA microarrays may be selectively measured by specific (antibody mediated) capture to the SELDI protein disc (e.g., selective SELDI). Gene products discovered by protein screening (e.g., with 2-D gels), may be resolved by “total protein SELDI” optimized to visualize those particular markers of interest from among SEQ ID NOs: 1, 3, 4, 6, 8, and/or 10. Predictive models of cardiovascular disease from SELDI measurement of multiple markers from among SEQ ID NOs: 1, 3, 4, 6, 8, and/or 10, may be utilized for the SELDI strategies.

The use of any of the foregoing microarray methods to determine expression of cardiovascular disease nucleic acids can be done with routine methods known to those of ordinary skill in the art and the expression determined by protein measurement methods may be correlated to predetermined levels of a marker used as a prognostic method for selecting treatment strategies for cardiovascular disease patients.

The invention will be more fully understood by reference to the following examples. These examples, however, are merely intended to illustrate the embodiments of the invention and are not to be construed to limit the scope of the invention.

Examples

Experimental Procedures

Materials and Methods

DMEM and Ham's F-12 were obtained from Biowhittaker. Dulbecco's PBS solution, Hanks' balanced salt solution, fibronectin, and other materials required for tissue culture were

purchased from Gibco-BRL. [α - 32 P] dCTP (3000 Ci/mmol) was purchased from Dupont NEN.

Culture of VSMCs

Cells were prepared from explants from excess aortic tissue from the donor at the time of organ harvest for orthotopic cardiac transplantation at Brigham and Women's Hospital. Vascular smooth muscle cells (VSMCs) were maintained in DMEM, 10% FCS, and 1% penicillin/streptomycin sulfate. These conditions are selective for growth of VSMCs over endothelial cells. VSMCs were maintained at 37°C, 5% CO₂ up to passage 6 to 7 for experiments. Under these conditions, 50% to 60% of human VSMCs routinely stain positive for a smooth muscle actin. The protocol was approved by the Brigham and Women's Hospital Committee for Human Research.

Culture of Cardiomyocytes

Cardiomyocytes were cultured essentially as described in Arstall MA, et al., *J Mol Cell Cardiol*, 1998, 30(5):1019-25.

Mechanical Strain Device

A mechanical strain device that provides controlled mechanical deformation to cells in culture was utilized. Such a device is well known in the art and has been previously described in detail as the subject matter of U.S. Patent No. 5,217,899 to Shapiro et al., issued June 8, 1993. Mechanical deformation in this device is applied to a thin and transparent membrane on which cells are cultured, an approach that produces controlled cellular strain and allows visualization of cells. In addition, a nearly homogeneous biaxial strain profile (strains that are equal at all locations on the membrane and in all directions) is generated (Cheng, et al., *Circ. Res.*, 1997, 80:28-36). An advantage of this device over some commonly used systems is that it eliminates locations on the substrate that have very high strains (20% to 30%) in one direction. The membrane undergoes cyclic deformation as the platen assembly moves sinusoidally with a frequency and amplitude derived by the motor speed and the cam size, respectively. It has been previously measured membrane strains with a high-resolution video device (Cheng, et al., *Circ. Res.*, 1997, 80:28-36); the cams used for this study gave strains of 1%, 4%, and 9%.

The cell culture silicone membrane itself supports negligible adhesion of VSMCs. For the preparation of VSMCs to be subjected to mechanical strain, autoclaved membrane dishes were coated with 2 μ g/ml of fibronectin in Hanks' solution for 6 to 12 hours at 4°C and then washed twice with 10 ml PBS. VSMCs were plated on the coated membrane dish at a density

-70-

of 700,000 cells/dish in 13 ml of DMEM containing 10% Fetal Bovine Serum (FBS) and incubated 16 to 24 hours. Cells were then washed with 10 ml of Hanks' solution four times to remove residual serum and incubated with 10 ml of serum-free IT medium (equal volumes of DMEM and Ham's F-12 supplemented with 1 μ mol/L insulin and 5 μ g/ml transferrin) for 48 hours. Before mechanical strain, 10 ml of fresh IT medium was exchanged. Mechanical strain was then applied at a specified constant frequency and amplitude, and control dishes received no mechanical strain.

Transcriptional Profiling

The DNA microarray experiment was performed with human aortic smooth muscle cells cultured on fibronectin-coated membranes with serum-free medium for 48 hours. Cells from a single patient donor were then exposed to 12 hours or 24 hours of cyclic deformation (1 Hz, 4% amplitude) or no deformation, and RNA was prepared. The choice of these time points was based on previous observations indicating that small strains regulated gene induction at these time points (Yang, et al., *J. Biol. Chem.*, 1998, 273:6550-6555). The DNA microarray hybridization experiment was performed using the UniGem 1.0 array (Incyte Genomics, Inc., Palo Alto, CA) using methods previously described. (Iyer, et al., *Science*, 1999, 283:83-87; Lockhart, et al., *Nat. Biotechnol.*, 1996, 14:1675-1680). The UniGem 1.0 array has 5000 well-characterized genes with putative functions. Data were analyzed using the GemTools software package (Incyte Genomics, Inc.). The sensitivity of the assay was detection of one transcript in 75,000.

Microarray reproducibility was determined using two independent assays. First, 200ng of human RNA was labeled with either Cy3 or Cy5dCTP, mixed, and hybridized to an array. Fluorescent ratios were calculated for all called elements. These data demonstrated that when the same RNA is used for both fluorescent channels, 99% of elements of the UniGem 1.0 microarray give differential expression values within 2-fold. A second series of experiments used RNA isolated from two unrelated cell lines. Comparison of these two RNAs over three separate hybridizations yielded an average correlation coefficient of $r=0.97$. For the present study, we used a threshold value of 2.5-fold to define differential gene induction to minimize false positive elements. Furthermore, we compared the results for > 1000 genes to hybridizations with the GeneChip HU6800 (Affymetrix, Inc., Santa Clara, CA), using a different cell donor and methods previously described. (Lockhart, et al., *Nat. Biotechnol.*, 1996, 14:1675-1680).

Northern Blot Hybridization Analyses

The cDNA clones for differentially expressed genes were ordered from the IMAGE consortium. Each clone was sequenced from both 5' and 3' ends to confirm identity. Positive elements in the DNA microarray were confirmed by Northern blot hybridization analysis in at least three independent experiments using three different patient sources of human aortic smooth muscle cells. Total RNA was isolated by the guanidium thiocyanate and phenol chloroform method (Chomczynski, et al., *Anal. Biochem.*, 1987, 162:156-159). For Northern blotting, 15 µg RNA was loaded on a 1.0% agarose-formaldehyde gel (2.0 mol/l), transferred to a nylon membrane (Amersham Pharmacia Biotech AB, Piscataway, NJ), and UV cross-linked with a UV Stratalinker (Stratagene, Inc., La Jolla, CA). The probe was hybridized with ExpressHyb solution (Clontech Labs., Inc., Palo Alto, CA) at 68°C for 1 hour. The membrane was washed with 2 x SSC, 0.05% SDS solution for 30 to 40 minutes and three times at room temperature and 0.1 x SSC, 0.1% SDS solution with continuous shaking at 50°C for 40 minutes. The membrane was exposed to film at -80°C, and radiographs were scanned and analyzed with Optimas 5.0 software (Optimas Co./Media Cybernetics, Silver Springs, MD). Densitometric units were normalized to the ethidium-stained 28S ribosomal subunit on the membrane.

Protein Assays

Enzyme-linked immunoassays were performed using commercially available ELISA kits (e.g., Biopool, Ventura, CA). For Western analyses, cell lysates (50 µg) were loaded on a 10% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane in 25 mmol/L Tris base (pH 8.5), 0.2 mol/L glycine, and 20% methanol. The nitrocellulose membrane was blocked by 5% nonfat dried milk in TBS washing buffer containing 20 mmol/L Tris base (pH 7.6), 137 mmol/L NaCl, and 0.1% Tween 20 for 2 hours.

Strain-Apoptosis Assays

In order to assay the function of the genes of interest in terms of the regulation of strain-dependent cell survival we adapted the TUNEL assay, as described herein, for examining apoptosis in strain-exposed cardiomyocytes. Cardiomyocytes were exposed to strain (as described earlier) or daunorubicine (positive control). After stimulation, the cells were washed with PBS, fixed with 4% paraformaldehyde, parafin embedded, and cut into 5µm sections. The paraformaldehyde fixed sections were deparafinized and rehydrated. TdT enzyme and dUTP conjugated to a fluorescein cocktail were added to the sections according to the manufacturer's specifications (Roche Diagnostics *in situ* death-detection kit, Roche,

Berkeley, CA). Nuclei were counterstained with Hoescht 33258 (Sigma), and mounted for examination using mounting media for fluorescence (Kirkegaard & Perry Laboratories, Inc.). Specimens were examined and photographed on a Diaphot microscope (Nikon Inc.) equipped with a phase-contrast and epifluorescence optics (x100) lens. Pictures were recorded on
5 Kodak Gold Plus film (Eastman Kodak Co.). The percentage of apoptotic nuclei were calculated by determining the number of Hoechst stained nuclei that were positive for TUNEL staining. Approximately 100 nuclei were counted for each section.

Results

10 MIVR-1 in cardiomyocytes and smooth muscle cells

By applying a highly uniform biaxial cyclic strain to cultured human aorta smooth muscle cells, we found a novel mechanically induced gene, MIVR-1. The message of the human MIVR-1 in smooth muscle cells is ~ 5kb in length, and appears as a single mRNA species which is heavily expressed in vascular tissues following strain.

15 The isolated and characterized MIVR-1 cDNA (SEQ ID NO. 1) encodes for a putative MIVR-1 protein sequence (SEQ ID. NO. 2), at a size of ~30kD, having one transmembrane domain, no secretory sequence, and a long cytoplasmic tail.

The Northern hybridization blot of mouse tissue and mouse embryonic stem cells showed hybridization to two mRNA species ~8kb and ~5kb in left ventricle (L) and aorta
20 (Ao) mRNA.

IEX-1 in cardiomyocytes and smooth muscle cells

IEX-1 (SEQ ID NOs. 4 and 5) was originally identified as a radiation induced gene in human squamous cell carcinoma cells (Cancer Research;1996:56:1498). The rat homologue was identified as prg-1 (proliferation-related gene-1). A third name for this gene is p22, a
25 gene known to be downregulated during monocyte differentiation. Promoter deletion studies indicate that IEX-1 is induced by NF-kB and p53. A dominant negative mutant of IEX-1 called IEX-1L has been accidentally cloned through a differential display approach in Jurkat cells by a group searching for NF-kB responsive genes that prevent apoptosis (Science 1998;281:998). Similar to the other mechanically regulated gene that regulates apoptosis
30 (VDUP-1: SEQ ID NOs. 6 and 7), nothing was previously reported about this gene and its involvement in the cardiovascular system.

We initially identified IEX-1 in an SMC strain experiment with HU-6800 arrays. Because we were pursuing a redox and NF-kB regulated mechanical response in cardiac

myocytes, IEX-1 was evaluated in both cardiomyocytes (CMs) and VSMCs. We confirmed robust upregulation of IEX-1 in human CMs but explored the homologue prg-1 in rat neonatal CM due to availability. A Northern blot hybridization indicated that in rat neonatal CM, prg-1 is rapidly and robustly induced. An amplitude response Northern blot hybridization in rat neonatal CM confirmed that prg-1/IEX-1 is induced by strain in a dose-dependent manner:

We hypothesized that IEX-1/prg-1 induction would not be related to angiotensin II (AngII), since it has been previously determined that Ang II is not required for mechanical induction of NF-kB. However, in two experiments performed partial inhibition by an Ang II inhibitor was observed. Thus, IEX-1/prg-1 is a gene that is mechanically induced and has an apoptosis regulatory function.

BTG-2 and TIS-11d in cardiomyocytes and smooth muscle cells

Using Northern blot hybridization analyses, two additional hits from the microarray screen were assayed. Rat cDNA probes were generated by PCR using a cardiomyocyte cDNA template. The two new hits included (i) BTG-2 (NGF-inducible anti-proliferative protein PC3, SEQ ID NOs. 8 and 9), a gene downstream of p53 that has anti-proliferative effects, and (ii) TIS-11d (zinc finger transcription factor ERF-2: SEQ ID NOs. 10 and 11), an immediate early gene induced by extracellular hormones and growth factor signals that causes apoptosis when continuously expressed at physiological levels.

Strain-Apoptosis Assays

Strain-apoptosis assays were performed as described elsewhere herein. These assays showed that both in serum-rich and serum-free conditions, exposure of cardiovascular cells to strain diminishes the degree of apoptosis.

All references disclosed herein are incorporated by reference in their entirety. What is claimed is presented below and is followed by a Sequence Listing.

We claim:

Claims

1. An isolated nucleic acid molecule selected from the group consisting of:
 - (a) nucleic acid molecules which hybridize under stringent conditions to a molecule consisting of a nucleotide sequence set forth as SEQ ID NO:1 and which code for a MIVR-1 polypeptide having cardiac cell anti-apoptotic activity,
 - (b) deletions, additions and substitutions of (a) which code for a MIVR-1 polypeptide having cardiac cell anti-apoptotic activity,
 - (c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and
 - (d) complements of (a), (b) or (c).
2. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleotide sequence set forth as SEQ ID NO:1.
3. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule consists of the nucleotide sequence set forth as SEQ ID NO:3 or a fragment thereof.
4. An isolated nucleic acid molecule selected from the group consisting of
 - (a) unique fragments of a nucleotide sequence set forth as SEQ ID NO:1, and
 - (b) complements of (a),provided that a unique fragment of (a) includes a sequence of contiguous nucleotides which is not identical to any sequence selected from the sequence group consisting of
 - (1) sequences selected from the group consisting of SEQ ID NOs. 14-16, and 17,
 - (2) complements of (1), and
 - (3) fragments of (1) and (2).
5. The isolated nucleic acid molecule of claim 4, wherein the sequence of contiguous nucleotides is selected from the group consisting of:
 - (1) at least two contiguous nucleotides nonidentical to the sequence group,
 - (2) at least three contiguous nucleotides nonidentical to the sequence group,
 - (3) at least four contiguous nucleotides nonidentical to the sequence group,
 - (4) at least five contiguous nucleotides nonidentical to the sequence group,
 - (5) at least six contiguous nucleotides nonidentical to the sequence group, and
 - (6) at least seven contiguous nucleotides nonidentical to the sequence group.

6. The isolated nucleic acid molecule of claim 4, wherein the unique fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, and 200 nucleotides.
7. The isolated nucleic acid molecule of claim 4, wherein the molecule encodes a polypeptide which is immunogenic.
8. An expression vector comprising the isolated nucleic acid molecule of claim 1, 2, 3, 4, 5, 6, or 7 operably linked to a promoter.
9. An expression vector comprising the isolated nucleic acid molecule of claim 4 operably linked to a promoter.
10. A host cell transformed or transfected with the expression vector of claim 8.
11. A host cell transformed or transfected with the expression vector of claim 9.
12. An isolated polypeptide encoded by a nucleic acid molecule of claim 1, 2, 3, or 4, wherein the polypeptide, or fragment of the polypeptide, has cardiac cell anti-apoptotic activity.
13. The isolated polypeptide of claim 12, wherein the polypeptide is encoded by the nucleic acid molecule of claim 2.
14. The isolated polypeptide of claim 13, wherein the polypeptide comprises a polypeptide having the sequence of amino acids 1-287 of SEQ ID NO:2.
15. An isolated polypeptide encoded by a nucleic acid molecule of claim 1, 2, 3, or 4, wherein the polypeptide, or fragment of the polypeptide, is immunogenic.
16. The isolated polypeptide of claim 15, wherein the fragment of the polypeptide, or portion of the fragment, binds to a human antibody.
17. An isolated binding polypeptide which binds selectively a polypeptide encoded by an isolated nucleic acid molecule of claim 1, 2, 3, or 4.

18. The isolated binding polypeptide of claim 17, wherein the isolated binding polypeptide binds to a polypeptide having the sequence of amino acids of SEQ ID NO:2.
19. The isolated binding polypeptide of claim 18, wherein the isolated binding polypeptide is an antibody or an antibody fragment selected from the group consisting of a Fab fragment, a F(ab)₂ fragment or a fragment including a CDR3 region.
20. A method for determining the level of MIVR-1 expression in a subject, comprising measuring expression of MIVR-1 in a test sample from the subject to determine the level of MIVR-1 expression in the subject.
21. The method of claim 20, wherein the measured MIVR-1 expression in the test sample is compared to MIVR-1 expression in a control containing a known level of expression.
22. The method of claim 20, wherein the expression of MIVR-1 is MIVR-1 mRNA expression.
23. The method of claim 20, wherein the expression of MIVR-1 is MIVR-1 polypeptide expression.
24. The method of claim 20, wherein the test sample is tissue.
25. The method of claim 20, wherein the test sample is a biological fluid.
26. The method of claim 22, wherein MIVR-1 mRNA expression is measured using PCR.
27. The method of claim 22, wherein MIVR-1 mRNA expression is measured using Northern blotting.
28. The method of claim 23, wherein MIVR-1 polypeptide expression is measured using monoclonal antibodies to MIVR-1.
29. The method of claim 23, wherein MIVR-1 polypeptide expression is measured using polyclonal antisera to MIVR-1.
30. The method of claim 23, wherein expression of MIVR-1 is measured using MIVR-1 cardiac cell anti-apoptotic activity.

31. A method for identifying an agent useful in modulating cardiac cell anti-apoptotic activity of a molecule, comprising:

(a) contacting a molecule having cardiac cell anti-apoptotic activity with a candidate agent,

(b) measuring cardiac cell anti-apoptotic activity of the molecule, and

(c) comparing the measured cardiac cell anti-apoptotic activity of the molecule to a control to determine whether the candidate agent modulates cardiac cell anti-apoptotic activity of the molecule,

wherein the molecule is a nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, or an expression product thereof.

32. A method of diagnosing a condition characterized by aberrant expression of a nucleic acid molecule or an expression product thereof, said method comprising:

a) contacting a biological sample from a subject with an agent, wherein said agent specifically binds to said nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof; and

b) measuring the amount of bound agent and determining therefrom if the expression of said nucleic acid molecule or of an expression product thereof is aberrant, aberrant expression being diagnostic of the condition;

wherein the nucleic acid molecule is at least one nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

33. The method of claim 32, wherein the nucleic acid molecule is at least two nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

34. The method of claim 32, wherein the nucleic acid molecule is at least three nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

35. The method of claim 32, wherein the nucleic acid molecule is at least four nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

36. The method of claim 32, wherein the nucleic acid molecule is at least five nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

37. The method of claim 32, wherein the condition is a cardiovascular condition selected from the group consisting of myocardial infarction, stroke, arteriosclerosis, and heart failure.

38. The method of claim 32, wherein the condition is cardiac hypertrophy.

39. A method for determining regression, progression or onset of a vascular condition in a subject characterized by aberrant expression of a nucleic acid molecule or an expression product thereof, comprising:

monitoring a sample from a patient, for a parameter selected from the group consisting of

- (i) a nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, BTG-2, TIS-11d, and VDUP-1,
- (ii) a polypeptide encoded by the nucleic acid molecule,
- (iii) a peptide derived from the polypeptide, and
- (iv) an antibody which selectively binds the polypeptide or peptide,

as a determination of regression, progression or onset of said vascular condition in the subject.

40. The method of claim 39, wherein the sample is a biological fluid or a tissue.

41. The method of claim 39, wherein the step of monitoring comprises contacting the sample with a detectable agent selected from the group consisting of

(a) an isolated nucleic acid molecule which selectively hybridizes under stringent conditions to the nucleic acid molecule of (i),

(b) an antibody which selectively binds the polypeptide of (ii), or the peptide of (iii), and

(c) a polypeptide or peptide which binds the antibody of (iv).

42. The method of claim 41, wherein the antibody, the polypeptide, the peptide or the nucleic acid is labeled with a radioactive label or an enzyme.

43. The method of claim 39, comprising assaying the sample for the peptide.

44. A kit, comprising a package containing:

an agent that selectively binds to the isolated nucleic acid of claim 1 or an expression product thereof, and

a control for comparing to a measured value of binding of said agent to said isolated nucleic acid of claim 1 or expression product thereof.

45. The kit of claim 44, wherein the control is a predetermined value for comparing to the measured value.

46. The kit of claim 44, wherein the control comprises an epitope of the expression product of the nucleic acid of claim 1.

47. The kit of claim 44, further comprising a second agent that selectively binds to an isolated nucleic acid molecule selected from the group consisting of IEX-1, VDUP-1, BTG-2, and TIS-11d, or an expression product thereof, and

a control for comparing to a measured value of binding of said second agent to said nucleic acid molecule or expression product thereof.

48. A method for treating a cardiovascular condition, comprising:

administering to a subject in need of such treatment an agent that modulates expression of a molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, in an amount effective to treat the cardiovascular condition.

49. The method of claim 48, further comprising co-administering an agent selected from the group consisting of an anti-inflammatory agent, an anti-thrombotic agent, an anti-platelet agent, a fibrinolytic agent, a lipid reducing agent, a direct thrombin inhibitor, a glycoprotein IIb/IIIa receptor inhibitor, an agent that binds to cellular adhesion molecules and inhibits the ability of white blood cells to attach to such molecules, a calcium channel blocker, a beta-adrenergic receptor blocker, a cyclooxygenase-2 inhibitor, or an angiotensin system inhibitor.

50. A method of treating apoptotic cell-death of a cardiac cell in a subject, comprising:
administering to a subject in need of such treatment an agent that modulates expression of a molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, in an effective amount to inhibit apoptotic cell-death of the cardiac cell in the subject.

51. The method of claim 50, wherein the subject has a condition selected from the group consisting of myocardial infarction, stroke, arteriosclerosis, and heart failure.

52. A method for inhibiting apoptotic cell-death of a cell, comprising:
contacting a molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, with a cell under conditions that permit entry of the molecule into the cell, in an amount effective to inhibit apoptotic cell-death of the cell.

53. The method of claim 52, wherein the cell is selected from the group consisting of a cardiomyocyte and a vascular endothelial cell.

54. A method for treating a condition mediated by increased apoptotic cell-death of vascular endothelial cells in a subject, comprising:

administering to a subject in need of such treatment a molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, in an amount effective to inhibit increased apoptotic cell-death of vascular endothelial cells.

55. A method for treating cardiac hypertrophy, comprising:

administering to a subject in need of such treatment an agent that increases cardiac cell-death, in an amount effective to treat cardiac hypertrophy in the subject,

wherein the agent that increases cardiac cell-death is an inhibitor of a nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, or an expression product thereof.

56. A method for treating a subject to reduce the risk of a cardiovascular condition developing in the subject, comprising:

administering to a subject who is known to express decreased levels of a molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, an agent for reducing the risk of the cardiovascular disorder in an amount effective to lower the risk of the subject developing a future cardiovascular disorder,

wherein the agent is an anti-inflammatory agent, an anti-thrombotic agent, an anti-platelet agent, a fibrinolytic agent, a lipid reducing agent, a direct thrombin inhibitor, a glycoprotein IIb/IIIa receptor inhibitor, an agent that binds to cellular adhesion molecules and inhibits the ability of white blood cells to attach to such molecules, a calcium channel blocker, a beta-adrenergic receptor blocker, a cyclooxygenase-2 inhibitor, or an angiotensin system inhibitor, or an agent that modulates expression of a molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

57. A method for identifying a candidate agent useful in the treatment of a cardiovascular condition, comprising:

determining expression of a set of nucleic acid molecules in a cardiac cell or tissue under conditions which, in the absence of a candidate agent, permit a first amount of expression of the set of nucleic acid molecules, wherein the set of nucleic acid molecules comprises at least one nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d,

contacting the cardiac cell or tissue with the candidate agent, and

detecting a test amount of expression of the set of nucleic acid molecules, wherein an increase in the test amount of expression in the presence of the candidate agent relative to the first amount of expression indicates that the candidate agent is useful in the treatment of the cardiovascular condition.

58. The method of claim 57, wherein the cardiovascular condition is selected from the group consisting of myocardial infarction, stroke, arteriosclerosis, and heart failure.

59. The method of claim 57, wherein the set of nucleic acid molecules comprises at least two nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

60. The method of claim 57, wherein the set of nucleic acid molecules comprises at least three nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

61. The method of claim 57, wherein the set of nucleic acid molecules comprises at least four nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

62. The method of claim 57, wherein the set of nucleic acid molecules comprises at least five nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

63. A method for identifying a candidate agent useful in the treatment of cardiac hypertrophy, comprising:

determining expression of a set of nucleic acid molecules in a cardiac cell or tissue under conditions which, in the absence of a candidate agent, permit a first amount of expression of the set of nucleic acid molecules, wherein the set of nucleic acid molecules comprises at least one nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d,

contacting the cardiac cell or tissue with the candidate agent, and

detecting a test amount of expression of the set of nucleic acid molecules, wherein a decrease in the test amount of expression in the presence of the candidate agent relative to the first amount of expression indicates that the candidate agent is useful in the treatment of cardiac hypertrophy.

64. The method of claim 63, wherein the set of nucleic acid molecules comprises at least two nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

65. The method of claim 63, wherein the set of nucleic acid molecules comprises at least three nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

66. The method of claim 63, wherein the set of nucleic acid molecules comprises at least four nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

67. The method of claim 63, wherein the set of nucleic acid molecules comprises at least five nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

68. A pharmaceutical composition, comprising:

an agent comprising an isolated nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, or an expression product thereof, in a pharmaceutically effective amount to treat a cardiovascular condition, and

a pharmaceutically acceptable carrier.

69. The pharmaceutical composition of claim 68, wherein the agent is an expression product of the isolated nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

70. The pharmaceutical composition of claim 68, wherein the cardiovascular condition is selected from the group consisting of myocardial infarction, stroke, arteriosclerosis, and heart failure.

71. A pharmaceutical composition, comprising:

an agent that increases cardiac cell-death in a pharmaceutically effective amount to treat cardiac hypertrophy, wherein the agent that increases cardiac cell-death is an inhibitor of a nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, or an expression product thereof, and

a pharmaceutically acceptable carrier.

72. A solid-phase nucleic acid molecule array consisting essentially of a set of nucleic acid molecules, expression products thereof, or fragments thereof, each nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d, fixed to a solid substrate.

73. The solid-phase nucleic acid molecule array of claim 72, further comprising at least one control nucleic acid molecule.

74. The solid-phase nucleic acid molecule array of claim 72, wherein the set of nucleic acid molecules comprises at least one nucleic acid molecule selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

75. The solid-phase nucleic acid molecule array of claim 72, wherein the set of nucleic acid molecules comprises at least two nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

76. The solid-phase nucleic acid molecule array of claim 72, wherein the set of nucleic acid molecules comprises at least three nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

77. The solid-phase nucleic acid molecule array of claim 72, wherein the set of nucleic acid molecules includes at least four nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.

78. The solid-phase nucleic acid molecule array of claim 72, wherein the set of nucleic acid molecules includes at least 5 nucleic acid molecules, each selected from the group consisting of MIVR-1, IEX-1, VDUP-1, BTG-2, and TIS-11d.




Fig. 1

SEQUENCE LISTING

<110> Lee, Richard T.
 Landschulz, Katherine T.
 Turi, Thomas G.
 Thompson, John F.
 Kennedy, Scott P.

<120> DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR CONDITIONS

<130> P0738/7001WO/ERP/KA

<150> US 60/227,159

<151> 2000-08-22

<160> 17

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1321

<212> DNA

<213> Homo Sapiens

<220>

<221> CDS

<222> (413)...(1273)

<400> 1

cgaccgcggt	ctcggagcga	aaccgatct	ccttggactt	gaatgaggag	gaggaggcgg	60
cggcggcggc	ggcggcggag	gcgctcggct	ggggaaagct	agcggcagag	gctcagcccc	120
ggcggcagcg	cgcgccccgc	tgccagccca	ttttccggac	gccaccgcg	ggcactgccg	180
acgcccccg	ggctgcccag	gggaggcccg	gggggcgcag	cggagcgcgg	tcccgcgcac	240
tgagccccgc	ggcgcccccg	gaacttggcg	gcgacccgag	cccggcgcgc	cggggcgcgc	300
ctcccccgcc	gcgcgcctcc	tgcatgccc	gccccagctc	cgggcgcgg	ccggagcccc	360
ccccggccgc	ccccgagccc	cccgcgcccc	gcgcgcgcgc	gcccgcgcgt	cc atg cac	418
					Met His	
					1	
cgc ttg atg	ggg gtc aac	agc acc gcc	gcc gcc gcc	gcc gcc ggg	cag ccc	466
Arg Leu Met	Gly Val Asn	Ser Thr Ala	Ala Ala Ala	Ala Ala Gly	Gln Pro	
	5		10		15	
aat gtc tcc	tgc acg tgc	aac tgc aaa	cgc tct ttg	ttc cag agc	atg	514
Asn Val Ser	Cys Thr Cys	Asn Cys Lys	Arg Ser Leu	Phe Gln Ser	Met	
	20		25		30	
gag atc acg	gag ctg gag	ttt gtt cag	atc atc atc	atc atc gtg	gtg gtg	562
Glu Ile Thr	Glu Leu Glu	Phe Val Gln	Ile Ile Ile	Ile Ile Val	Val Val	
	35		40		45	50
atg atg gtg	atg gtg gtg	gtg atc acg	tgc ctg ctg	agc cac tac	aag	610
Met Met Val	Met Val Val	Val Val Ile	Thr Cys Leu	Leu Leu Ser	His Tyr Lys	
	55		60		65	
ctg tct gca	cgg tcc ttc	atc agc cgg	cac agc cag	ggg cgg agg	aga	658
Leu Ser Ala	Arg Ser Phe	Ile Ser Arg	His Ser Gln	Gly Arg Arg	Arg Arg	
	70		75		80	
gaa gat gcc	ctg tcc tca	gaa gga tgc	ctg tgg ccc	tcg gag agc	aca	706
Glu Asp Ala	Leu Ser Ser	Glu Gly Cys	Leu Trp Pro	Ser Glu Ser	Thr	

85	90	95	
gtg tca ggc aac gga atc cca gag ccg cag gtc tac gcc ccg cct cgg			754
Val Ser Gly Asn Gly Ile Pro Glu Pro Gln Val Tyr Ala Pro Pro Arg			
100	105	110	
ccc acc gac cgc ctg gcc gtg ccg ccc ttc gcc cag cgg gag cgc ttc			802
Pro Thr Asp Arg Leu Ala Val Pro Pro Phe Ala Gln Arg Glu Arg Phe			
115	120	125	130
cac cgc ttc cag ccc acc tat ccg tac ctg cag cac gag atc gac ctg			850
His Arg Phe Gln Pro Thr Tyr Pro Tyr Leu Gln His Glu Ile Asp Leu			
	135	140	145
cca ccc acc atc tcg ctg tca gac ggg gag gag ccc cca ccc tac cag			898
Pro Pro Thr Ile Ser Leu Ser Asp Gly Glu Glu Pro Pro Pro Tyr Gln			
	150	155	160
ggc ccc tgc acc ctc cag ctt ccg gac ccc gag cag cag ctg gaa ctg			946
Gly Pro Cys Thr Leu Gln Leu Arg Asp Pro Glu Gln Gln Leu Glu Leu			
	165	170	175
aac cgg gag tcg gtg cgc gca ccc cca aac aga acc atc ttc gac agt			994
Asn Arg Glu Ser Val Arg Ala Pro Pro Asn Arg Thr Ile Phe Asp Ser			
	180	185	190
gac ctg atg gat agt gcc agg ctg ggc ggc ccc tgc ccc ccc agc agt			1042
Asp Leu Met Asp Ser Ala Arg Leu Gly Gly Pro Cys Pro Pro Ser Ser			
195	200	205	210
aac tcg ggc atc agc gcc acg tgc tac ggc agc ggc ggg cgc atg gag			1090
Asn Ser Gly Ile Ser Ala Thr Cys Tyr Gly Ser Gly Gly Arg Met Glu			
	215	220	225
ggg ccg ccg ccc acc tac agc gag gtc atc ggc cac tac ccg ggg tcc			1138
Gly Pro Pro Pro Thr Tyr Ser Glu Val Ile Gly His Tyr Pro Gly Ser			
	230	235	240
tcc ttc cag cac cag cag agc agt ggg ccg ccc tcc ttg ctg gag ggg			1186
Ser Phe Gln His Gln Gln Ser Ser Gly Pro Pro Ser Leu Leu Glu Gly			
	245	250	255
acc cgg ctc cac cac aca cac atc gcg ccc cta gag agc gca gcc atc			1234
Thr Arg Leu His His Thr His Ile Ala Pro Leu Glu Ser Ala Ala Ile			
	260	265	270
tgg agc aaa gag aag gat aaa cag aaa gga cac cct ctc taggggtcccc			1283
Trp Ser Lys Glu Lys Asp Lys Gln Lys Gly His Pro Leu			
275	280	285	
agggggggccg ggctggggct gcgtaggtga aaaggcag			1321
<210> 2			
<211> 287			
<212> PRT			
<213> Homo Sapiens			
<400> 2			
Met His Arg Leu Met Gly Val Asn Ser Thr Ala Ala Ala Ala Ala Gly			
1	5	10	15
Gln Pro Asn Val Ser Cys Thr Cys Asn Cys Lys Arg Ser Leu Phe Gln			

	20		25		30										
Ser	Met	Glu	Ile	Thr	Glu	Leu	Glu	Phe	Val	Gln	Ile	Ile	Ile	Ile	Val
	35		40		45										
Val	Val	Met	Met	Val	Met	Val	Val	Ile	Thr	Cys	Leu	Leu	Ser	His	
	50		55		60										
Tyr	Lys	Leu	Ser	Ala	Arg	Ser	Phe	Ile	Ser	Arg	His	Ser	Gln	Gly	Arg
65			70		75		80								
Arg	Arg	Glu	Asp	Ala	Leu	Ser	Ser	Glu	Gly	Cys	Leu	Trp	Pro	Ser	Glu
			85		90		95								
Ser	Thr	Val	Ser	Gly	Asn	Gly	Ile	Pro	Glu	Pro	Gln	Val	Tyr	Ala	Pro
			100		105		110								
Pro	Arg	Pro	Thr	Asp	Arg	Leu	Ala	Val	Pro	Pro	Phe	Ala	Gln	Arg	Glu
			115		120		125								
Arg	Phe	His	Arg	Phe	Gln	Pro	Thr	Tyr	Pro	Tyr	Leu	Gln	His	Glu	Ile
			130		135		140								
Asp	Leu	Pro	Pro	Thr	Ile	Ser	Leu	Ser	Asp	Gly	Glu	Glu	Pro	Pro	Pro
145			150		155		160								
Tyr	Gln	Gly	Pro	Cys	Thr	Leu	Gln	Leu	Arg	Asp	Pro	Glu	Gln	Gln	Leu
			165		170		175								
Glu	Leu	Asn	Arg	Glu	Ser	Val	Arg	Ala	Pro	Pro	Asn	Arg	Thr	Ile	Phe
			180		185		190								
Asp	Ser	Asp	Leu	Met	Asp	Ser	Ala	Arg	Leu	Gly	Gly	Pro	Cys	Pro	Pro
			195		200		205								
Ser	Ser	Asn	Ser	Gly	Ile	Ser	Ala	Thr	Cys	Tyr	Gly	Ser	Gly	Gly	Arg
			210		215		220								
Met	Glu	Gly	Pro	Pro	Pro	Thr	Tyr	Ser	Glu	Val	Ile	Gly	His	Tyr	Pro
225			230		235		240								
Gly	Ser	Ser	Phe	Gln	His	Gln	Gln	Ser	Ser	Gly	Pro	Pro	Ser	Leu	Leu
			245		250		255								
Glu	Gly	Thr	Arg	Leu	His	His	Thr	His	Ile	Ala	Pro	Leu	Glu	Ser	Ala
			260		265		270								
Ala	Ile	Trp	Ser	Lys	Glu	Lys	Asp	Lys	Gln	Lys	Gly	His	Pro	Leu	
			275		280		285								

<210> 3
 <211> 861
 <212> DNA
 <213> Homo Sapiens

 <220>
 <221> CDS
 <222> (1)...(861)

? <400> 3

atgcaccgct	tgatgggggt	caacagcacc	gccgcccgcg	ccgcccgggca	gcccacatgtc	60
tcctgacagt	gcaactgcaa	acgctctttg	ttccagagca	tgagatcac	ggagctggag	120
tttgttcaga	tcatcatcat	cgtgggtggt	atgatggtga	tggtggtggt	gatcacgtgc	180
ctgctgagcc	actacaagct	gtctgcacgg	tccttcatca	gccggcacag	ccagggcgcg	240
aggagagaag	atgccctgtc	ctcagaagga	tgccctgtggc	cctcggagag	cacagtgtca	300
ggcaacggaa	tcccagagcc	gcaggtctac	gccccgcctc	ggcccaccga	ccgcctggcc	360
gtgccgccct	tcgcccagcg	ggagcgttc	caccgcttcc	agcccaccta	tccgtacctg	420
cagcacgaga	tcgacctgcc	accaccatc	tcgctgtcag	acggggagga	gccccaccc	480
taccagggcc	cctgcaccct	ccagcttcgg	gaccccagc	agcagctgga	actgaaccgg	540
gagtcgggtc	gcgcaccccc	aaacagaacc	atcttcgaca	gtgacctgat	ggatagtgcc	600
aggctgggcg	gcccctgccc	ccccagcagt	aactcgggca	tcagcggcac	gtgctacggc	660
agcggcgggc	gcatggaggg	gccgccgccc	acctacagcg	aggatcatcg	ccactaccgg	720
gggtcctcct	tccagcacca	gcagagcagt	gggccgccct	ccttgctgga	ggggaccggg	780
ctccaccaca	cacacatcgc	gcccctagag	agcgcagcca	tctggagcaa	agagaaggat	840
aaacagaaag	gacaccctct	c				861

<210> 4

<211> 477
 <212> DNA
 <213> Homo Sapiens

<220>
 <221> CDS
 <222> (7)...(474)
 <223> IEX1

<400> 4
 ctcacc atg tgt cac tct cgc agc tgc cac ccg acc atg acc atc ctg 48
 Met Cys His Ser Arg Ser Cys His Pro Thr Met Thr Ile Leu
 1 5 10

cag gcc ccg acc ccg gcc ccc tcc acc atc ccg gga ccc cgg cgg ggc 96
 Gln Ala Pro Thr Pro Ala Pro Ser Thr Ile Pro Gly Pro Arg Arg Gly
 15 20 25 30

tcc ggt cct gag atc ttc acc ttc gac cct ctc ccg gag ccc gca gcg 144
 Ser Gly Pro Glu Ile Phe Thr Phe Asp Pro Leu Pro Glu Pro Ala Ala
 35 40 45

gcc cct gcc ggg cgc ccc agc gcc tct cgc ggg cac cga aag cgc agc 192
 Ala Pro Ala Gly Arg Pro Ser Ala Ser Arg Gly His Arg Lys Arg Ser
 50 55 60

cgc agg gtt ctc tac cct cga gtg gtc ccg cgc cag ctg cca gtc gag 240
 Arg Arg Val Leu Tyr Pro Arg Val Val Arg Arg Gln Leu Pro Val Glu
 65 70 75

gaa ccg aac cca gcc aaa agg ctt ctc ttt ctg ctg ctc acc atc gtc 288
 Glu Pro Asn Pro Ala Lys Arg Leu Leu Phe Leu Leu Thr Ile Val
 80 85 90

ttc tgc cag atc ctg atg gct gaa gag ggt gtg ccg gcg ccc ctg cct 336
 Phe Cys Gln Ile Leu Met Ala Glu Glu Gly Val Pro Ala Pro Leu Pro
 95 100 105 110

cca gag gac gcc cct aac gcc gca tcc ctg gcg ccc acc cct gtg tcc 384
 Pro Glu Asp Ala Pro Asn Ala Ala Ser Leu Ala Pro Thr Pro Val Ser
 115 120 125

ccc gtc ctc gag ccc ttt aat ctg act tcg gag ccc tcg gac tac gct 432
 Pro Val Leu Glu Pro Phe Asn Leu Thr Ser Glu Pro Ser Asp Tyr Ala
 130 135 140

ctg gac ctc agc act ttc ctc cag caa cac ccg gcc gcc ttc 474
 Leu Asp Leu Ser Thr Phe Leu Gln Gln His Pro Ala Ala Phe
 145 150 155

taa 477

<210> 5
 <211> 156
 <212> PRT
 <213> Homo Sapiens

<400> 5
 Met Cys His Ser Arg Ser Cys His Pro Thr Met Thr Ile Leu Gln Ala
 1 5 10 15
 Pro Thr Pro Ala Pro Ser Thr Ile Pro Gly Pro Arg Arg Gly Ser Gly

	20		25		30
Pro	Glu Ile Phe Thr Phe Asp	Pro Leu Pro Glu Pro	Ala Ala Ala Pro		
	35	40	45		
Ala	Gly Arg Pro Ser Ala Ser	Arg Gly His Arg Lys	Arg Ser Arg Arg		
	50	55	60		
Val	Leu Tyr Pro Arg Val Val	Arg Arg Gln Leu Pro	Val Glu Glu Pro		
	65	70	75	80	
Asn	Pro Ala Lys Arg Leu Leu	Phe Leu Leu Thr Ile	Val Phe Cys		
	85	90	95		
Gln	Ile Leu Met Ala Glu Glu	Gly Val Pro Ala Pro	Leu Pro Pro Glu		
	100	105	110		
Asp	Ala Pro Asn Ala Ala Ser	Leu Ala Pro Thr Pro	Val Ser Pro Val		
	115	120	125		
Leu	Glu Pro Phe Asn Leu Thr	Ser Glu Pro Ser Asp	Tyr Ala Leu Asp		
	130	135	140		
Leu	Ser Thr Phe Leu Gln Gln	His Pro Ala Ala Phe			
	145	150	155		

<210> 6
 <211> 2704
 <212> DNA
 <213> Homo Sapiens

<220>
 <221> CDS
 <222> (222)...(1394)
 <223> VDUP1

<400> 6

gcttagtgta accagcggcg tatatTTTTT aggcgccttt tcgaaaacct agtagttaat	60
attcatttgt ttaaactctta tttatTTTTT aagctcaaac tgcttaagaa taccttaatt	120
ccttaaagtg aaataatTTTT ttgcaaaggg gtttctctcga tttggagctt tttttttctt	180
ccaccgtcat ttctaactct taaaaccaac tcagttccat c atg gtg atg ttc aag	236
	Met Val Met Phe Lys
	1 5
aag atc aag tct ttt gag gtg gtc ttt aac gac cct gaa aag gtg tac	284
Lys Ile Lys Ser Phe Glu Val Val Phe Asn Asp Pro Glu Lys Val Tyr	
	10 15 20
ggc agt ggc gag agg gtg gct ggc cgg gtg ata gtg gag gtg tgt gaa	332
Gly Ser Gly Glu Arg Val Ala Gly Arg Val Ile Val Glu Val Cys Glu	
	25 30 35
gtt act cgt gtc aaa gcc gtt agg atc ctg gct tgc gga gtg gct aaa	380
Val Thr Arg Val Lys Ala Val Arg Ile Leu Ala Cys Gly Val Ala Lys	
	40 45 50
gtg ctt tgg atg cag gga tcc cag cag tgc aaa cag act tcg gag tac	428
Val Leu Trp Met Gln Gly Ser Gln Gln Cys Lys Gln Thr Ser Glu Tyr	
	55 60 65
ctg cgc tat gaa gac acg ctt ctt ctg gaa gac cag cca aca ggt gag	476
Leu Arg Tyr Glu Asp Thr Leu Leu Leu Glu Asp Gln Pro Thr Gly Glu	
	70 75 80 85
aat gag atg gtg atc atg aga cct gga aac aaa tat gag tac aag ttc	524
Asn Glu Met Val Ile Met Arg Pro Gly Asn Lys Tyr Glu Tyr Lys Phe	
	90 95 100
ggc ttt gag ctt cct cag ggg cct ctg gga aca tcc ttc aaa gga aaa	572

Gly	Phe	Glu	Leu	Pro	Gln	Gly	Pro	Leu	Gly	Thr	Ser	Phe	Lys	Gly	Lys	
			105					110					115			
tat	ggg	tgt	gta	gac	tac	tgg	gtg	aag	gct	ttt	ctt	gac	cgc	ccg	agc	620
Tyr	Gly	Cys	Val	Asp	Tyr	Trp	Val	Lys	Ala	Phe	Leu	Asp	Arg	Pro	Ser	
		120					125					130				
cag	cca	act	caa	gag	aca	aag	aaa	aac	ttt	gaa	gta	gtg	gat	ctg	gtg	668
Gln	Pro	Thr	Gln	Glu	Thr	Lys	Lys	Asn	Phe	Glu	Val	Val	Asp	Leu	Val	
	135					140					145					
gat	gtc	aat	acc	cct	gat	tta	atg	gca	cct	gtg	tct	gct	aaa	aaa	gaa	716
Asp	Val	Asn	Thr	Pro	Asp	Leu	Met	Ala	Pro	Val	Ser	Ala	Lys	Lys	Glu	
150					155					160					165	
aag	aaa	gtt	tcc	tgc	atg	ttc	att	cct	gat	ggg	cgg	gtg	tct	gtc	tct	764
Lys	Lys	Val	Ser	Cys	Met	Phe	Ile	Pro	Asp	Gly	Arg	Val	Ser	Val	Ser	
				170					175					180		
gct	cga	att	gac	aga	aaa	gga	ttc	tgt	gaa	ggg	gat	gag	att	tcc	atc	812
Ala	Arg	Ile	Asp	Arg	Lys	Gly	Phe	Cys	Glu	Gly	Asp	Glu	Ile	Ser	Ile	
			185					190					195			
cat	gct	gac	ttt	gag	aat	aca	tgt	tcc	cga	att	gtg	gtc	ccc	aaa	gct	860
His	Ala	Asp	Phe	Glu	Asn	Thr	Cys	Ser	Arg	Ile	Val	Val	Pro	Lys	Ala	
		200					205					210				
gcc	att	gtg	gcc	cgc	cac	act	tac	ctt	gcc	aat	ggc	cag	acc	aag	gtg	908
Ala	Ile	Val	Ala	Arg	His	Thr	Tyr	Leu	Ala	Asn	Gly	Gln	Thr	Lys	Val	
	215					220					225					
ctg	act	cag	aag	ttg	tca	tca	gtc	aga	ggc	aat	cat	att	atc	tca	ggg	956
Leu	Thr	Gln	Lys	Leu	Ser	Ser	Val	Arg	Gly	Asn	His	Ile	Ile	Ser	Gly	
230					235					240					245	
aca	tgc	gca	tca	tgg	cgT	ggc	aag	agc	ctt	cgg	ggt	cag	aag	atc	agg	1004
Thr	Cys	Ala	Ser	Trp	Arg	Gly	Lys	Ser	Leu	Arg	Val	Gln	Lys	Ile	Arg	
				250					255					260		
cct	tct	atc	ctg	ggc	tgc	aac	atc	ctt	cga	ggt	gaa	tat	tcc	tta	ctg	1052
Pro	Ser	Ile	Leu	Gly	Cys	Asn	Ile	Leu	Arg	Val	Glu	Tyr	Ser	Leu	Leu	
			265					270					275			
atc	tat	ggt	agc	ggt	cct	gga	tcc	aag	aag	gtc	atc	ctt	gac	ctg	ccc	1100
Ile	Tyr	Val	Ser	Val	Pro	Gly	Ser	Lys	Lys	Val	Ile	Leu	Asp	Leu	Pro	
		280					285					290				
ctg	gta	att	ggc	agc	aga	tca	ggg	cta	agc	agc	aga	aca	tcc	agc	atg	1148
Leu	Val	Ile	Gly	Ser	Arg	Ser	Gly	Leu	Ser	Ser	Arg	Thr	Ser	Ser	Met	
	295					300					305					
gcc	agc	cga	acc	agc	tct	gag	atg	agt	tgg	gta	gat	ctg	aac	atc	cct	1196
Ala	Ser	Arg	Thr	Ser	Ser	Glu	Met	Ser	Trp	Val	Asp	Leu	Asn	Ile	Pro	
310					315					320					325	
gat	acc	cca	gaa	gct	cct	ccc	tgc	tat	atg	gat	gtc	att	cct	gaa	gat	1244
Asp	Thr	Pro	Glu	Ala	Pro	Pro	Cys	Tyr	Met	Asp	Val	Ile	Pro	Glu	Asp	
				330					335					340		
cac	cga	ttg	gag	agc	cca	aca	act	cct	ctg	cta	gat	gac	atg	gat	ggc	1292
His	Arg	Leu	Glu	Ser	Pro	Thr	Thr	Pro	Leu	Leu	Asp	Asp	Met	Asp	Gly	

345	350	355	
tct caa gac agc cct atc ttt atg tat gcc cct gag ttc aag ttc atg			1340
Ser Gln Asp Ser Pro Ile Phe Met Tyr Ala Pro Glu Phe Lys Phe Met			
360	365	370	
cca cca ccg act tat act gag gtg gat ccc tgc atc ctc aac aac aat			1388
Pro Pro Pro Thr Tyr Thr Glu Val Asp Pro Cys Ile Leu Asn Asn Asn			
375	380	385	
gtg cag tgagcatgtg gaagaaaaga agcagcttta cctacttggt tctttttgtc			1444
Val Gln			
390			

tctcttcctg	gacactcact	ttttcagaga	ctcaacagtc	togtcaatgg	agtgtgggtc	1504
caccttagcc	tctgacttcc	taatgtagga	ggtggtcagc	aggcaatctc	ctgggcctta	1564
aaggatgceg	actcatcctc	agccagcgcc	catgttgtga	tacaggggtg	tttgttggat	1624
gggtttaaaa	ataactagaa	aaactcaggc	ccatccattt	tctcagatct	ccttgaaaaat	1684
tgaggccttt	tcgatagttt	cgggtcaggt	aaaaatggcc	tcctggcgta	agcttttcaa	1744
ggttttttgg	aggctttttg	taaattgtga	taggaacttt	ggaccttgaa	cttacgtatc	1804
atgtggagaa	gagccaattt	aacaaactag	gaagatgaaa	agggaaattg	tggccaaaac	1864
tttgggaaaa	ggaggttctt	aaaatcagtg	tttccccttt	gtgcacttgt	agaaaaaaaa	1924
gaaaaacctt	ctagagctga	tttgatggac	aatggagaga	gctttccctg	tgattataaa	1984
aaaggaagct	agctgctcta	cggtcactct	tgcttagagt	atactttaac	ctggccttta	2044
aagcagtagt	aactgcccc	ccaaaggtct	taaaagccat	ttttggagcc	tattgactgt	2104
tgttctccta	ctgcaaatat	tttcatatgg	gaggatgggt	ttctcttcat	gtaagtcctt	2164
ggaattgatt	ctaaggtgat	gttcttagca	ctttaattcc	tgtcaaattt	tttgttctcc	2224
ccttctgcc	tcttaaagt	aagctgaaac	tggtctactg	tgtctctagg	gtaaagccaa	2284
aagacaaaa	aaatthtact	acttttgaga	ttgccccaat	gtacagaatt	atataattct	2344
aacgcttaaa	tcatgtgaaa	gggttgctgc	tgtcagcctt	gcccactgtg	acttcaaacc	2404
caaggaggaa	ctcttgatca	agatgcccc	ccctgtgatc	agaacctcca	aatactgcca	2464
tgagaaacta	gagggcaggt	gttcataaaa	gccctttgaa	cccccttctt	gccctgtggt	2524
aggagatagg	gatattggcc	cctcactgca	gctgccagca	cttggtcagt	cactctcagc	2584
catagcactt	gtttcactgt	cctgtgtcag	agcactgagc	tccacccttt	tctgagagtt	2644
attacagcca	gaaagtgtgg	gctgaagatg	gttggtttca	tgtgggggta	ttatgtacc	2704

<210> 7
 <211> 391
 <212> PRT
 <213> Homo Sapiens

<400> 7	
Met Val Met Phe Lys Lys Ile Lys Ser Phe Glu Val Val Phe Asn Asp	
1 5 10 15	
Pro Glu Lys Val Tyr Gly Ser Gly Glu Arg Val Ala Gly Arg Val Ile	
20 25 30	
Val Glu Val Cys Glu Val Thr Arg Val Lys Ala Val Arg Ile Leu Ala	
35 40 45	
Cys Gly Val Ala Lys Val Leu Trp Met Gln Gly Ser Gln Gln Cys Lys	
50 55 60	
Gln Thr Ser Glu Tyr Leu Arg Tyr Glu Asp Thr Leu Leu Leu Glu Asp	
65 70 75 80	
Gln Pro Thr Gly Glu Asn Glu Met Val Ile Met Arg Pro Gly Asn Lys	
85 90 95	
Tyr Glu Tyr Lys Phe Gly Phe Glu Leu Pro Gln Gly Pro Leu Gly Thr	
100 105 110	
Ser Phe Lys Gly Lys Tyr Gly Cys Val Asp Tyr Trp Val Lys Ala Phe	
115 120 125	
Leu Asp Arg Pro Ser Gln Pro Thr Gln Glu Thr Lys Lys Asn Phe Glu	
130 135 140	
Val Val Asp Leu Val Asp Val Asn Thr Pro Asp Leu Met Ala Pro Val	

<210> 9
 <211> 157
 <212> PRT
 <213> Homo Sapiens

<400> 9
 Met Ser His Gly Lys Gly Thr Asp Met Leu Pro Glu Ile Ala Ala Ala
 1 5 10 15
 Val Gly Phe Leu Ser Ser Leu Leu Arg Thr Arg Gly Cys Val Ser Glu
 20 25 30
 Gln Arg Leu Lys Val Phe Ser Gly Ala Leu Gln Glu Ala Leu Thr Glu
 35 40 45
 His Tyr Lys His His Trp Phe Pro Glu Lys Pro Ser Lys Gly Ser Gly
 50 55 60
 Tyr Arg Cys Ile Arg Ile Asn His Lys Met Asp Pro Ile Ile Ser Arg
 65 70 75 80
 Val Ala Ser Gln Ile Gly Leu Ser Gln Pro Gln Leu His Gln Leu Leu
 85 90 95
 Pro Ser Glu Leu Thr Leu Trp Val Asp Pro Tyr Glu Val Ser Tyr Arg
 100 105 110
 Ile Gly Glu Asp Gly Ser Ile Cys Val Leu Tyr Glu Glu Ala Pro Leu
 115 120 125
 Ala Ala Ser Cys Gly Leu Leu Thr Cys Lys Asn Gln Val Leu Leu Gly
 130 135 140
 Arg Ser Ser Pro Ser Lys Asn Tyr Val Met Ala Val Ser
 145 150 155

<210> 10
 <211> 1746
 <212> DNA
 <213> Homo Sapiens

<220>
 <221> CDS
 <222> (60)...(1037)
 <223> TIS11d

<400> 10
 gagcctgact tcagcgtctcc cactctcggc cgacaccct catggccaac cgttacacc 59
 atg gat ctg act gcc atc tac gag agc ctc ctg tcg ctg agc cct gac 107
 Met Asp Leu Thr Ala Ile Tyr Glu Ser Leu Leu Ser Leu Ser Pro Asp
 1 5 10 15
 gtg ccc gtg cca tcc gac cat gga ggg act gag tcc agc cca ggc tgg 155
 Val Pro Val Pro Ser Asp His Gly Gly Thr Glu Ser Ser Pro Gly Trp
 20 25 30
 ggc tcc tcg gga ccc tgg agc ctg agc ccc tcc gac tcc agc ccg tct 203
 Gly Ser Ser Gly Pro Trp Ser Leu Ser Pro Ser Asp Ser Ser Pro Ser
 35 40 45
 ggg gtc acc tcc cgc ctg cct ggc cgc tcc acc agc cta gtg gag ggc 251
 Gly Val Thr Ser Arg Leu Pro Gly Arg Ser Thr Ser Leu Val Glu Gly
 50 55 60
 cgc agc tgt ggc tgg gtg ccc cca ccc cct ggc ttc gca ccg ctg gct 299
 Arg Ser Cys Gly Trp Val Pro Pro Pro Pro Gly Phe Ala Pro Leu Ala
 65 70 75 80
 ccc cgc ctg ggc cct gag ctg tca ccc tca ccc act tcg ccc act gca 347
 Pro Arg Leu Gly Pro Glu Leu Ser Pro Ser Pro Thr Ser Pro Thr Ala


```

ggatctcagc ggggagccac gtctcttgca ctgtgggtctc tgcattggacc ccagggctgt 1127
ggggacttgg gggacagtaa tcaagtaatc ccctttttcca gaatgcatta acccactccc 1187
ctgacctcac gctggggcag gtccccaagt gtgcaagctc agtattcatg atgggtggggg 1247
atggagtgtc ttccgagggtt cttgggggaa aaaaaattgt agcatattta agggaggcaa 1307
tgaaccctct cccccacctc ttccctgccc aaatctgtct cctagaatct tatgtgctgt 1367
gaataatagc ccttccactgc ccctccagtt tttatagacc tgaggttcca gtgtctcctg 1427
gtaactggaa cctctcctga gggggaatcc tgggtgctcaa attaccctcc aaaagcaagt 1487
agccaaagcc gttgccaaac cccaccata aatcaatggg ccctttattt atgacgactt 1547
tatttattct aatatgattt tatagtattt atatatattg ggtcgtctgc ttcccttgta 1607
tttttcttcc tttttttgta atattgaaaa cgacgatata attattataa gtagactata 1667
atatatttag taatatatat tattacctta aaagtctatt tttgtgtttt gggcattttt 1727
aaataacaa tctgagtgt 1746
    
```

```

<210> 11
<211> 326
<212> PRT
<213> Homo Sapiens
    
```

<400> 11

```

Met Asp Leu Thr Ala Ile Tyr Glu Ser Leu Leu Ser Leu Ser Pro Asp
 1          5          10          15
Val Pro Val Pro Ser Asp His Gly Gly Thr Glu Ser Ser Pro Gly Trp
          20          25          30
Gly Ser Ser Gly Pro Trp Ser Leu Ser Pro Ser Asp Ser Ser Pro Ser
          35          40          45
Gly Val Thr Ser Arg Leu Pro Gly Arg Ser Thr Ser Leu Val Glu Gly
          50          55          60
Arg Ser Cys Gly Trp Val Pro Pro Pro Pro Gly Phe Ala Pro Leu Ala
65          70          75          80
Pro Arg Leu Gly Pro Glu Leu Ser Pro Ser Pro Thr Ser Pro Thr Ala
          85          90          95
Thr Ser Thr Thr Pro Ser Arg Tyr Lys Thr Glu Leu Cys Arg Thr Phe
          100          105          110
Ser Glu Ser Gly Arg Cys Arg Tyr Gly Ala Lys Cys Gln Phe Ala His
          115          120          125
Gly Leu Gly Glu Leu Arg Gln Ala Asn Arg His Pro Lys Tyr Lys Thr
          130          135          140
Glu Leu Cys His Lys Phe Tyr Leu Gln Gly Arg Cys Pro Tyr Gly Ser
145          150          155          160
Arg Cys His Phe Ile His Asn Pro Ser Glu Asp Leu Ala Ala Pro Gly
          165          170          175
His Pro Pro Val Leu Arg Gln Ser Ile Ser Phe Ser Gly Leu Pro Ser
          180          185          190
Gly Arg Arg Thr Ser Pro Pro Pro Gly Leu Ala Gly Pro Ser Leu
          195          200          205
Ser Ser Ser Ser Phe Ser Pro Ser Ser Ser Pro Pro Pro Gly Asp
          210          215          220
Leu Pro Leu Ser Pro Ser Ala Phe Ser Ala Ala Pro Gly Thr Pro Leu
225          230          235          240
Ala Arg Arg Asp Pro Thr Pro Val Cys Cys Pro Ser Cys Arg Arg Ala
          245          250          255
Thr Pro Ile Ser Val Trp Gly Pro Leu Gly Gly Leu Val Arg Thr Pro
          260          265          270
Ser Val Gln Ser Leu Gly Ser Asp Pro Asp Glu Tyr Ala Ser Ser Gly
          275          280          285
Ser Ser Leu Gly Gly Ser Asp Ser Pro Val Phe Glu Ala Gly Val Phe
290          295          300
Ala Pro Pro Gln Pro Val Ala Ala Pro Arg Arg Leu Pro Ile Phe Asn
305          310          315          320
Arg Ile Ser Val Ser Glu
    
```

325

<210> 12
 <211> 878
 <212> DNA
 <213> Mus Musculus

<220>
 <221> CDS
 <222> (20)...(841)

<400> 12

```

aattcgtcga catggcttg atg ggg gtc aac ggc acc gcc gcc gcc gcc gcc      52
      Met Gly Val Asn Gly Thr Ala Ala Ala Ala Ala
          1                5                10

ggg cag ccc aat gtc tcc tgc gcg tgc aac tgc cag cgc tct ttg ttc      100
Gly Gln Pro Asn Val Ser Cys Ala Cys Asn Cys Gln Arg Ser Leu Phe
          15                20                25

ccc agc atg gag atc acg gag ctg gag ttc gtg caa atc gtg gtc atc      148
Pro Ser Met Glu Ile Thr Glu Leu Glu Phe Val Gln Ile Val Val Ile
          30                35                40

gtg gta gtg atg atg gtg atg gtg gtt atg att acg tgc ctg ctg agc      196
Val Val Val Met Met Val Met Val Val Met Ile Thr Cys Leu Leu Ser
          45                50                55

cac tac aag ctg tca gcc cgc tcc ttc atc agc cga cac agc cag gcc      244
His Tyr Lys Leu Ser Ala Arg Ser Phe Ile Ser Arg His Ser Gln Ala
          60                65                70                75

agg agg aga gac gat gga ctg tcc tcg gaa gga tgc ctc tgg ccc tca      292
Arg Arg Arg Asp Asp Gly Leu Ser Ser Glu Gly Cys Leu Trp Pro Ser
          80                85                90

gag agt acg gtg tca ggt gga atg ccg gag cca cag gtc tat gcc ccg      340
Glu Ser Thr Val Ser Gly Gly Met Pro Glu Pro Gln Val Tyr Ala Pro
          95                100                105

cct cgg ccc act gac cga ctc gct gtg ccc ccc ttc atc cag cgg agc      388
Pro Arg Pro Thr Asp Arg Leu Ala Val Pro Pro Phe Ile Gln Arg Ser
          110                115                120

cga ttc caa ccc acc tac ccc tac ctg cag cac gaa att gcc ctg cca      436
Arg Phe Gln Pro Thr Tyr Pro Tyr Leu Gln His Glu Ile Ala Leu Pro
          125                130                135

ccc acc atc tca ctg tct gat ggg gag gag ccc cca ccc tac cag ggc      484
Pro Thr Ile Ser Leu Ser Asp Gly Glu Glu Pro Pro Pro Tyr Gln Gly
          140                145                150                155

ccc tgc acc ctc cag cta cgg gac cct gag caa cag ctg gag ctg aac      532
Pro Cys Thr Leu Gln Leu Arg Asp Pro Glu Gln Gln Leu Glu Leu Asn
          160                165                170

cgg gaa tct gtg cgc gca ccc cct aac cgg acc atc ttc gac agt gac      580
Arg Glu Ser Val Arg Ala Pro Pro Asn Arg Thr Ile Phe Asp Ser Asp
          175                180                185

ctt ata gac agc acc atg ctg ggg ggc ccc tgt ccc ccc agc agt aac      628
    
```

Leu Ile Asp Ser Thr Met Leu Gly Gly Pro Cys Pro Pro Ser Ser Asn
 190 195 200

tcg ggc atc agc gcc acc tgc tac agc agc ggt ggg cgc atg gag ggg 676
 Ser Gly Ile Ser Ala Thr Cys Tyr Ser Ser Gly Gly Arg Met Glu Gly
 205 210 215

ccg ccc ccc acc tac agc gag gtc att ggc cac tac cct ggc tcc tcc 724
 Pro Pro Pro Thr Tyr Ser Glu Val Ile Gly His Tyr Pro Gly Ser Ser
 220 225 230 235

ttc cag cac cag caa agt aac ggg cca tcc tcc ctg cta gag ggg acc 772
 Phe Gln His Gln Gln Ser Asn Gly Pro Ser Ser Leu Leu Glu Gly Thr
 240 245 250

cgg ctc cat cac tcg cac att gcc cca ctg gag aac aag gag aag gag 820
 Arg Leu His His Ser His Ile Ala Pro Leu Glu Asn Lys Glu Lys Glu
 255 260 265

aaa cag aaa ggt cac ccc ctc taggagtggg ggccggggcg cctgtaggca 871
 Lys Gln Lys Gly His Pro Leu
 270

aaaccgc 878

<210> 13
 <211> 274
 <212> PRT
 <213> Mus Musculus

<400> 13

Met Gly Val Asn Gly Thr Ala Ala Ala Ala Ala Gly Gln Pro Asn Val
 1 5 10 15
 Ser Cys Ala Cys Asn Cys Gln Arg Ser Leu Phe Pro Ser Met Glu Ile
 20 25 30
 Thr Glu Leu Glu Phe Val Gln Ile Val Val Ile Val Val Val Met Met
 35 40 45
 Val Met Val Val Met Ile Thr Cys Leu Leu Ser His Tyr Lys Leu Ser
 50 55 60
 Ala Arg Ser Phe Ile Ser Arg His Ser Gln Ala Arg Arg Arg Asp Asp
 65 70 75 80
 Gly Leu Ser Ser Glu Gly Cys Leu Trp Pro Ser Glu Ser Thr Val Ser
 85 90 95
 Gly Gly Met Pro Glu Pro Gln Val Tyr Ala Pro Pro Arg Pro Thr Asp
 100 105 110
 Arg Leu Ala Val Pro Pro Phe Ile Gln Arg Ser Arg Phe Gln Pro Thr
 115 120 125
 Tyr Pro Tyr Leu Gln His Glu Ile Ala Leu Pro Pro Thr Ile Ser Leu
 130 135 140
 Ser Asp Gly Glu Glu Pro Pro Pro Tyr Gln Gly Pro Cys Thr Leu Gln
 145 150 155 160
 Leu Arg Asp Pro Glu Gln Gln Leu Glu Leu Asn Arg Glu Ser Val Arg
 165 170 175
 Ala Pro Pro Asn Arg Thr Ile Phe Asp Ser Asp Leu Ile Asp Ser Thr
 180 185 190
 Met Leu Gly Gly Pro Cys Pro Pro Ser Ser Asn Ser Gly Ile Ser Ala
 195 200 205
 Thr Cys Tyr Ser Ser Gly Gly Arg Met Glu Gly Pro Pro Pro Thr Tyr
 210 215 220
 Ser Glu Val Ile Gly His Tyr Pro Gly Ser Ser Phe Gln His Gln Gln
 225 230 235 240

Ser Asn Gly Pro Ser Ser Leu Leu Glu Gly Thr Arg Leu His His Ser
 245 250 255
 His Ile Ala Pro Leu Glu Asn Lys Glu Lys Glu Lys Gln Lys Gly His
 260 265 270
 Pro Leu

<210> 14
 <211> 693
 <212> DNA
 <213> Homo Sapiens

 <220>
 <221> unsure
 <222> (639)...(639)
 <223> a, c, g, or t/u

<400> 14
 tttttttgca agctctctta gcttgtgcat tcagaccaga catcacatgt aaatatttat 60
 acacagggag gtgggagggg agggccacac gatgcgttgc tgcgcccccc gccttcctct 120
 cactcctctt ctaagaagcg cggagtgttc tgccttttca cctacgcagc cccagcccgg 180
 cccccctggg gaccctagag aggggtgcct ttctgtttat ccttctcttt gctccagatg 240
 gctgcgctct ctagggggcg gatgtgtgtg tgggggaacc cgggtccccct ccagcaagga 300
 gggcggccca ctgctctgct ggtgctggaa ggaggacccc gggtagtggc cgatgacctc 360
 gctgtagggtg ggcggcggcc cctccatgcg cccgccgctg ccgtagcacg tggcgtgat 420
 gcccgagtta ctgctggggg ggcaggggcc gccagcctg gcactatcca tcaggtcact 480
 gtcgaagatg gttctgtttg ggggtgcgcg caccgactcc cggttcagtt ccagctgctg 540
 ctcggggtcc cgaagctgga ggggtcaggg gccctggtag ggtggggctc ctcccgtctg 600
 acagcgagat ggtgggcggc agtcgatctc gtgctgcang tacggatagg tgggctgga 660
 gcggtggaag cgctcccgt gggcgaag cgg 693

<210> 15
 <211> 475
 <212> DNA
 <213> Mus Musculus

<400> 15
 aattcgtcga catggcttga tgggggtcaa cggcaccgcc gccgccgcc cggggcagcc 60
 caatgtctcc tgcgctgca actgccagcg ctctttgttc cccagcatgg agatcacgga 120
 gctggagtcc gtgcaaactc tggatcatct ggtagtgatg atgggtgatg tggttatgat 180
 tacgtgcctg ctgagccact acaagctgtc agcccgtcc ttcatcagcc gacacagcca 240
 ggccaggagg agagacgatg gactgtcctc ggaaggatgc ctctggccct cagagagtac 300
 ggtgtcagggt ggaatgccgg agccacaggt ctatgccccg cctcggecca ctgaccgact 360
 cgctgtgccc cccttcatcc agcggagccg attccaacc acctaccct acctgcagca 420
 cgaaattgcc ctgccacca ccatctcact gtctgatggg gaggagcccc cacc 475

<210> 16
 <211> 8093
 <212> DNA
 <213> Homo Sapiens

<220>
 <221> unsure
 <222> (6477)...(6477)
 <223> c or t/u

<221> unsure
 <222> (6837)...(6837)
 <223> a or c

<400> 16

ctcagctccc	tgtggtgggg	gatggcagag	gcttcccgcct	ccccgcagct	ggtttgcaca	60
gcctcccagc	tgtgccgtgg	tgtctccttc	cctaaagtgg	gacagtctgt	tctgtgtcct	120
gctggcctct	gaggaacaga	cgtgtgtgag	aggccttcag	ggcctgatgg	ctgggggtgt	180
gacagtgcct	ggagaatggg	tggggactgg	aggggccagg	tggctaacca	ctctcctctt	240
ccatggcagc	ggagctggag	ttcgcccaaa	tcatcatcat	cgtcgtgggt	gtcacgggtga	300
tggtggtggg	catcgtctgc	ctgctgaacc	actacaaagt	ctccacgcgg	tccttcatca	360
accgcccga	ccagagccgg	aggcgggagg	acgggctgcc	gcaggaaggg	tgcctgtggc	420
cttcagacag	caccgcaccg	cggctgggcg	cctcggagat	catgcatgcc	ccgcgggtcca	480
gggacaggtt	cgacgcgccg	tccttcatcc	agagggatcg	cttcagccgc	ttccagccca	540
cctaccctta	tgtgcagcac	gagattgatc	ttcctcccac	catctccctg	tcggacgggtg	600
aagagccacc	tccttaccag	gggcccctgca	ccctgcagct	ccgggaccct	gaacagcaga	660
tggaaactcaa	ccgagagtcc	gtgagggccc	cacccaaccg	aaccatattt	gacagtgatt	720
taatagacat	tgctatgtat	agcgggggtc	catgccacc	cagcagcaac	tcgggcatca	780
gtgcaagcac	ctgcagcagt	aacggggagga	tggaggggcc	acccccaca	tacagcgagg	840
tgatgggcca	ccaccagggc	gcctctttcc	tccatcacca	gcgcagcaac	gcacacaggg	900
gcagcagact	gcagtttcag	cagaacaatg	cagagagcac	aatagtacc	atcaaaggca	960
aagataggaa	gcctgggaac	ctggtctgat	tccttccaac	gtgcacttca	gctggagaaa	1020
gaaaccaaga	aggggaagcg	ccgctggggc	cctcctgcgc	acagtgttgt	tcagtttcac	1080
atggtacaaa	taagtaaaac	caaatgagca	aacacggtct	ttgtttctga	ttccttttag	1140
gggaattgca	tgcaaaactag	actgaaaatg	tacaaaactc	catctggtct	gaccgcaaac	1200
agtgtttatt	tggggacag	ggttgggatg	ggggtgtggg	caggggaaaa	caagaaacgg	1260
gatgctttga	agataccatg	aaataaaacc	cacagaggtg	tttgatgtat	ttaattgtga	1320
aaggagactt	tgcaataaaa	tgaggccaga	atggcatggt	ttataattaa	ctgaataaag	1380
aaggaagcat	tattatata	tattgtgggg	aagaaccagc	cagttcgcct	tttctcctaa	1440
ggtgtggact	tttattttgt	tttaaaaata	tgaatcaaaa	ttcctgtggt	gtgtgcccaag	1500
gtataaagtg	gagaagttag	atgagtgcaa	ggagctcctt	tgtgtgtgga	tgatgtgttt	1560
taaaagttgc	actatcttaa	tgttgaaaat	atltacaagg	gaactgtttt	acgtgaagtt	1620
ctgtatgttg	tcttttcacc	tgtggattgt	aatcaggccc	aaggaatata	ctggagtggg	1680
ccccagaagc	atccaagaaa	agatatttgg	ggacgtagcc	taacatttta	ccaacttacg	1740
taaatcaaaa	aagtcattat	tgttgccagga	gtttgcatca	aatagcagtg	catcgtgaa	1800
gcttttggag	acttttggat	ggaagataag	ataggggaaga	ttaagttcca	gcatttctga	1860
cttgttattt	tgagttactc	tgctactctt	aggctgcata	gtttatgaga	aaatgaacac	1920
atgcatttat	ggatccagta	tcatgcagtg	ctgccctcat	cctccagcag	tgcaatttct	1980
tcagtaattt	agattttttt	cactatagca	tgaatatata	tcaaatacat	accttatttt	2040
atgcaataaaa	ttgtttaaaa	tgcaaggtgg	ttattctgca	tactgttgaa	atatgtgact	2100
cctcagtata	ttcccattgc	ctctccccct	ttcctcgaca	gcttagttca	gttctgcagg	2160
gctgctcagt	tcacaggagg	ctcccagcag	ccaccccaca	tccagcctac	acagaacttt	2220
cgtgtggggag	tgggtgtgggt	ggtggttttc	ttatgctttg	gaagccccta	gaaataatga	2280
cggaagaatg	ccatgttgct	gatcgtggta	ataagccatt	gtgggttatt	gtatgtcact	2340
agtattagca	tagcattctt	aaaggaatgc	agtgttcaaa	acctacccaa	attccccgca	2400
ggattttacc	aaacccttcc	ccaggccagt	tttgtactga	aggcaagaac	tggacagtca	2460
gagaacagtg	gagggggcaa	gtgactgaag	agcaccgggt	aaaaagcaca	acatgcagtt	2520
aaaatgcaaa	ctagaaaact	aattttaaat	attgttagtt	ttaatatttc	ctgatattta	2580
caaatattca	ttcttatata	caatgaaaaa	aataactttc	ttctgcagat	gtaagcactg	2640
gcttttataa	gagcagcagc	caacacgttt	agcagacact	gcgcgtggag	aagggccttat	2700
ctgcagtaca	ctctgccatg	tggaggggtg	gcctctgtgg	cctcttcaca	taacaagatg	2760
agctggaatg	atgattccat	gactcccacc	tatgcagcct	taaagccaaa	tccgcgtgtg	2820
tgtgtttgtg	tctgtctgtg	ggtctcgaag	gtgatccgtc	ggtgcggtgg	ctctgtgctg	2880
taactggaga	gactgttcca	aaccccaga	gttgtctgat	cctagtctgt	tccttctctg	2940
ttcttacctc	tgtagatagg	tcactggttt	ttgtttgttt	gttttgagga	ttggaatttc	3000
cattacattc	atcctttgca	cacagtaaca	tcacagaac	tagtccaact	cttaaaagga	3060
gagaggaaaa	acacaggcac	cagttgtcag	ctcatgctta	caacctgtgt	ggaagtatat	3120
acagttgaga	gtcacagtgg	aggttctgag	actggattca	gtctgttcc	agtgacagtt	3180
ggaaggcctc	tgctggagag	acaccagctc	tcagggcaga	gattggcttg	gggcccagaag	3240
gaccctcccc	aaccctggag	acaccctgaa	ggttccactgg	ctctccagat	tagcctctct	3300
tcctctgtca	ggcaaagatg	aggagcccgt	gttcccactg	ggccctgctg	gcagggactt	3360
gcagtggatt	cttggtcagg	tgtgcccaca	gatgcggagg	cgaggtgagt	gattccatca	3420
tttcagttct	cacctgcagt	tttgggtgaag	caggagatgc	accccacagc	tctagctctc	3480
aaatggcttc	acagtcctta	cttctctacc	tgctcaaga	aggggctcag	agcagagact	3540
tgtgaattcc	ttagtaactg	tgagtatatg	aatgtgttgc	acatgtccac	agtattggcg	3600
agataattac	ataattcaga	tacctttaat	catctttcaa	gaaagaggct	cctcccattc	3660

aaccacccta	gagaactgcc	tttgtaaata	agttatntaa	agactcatac	atatcaaacc	3720
atgactttga	aaggctctcg	aggctggggc	tctgtaatga	attagnttaa	aagccaaggt	3780
cataacatga	attgatggtc	aatttccctt	cagcagaagg	aaaaggtgat	ttagatcagt	3840
agctcttttg	aagggtgtgg	ctgacctgtt	cataccgtgt	cgcctcatgg	ctagtgtggc	3900
gttgaaagag	tagcgactgg	gaagatacaa	cttacacagt	ggggcctatt	gttctttcaa	3960
gaaccctttt	tttagcttat	agaacccatg	ggtccagttt	agtaacgagt	gatttaggca	4020
atcaatgata	ggtttataat	cttagattat	tccagcaaag	tgtggattgc	attgnttagga	4080
agaacatttg	gtgggaatga	acactcctgg	gcataccgct	gacttttgtc	ccttgttccc	4140
ggtgtaggag	acccaaggca	tcttgaatcc	catctataag	aacacaatct	tccagcatac	4200
gtttgctttt	tcagaaactc	tagcattctc	tttaaatact	gacgcaatcc	ttaatggaaa	4260
agagatttca	tgaagcaaat	tatgtatntc	aatagntctt	ctatnttttag	tgtccaaaat	4320
ttactaatac	agaagcttga	caagcatgtc	ctcaccctcc	ccaccacata	aacacatgga	4380
cacacacca	agccacaaga	aatcccaaga	gagcagaagc	gaatntttaa	aagatttatc	4440
gtgaggactg	catttccatt	cactaatntt	ggctcaaact	tatgaggcag	gaaatagggg	4500
ccaacagtaa	atgggggagg	cctcctgaca	ccagcagagg	aatntttgtac	ccaggcgagg	4560
acttcttgaa	cttctgcgta	tctccgnttg	atctctntca	cctnttattc	atcttcataa	4620
gaatgagaaa	ggctcaaaaag	gaagcactnt	tagaaatctt	ctctgaccta	gaagaatcca	4680
tccaaatccc	tgcttctctc	tctgaaccaa	cagnttccctt	ctctgacagg	gggccatcct	4740
ctatcttcca	tccagcggct	cttctnttta	ggaaggctct	ggtgcagagc	acttcaaata	4800
tgtcctcagg	ccagatctg	attgctagta	gagagacacc	cggcaccag	tccgaagccc	4860
tccctcaaa	gaccggctta	tggcgttgg	cactggcagg	ctcagagaca	ttctactgtg	4920
ggcgcaggga	gcccggcccc	ccatgcagcc	atgactggat	gcgcccccat	ctcgggggct	4980
tgctgcactg	cttgntttatt	gaatnttgct	acttagaatg	gcaacattaa	cnttggtgac	5040
cattcattnt	ttaaaaatnt	tccaaagctc	ggcagtgtat	gaaagaaaaa	actgggaaag	5100
atacttggnt	tctgttaact	tttgtgntgc	ttgcttaagt	gattaaagcc	agtgcttggga	5160
gccaagcctt	catgccacga	acatgctcca	cagcctgccc	tttgcctctc	tgctcacact	5220
gaccaagaat	gccgcgtgct	tggcctactg	aggtgaaagg	acaattgaat	gacaggtggg	5280
caaagggaga	acttcccctt	cttgggtgca	ggaaagtcac	aaatnttaaaa	atgnttgcttc	5340
cagcccagat	cctaaatgct	agntctcagc	agctgcgtgg	cttaccgntc	gccatntcca	5400
ccaccgccag	ctgccagcac	cgctacagat	cacagagatg	tgaacagaca	atggaaagca	5460
ctcttagcct	tgcaagtggc	tacatntntt	aggaaccaat	atnttcagcat	tctnttattac	5520
ccggcacgct	gtgtcctntg	cagagntcaa	gnttatgtta	ctgccaggg	cagacagtca	5580
tttgcctgct	ctgctgctgc	tgctgactgc	tctcgaactg	gatgcattag	gaagctgctg	5640
tctgagtgta	ggaatgtctt	gctaagaaga	caatgtcttc	cttcatcctt	cttcttcttc	5700
cctctgcgtg	tccntgnttt	tgtgtaatgc	gggagaggg	tagagctata	gagattatat	5760
atacactatc	cgtgcacatt	atataatgt	agatataccc	ctatcatgtc	agagatctgc	5820
atgtcagntt	ttcagcaact	aaggtgcctc	atgntctgag	ttcagcagat	ataggaacca	5880
agccgcccc	tccctgcactt	gatgctccca	cctntgntgt	gcctcactta	aaatgggtgct	5940
ttnttcagnt	gtctgtctnt	tcttatgntt	ttatnttgtaa	ggtgctgtat	ataagnttgaa	6000
tatattatgc	acatatccta	cccaatgggt	agaacaaaaa	gntgnttaata	ctgtaatata	6060
atgtatagat	gataccaatt	ttaacagaaa	tggcatagaa	tttgtgaatg	cctatgtgct	6120
ttgtcctctt	ttgtaaggaa	atnttgcaaat	ggatgcatac	agattaaagt	ctatgtagnt	6180
tatnttccca	ttaaatatca	atattataac	acaagagaaa	gaagtgtgaa	caaacaagca	6240
acagnttatg	accagcgtat	atatagcaat	ggaaagntgc	atcctntgctg	tgaaaacact	6300
ttaaagaaaa	tactntnttaa	aaaatcccac	agctntnttg	ttgccactag	acgcttctta	6360
ttntaatcat	tttagtaatg	ctcagctgga	ccagtnttag	ttatatttga	gtcagaaaaa	6420
tgttgtnttt	caacttgctt	tataatctcc	tgcactatc	tccctgctgta	gcatcaygaa	6480
ggtgtcaggc	aacagtgaaa	agtgcacatt	tttgttgttg	cagaaaactgt	gtcagaggaa	6540
taagtaaatc	agcctgcagc	agaagactnt	gntcagctcc	agaggcatct	gtgaccgtct	6600
gtgtccaagt	ctctctgtgc	cntnttctnt	tacaaaactga	agctgtggag	ccaatgaagt	6660
aacagtagag	attgtagggga	aagaatacct	caggaaaaac	aaatacactt	acaagaagac	6720
cctgttctta	gaaaatgtgt	ttagnttatgg	gnttagcacta	gaagagactt	ggctgtcagc	6780
cagccaagtg	aaggacctct	catccattcc	cattcatgtc	ccatcataat	acggacmcaa	6840
aaagcaaaact	cggntttgccc	atcagnttga	aattacgntt	tggattgtat	atntgntacat	6900
ctctcttcca	gcttagnttt	tagtgtctga	ttgtgacctc	tgcatttatc	ttcaaatacc	6960
ctaatntntaa	aacaaaagaa	caagaaaagt	ttataacacc	atgnttacta	aaaccacggt	7020
tgaatcttgg	gtgtgggcat	cctntcagagt	gntgtccata	agagcagntc	gtggaatntt	7080
gcccactctga	cccatattat	cagcttatctc	tgccaccaga	gtagagtcta	ataaatctca	7140
aagntntntat	ttgctccatg	gtgtatgntc	tgactnttgaa	aatgtcagat	tctataatca	7200
taccctaac	atccaggaga	caaatgacag	attatctnta	aactgaaatt	gactctacaa	7260
tgcaaccctt	aatgctgaat	ggatntaaaa	agtcagccct	tttagtatct	gnttgaaagg	7320

gccgtaaaaa	gttgacactt	ttgttggtt	ggatcctgcg	tgtctagacc	cacgtggtgt	7380
ttccatcgta	tactgtaggg	tgccccctt	gggattcatc	attaagaact	gaggctcact	7440
gttgtcagaa	acaaagctcc	cacccccag	gttcaacctt	gtgggagaac	tggtgagcat	7500
gagaatggtc	tagactcaga	ggtactaaaa	tttgttacca	catcattgct	tcctttctac	7560
aggacgaatt	gaggcttaaa	ctttactggt	aatgatactg	gttcatttta	atgtgcttgt	7620
tggtatggtg	ctatTTTTca	tttcatagct	ttcaaaaatc	atgctaattg	tatacttgtc	7680
tagtttaagg	ctatTTTTaaa	atatgtacaa	tactattcac	agcatttagt	tcgtttaatt	7740
tttattataa	agcaatctac	taaaaaagta	caactgtatt	tgaacttttc	aatagttggt	7800
tgtgagctat	gataatcaaa	agtcattaaa	gtctTTTTta	acaaacattc	gtgcttactt	7860
ttcaacataa	ttcccagtta	tatacagaaa	aagatttcca	cctgtcacgt	atctgcctct	7920
tttacctgag	caatgggtgta	gttcttagac	ctaaggctctg	taattgcaat	acttttaaaag	7980
aaagatggtg	ctctaagtgc	tgtttggttag	ttatgaaatc	agatttttct	gcttggttctt	8040
aatgctgtgg	tcaaaccata	gcacaaaatc	attaaaaata	atcagcggca	tac	8093

- <210> 17
- <211> 513
- <212> DNA
- <213> Homo Sapiens

- <220>
- <221> unsure
- <222> (8)...(9)
- <223> a, c, g, or t/u

- <221> unsure
- <222> (28)...(28)
- <223> a, c, g, or t/u

- <221> unsure
- <222> (34)...(34)
- <223> a, c, g, or t/u

- <221> unsure
- <222> (42)...(42)
- <223> a, c, g, or t/u

- <221> unsure
- <222> (44)...(44)
- <223> a, c, g, or t/u

- <221> unsure
- <222> (46)...(46)
- <223> a, c, g, or t/u

- <221> unsure
- <222> (49)...(49)
- <223> a, c, g, or t/u

- <221> unsure
- <222> (53)...(53)
- <223> a, c, g, or t/u

- <221> unsure
- <222> (55)...(55)
- <223> a, c, g, or t/u

- <221> unsure
- <222> (66)...(66)
- <223> a, c, g, or t/u

-19-

<221> unsure
 <222> (410)...(410)
 <223> a, c, g, or t/u

<400> 1.7

aggggganna	gagctgatcc	ttgtatanct	gacnactttg	cnananacnc	aanangaaga	60
ggaagnagcg	ccggtgcaca	cacaccagag	cgtttcgccc	atttgaacct	ttacctcctt	120
agcgagatgc	tgaatcgctg	atztatggca	tatcatccgc	cttgggcact	tttctcgact	180
atcctgttat	tcacctgtga	actgggacat	caataatgat	gggctcacta	gatcaagggg	240
gagaaagact	gcatacaaat	aaatgcgtaa	aagcactgat	taacctatga	cacgtgctgg	300
ataggggaatc	aacacatgac	aaggttcacg	gtatacgccc	ttcatatgct	ggtctacata	360
ggtctgcagg	cgactctgga	cctgaacgag	tatcatagcg	agccgagcan	cctagcctgc	420
cggtgtagagg	acgtgtagct	acgagcagaa	cttgatgaag	cccgaagggg	ctggtcatca	480
tgatgcccag	gctgtggacg	gacaccaca	cac			513

专利名称(译)	心血管疾病的诊断和治疗		
公开(公告)号	EP1311547A2	公开(公告)日	2003-05-21
申请号	EP2001964262	申请日	2001-08-21
[标]申请(专利权)人(译)	布赖汉姆妇女医院 美国辉瑞有限公司		
申请(专利权)人(译)	布里格姆妇女医院, INC. 辉瑞公司.		
当前申请(专利权)人(译)	布里格姆妇女医院, INC. 辉瑞公司.		
[标]发明人	LEE RICHARD T LANDSCHULZ KATHERINE T KENNEDY SCOTT P THOMPSON JOHN F TURI THOMAS G		
发明人	LEE, RICHARD, T. LANDSCHULZ, KATHERINE, T. KENNEDY, SCOTT, P. THOMPSON, JOHN, F. TURI, THOMAS, G.		
IPC分类号	G01N33/50 A61K38/00 A61K39/395 A61K45/00 A61K45/06 A61K48/00 A61P9/00 A61P9/04 A61P9/10 A61P43/00 C07K14/00 C07K14/47 C07K14/705 C07K16/18 C12N1/15 C12N1/19 C12N1/21 C12N5/02 C12N5/10 C12N15/09 C12N15/12 C12N15/63 C12Q1/02 C12Q1/68 G01N33/15 G01N33/53 G01N33 /577 G01N37/00 A61K38/17 C07K16/28		
CPC分类号	C07K14/705 A61K38/00		
优先权	60/227159 2000-08-22 US		
外部链接	Espacenet		

摘要(译)

本发明涉及用于诊断和治疗心血管病症的方法和组合物。更具体地，本发明涉及涉及可用于抑制心脏凋亡性细胞死亡的分离分子的诊断和治疗。